

AWARD NUMBER: W81XWH-17-1-0572

TITLE: Comparative Effectiveness of Psychotropic Medications for PTSD in Clinical Practice 

PRINCIPAL INVESTIGATOR: Brian Shiner, MD, MPH

CONTRACTING ORGANIZATION: Veterans Education and Research Association
of Norther New England

REPORT DATE: SEPTEMBER 2020

TYPE OF REPORT: Annual Technical Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE SEPTEMBER 2020		2. REPORT TYPE Annual		3. DATES COVERED 01 SEPT 2019 - 31 AUG 2020	
4. TITLE AND SUBTITLE Comparative Effectiveness of Psychotropic Medications for PTSD in Clinical Practice				5a. CONTRACT NUMBER W81XWH-17-1-0572	
				5b. GRANT NUMBER PR160206	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Brian Shiner, MD, MPH (PI) Sarah Cornelius (Research Coordinator) E-Mail: brian.shiner@va.gov; sarah.cornelius@va.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Veterans Education and Research Association of Northern New England 215 N Main Street White River Junction, VT 05001-3833				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We have achieved two main deliverables in Fiscal Year 2020. First, results of Aims 1-3 were published in The Journal of Clinical Psychiatry, explaining our methodology of extracting PTSD diagnoses and PCL measurements in VA users between 2016 and 2018. We also discussed clinical differences, including changes in PCL scores, among the five psychotropic medications assessed in this project (fluoxetine, sertraline, paroxetine, topiramate, and venlafaxine) . Second, we re-built the study cohort to include all VA users with a PTSD diagnosis between October 1, 1999 and September 30, 2019. This new cohort will be used to complete Aim 4 of the project.					
15. SUBJECT TERMS Posttraumatic stress disorder Retrospective cohort Psychotropic medications Routine practice Comparative effectiveness research Veterans					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRDC
Unclassified	Unclassified	Unclassified	Unclassified	106	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	Page
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	8
5. Changes/Problems	9
6. Products	9
7. Participants & Other Collaborating Organizations	11
8. Special Reporting Requirements	11
9. Appendices	12

INTRODUCTION

Exposure to traumatic events, which is commonly experienced by military service members, can lead to the development of posttraumatic stress disorder (PTSD). Using randomized controlled trials, researchers have identified five medications that consistently appear to treat PTSD: Zoloft® (sertraline), Paxil® (paroxetine), Prozac® (fluoxetine), Effexor® (venlafaxine), and Topamax® (topiramate). However, there are no randomized trials comparing the effects of these five medications in a single patient population. A logical and efficient approach to determine which medications may be most effective for Veterans who use the VA would be to leverage historical treatment data to compare the recommended psychotropic medications for PTSD. All five of these medications have been available and regularly prescribed in the VA for over 15 years, and the VA has a national corporate data warehouse (CDW) containing information from electronic medical records used in routine practice. In the short term, this research would help Veterans with posttraumatic stress by providing additional information about which medications work the best for their symptoms, and even tailor their choice based on their own unique situation. It would also help VA doctors by giving them additional information about how to best help their patients. In the long term, this research would help Veterans, VA doctors, and researchers by developing a way to learn from clinical practice and incorporate those findings to improve care for posttraumatic stress disorder.

KEYWORDS

Posttraumatic stress disorder
Psychotropic medications
Comparative effectiveness research
Retrospective cohort
Routine practice
Veterans

ACCOMPLISHMENTS

WHAT WERE THE MAJOR GOALS OF THE PROJECT?

The overarching objective of this project is to determine the comparative effectiveness of psychotropic medications to treat PTSD among Veterans in routine clinical practice. There are four aims total, three of which address changes in symptoms associated with an adequate trial of an effective psychotropic medication for PTSD. For the entire cohort, we will evaluate both changes in overall symptoms and changes in specific clusters of symptoms. For smaller clinically important subgroups, we will examine changes in overall symptoms only.

In order to accomplish these aims, we needed to update and merge existing data and datasets from the VA. With this new cohort, we developed psychotropic medication receipt variables, such as determining the number of Veterans to receive an adequate medication trial (AMT) of one or more of the five medications of interest and aligning these AMTs with available patient-reported outcome measurement.

Our statement of work (SOW) is divided into four main tasks:

Task 1. Update and Merge Existing Data and Datasets—100% completed

Task 2. Develop Psychotropic Medication Receipt Variables—100% completed

Task 3. Data Analysis—50% completed

Task 4. Finalize study requirements, prepare for future funding, and dissemination of findings—25% completed

Our initial SOW called for the completion of Task 3 and part of Task 4 to be completed by the end of Year 3. Due to delay in obtaining the correct cohort, as described in the Major Activities section below, we requested and were granted a no-cost extension for one additional year (9/1/20–8/31/21). Progress on subtasks is described in detail below.

WHAT WAS ACCOMPLISHED UNDER THESE GOALS?

Year 3 Objectives

2. Develop psychotropic medication receipt variables
 - a. Determine whether each Veteran in the final cohort received an adequate medication trial (AMT) of fluoxetine, sertraline, paroxetine, topiramate, venlafaxine during their initial year of VA PTSD treatment.
 - b. Determine whether each Veteran who received an AMT also received pre- and post-measurement with the PTSD Checklist (PCL).
 - c. Determine whether each Veteran who received an AMT plus pre/post-measurement meets symptomatic criteria for PTSD by examining individual PCL items.
3. Data Analysis
 - a. Create matched analytic cohorts using a propensity score matching approach. This will include an overall matched cohort and matched cohorts for each of 13 clinically important subgroups.
 - b. Create GEE models of PCL data to estimate change over time in overall symptoms and clusters of symptoms for patients included in the cohorts.
 - c. Perform analyses of continuous and categorical change for the entire cohort to complete Aims 1–3.
 - d. Perform analyses of continuous for each of 13 clinically important subgroups to complete Aim 4.
4. Finalize study requirements, prepare for future funding, and dissemination
 - a. Complete final report and manuscript draft.
 - b. Use final data to apply for future funding to continue work.
 - c. Disseminate findings through national conferences and DoD presentations.

Major Activities

As previously reported, in Year 2 we discovered that the original cohort provided to us by the VA Informatics and Computing Infrastructure (VINCI) only included VA users with a diagnosis of PTSD between FY 2016 and FY 2018. While this smaller cohort was sufficient for the completion of **Aims 1–3** (acute phase change in overall PTSD symptoms, follow-up phase acute psychiatric care use, and acute phase change in PTSD symptom clusters), it was not large enough for the completion of **Aim 4** (acute phase change in overall PTSD symptoms for clinically important subgroups). Therefore, **in Year 3 we used the smaller FY 2016–2018 cohort to complete Aims 1–3 while at the same time rebuilding a larger cohort include VA users with a diagnosis of PTSD between FY 1999 and FY 2019 in order to complete Aim 4 subgroup analyses.** As a result, we have fully completed **Task 2** and have made significant progress towards **Tasks 3 and 4.**

Our manuscript describing the results of Aims 1–3 has been accepted for publication at the *Journal of Clinical Psychiatry* and is described below under

Significant Results and Products. Notably, as our pilot analyses were previously published at the *Journal of Clinical Psychiatry* during Year 2, we now have two papers from the current award published in this prestigious journal. Additionally, during year 3 we published two methods papers regarding our use of medication and psychotherapy variables for causal analyses in *Administration and Policy in Mental Health and Mental Health Services Research*. These are also described below under Products. As we also published a methods paper during year 2, we now have five total papers from the current award.

Significant Results

With the smaller cohort, including VA users with a clinical diagnosis of PTSD between FY 2016 and 2018, we showed that when using the version of the PTSD Checklist (PCL) aligned to the current case definition for PTSD (the PCL-5, which reflects the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition, or DSM-5), venlafaxine is associated with superior acute-phase remission rates compared to fluoxetine, sertraline, paroxetine and topiramate. It appears that this could be driven by venlafaxine's superior effectiveness in the negative alterations in cognitions and mood symptom cluster, which was added to the diagnosis of PTSD in DSM-5. Additionally, medication continuation during the 6-month follow-up phase was protective against acute psychiatric care use regardless of the agent chosen. These results, summarizing **Aims 1 – 3**, were accepted for publication at the *Journal of Clinical Psychiatry*.

As shown in Table 1 below, we have repeated **Task 2** with the updated and expanded cohort, which includes all VA users with a diagnosis of PTSD between FY 1999 and FY 2019. Within this group, we have identified adequate medication trials (AMTs) meeting all inclusion and exclusion criteria for Aim 4 analyses (Table 1). This work involved mining PCL data from both structured fields in the VA Corporate Data Warehouse (CDW) and unstructured clinical notes, and then aligning those measurements with prescription data. We captured PCL data from clinical notes using a natural language processing (NLP) algorithm developed in another DoD-funded effort (JW140056, PI: Maguen). We also applied NLP algorithms to the same notes to detect use of evidence-based psychotherapy, an important explanatory covariate for our work. After identifying all available PCL scores, we used a crosswalk developed by the National Center for PTSD to convert scores from symptomatic assessments using the previous version of the PCL (PCL-IV) to PCL-5 scoring. This allowed us to apply the PCL-5 diagnostic cutoff of 31 across versions of the PCL. Thus, all patients to be included in our Aim 4 analysis have a severity score that is consistent with a diagnosis of PTSD near the initial medication fill (baseline) and have a follow-up PCL score near the 12-week point (follow-up).

Table 1: Adequate Medication Trials with Pre/Post PTSD Checklist (PCL) Data Availability*

Population	Agent					Total
	Fluoxetine	Sertraline	Paroxetine	Topiramate	Venlafaxine	
Overall	2,419	2,690	989	666	1,228	7,992
Women	365	272	104	138	183	1,062
White Non-Hispanic	1,585	1,702	669	423	872	5,251
Black Non-Hispanic	391	471	159	118	152	1,291
Hispanic	275	308	105	83	124	895
Post-9/11 Veteran	1,693	1,869	715	516	857	5,650
Vietnam Veteran	158	181	67	19	78	503
Combat	1,532	1,664	650	475	786	5,107
Military Sexual Trauma	333	286	105	117	170	1,011
Pain Disorder	1,471	1,618	604	483	847	5,023
Headache Disorder	543	552	220	379	353	2,047
Psychotic Disorder	50	73	17	10	44	194
Bipolar Disorder	102	104	55	71	54	386

Depressive Disorder	1,727	1,871	673	462	947	5,680
Anxiety Disorder	747	850	337	213	427	2,574
Traumatic Brain Injury	199	278	105	119	183	884
Alcohol Use Disorder	680	757	227	180	365	2,259
Opioid Use Disorder	125	138	41	36	71	411
Other Substance Disorder	370	466	165	99	200	1,300

Note. *Patients were selected for this cohort based on having a VHA PTSD diagnosis between October 1, 1999 and September 30, 2019. All PCL scores were scaled to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) scoring, including baseline PCL within one month before or two weeks after the first prescription, and follow-up PCL within 2 weeks before or one month after the 12-week mark.

Overall, there were a total of 7,992 AMTs involving both baseline and follow-up PCL measurement. This includes 2,491 AMTs of fluoxetine, 2,690 of sertraline, 989 of paroxetine, 666 of topiramate, and 1,228 of venlafaxine. For Aim 4 subgroup analyses, we will have adequate power to detect small between-group differences in effect for most comparisons (minimum cell size 288), although in some cases (e.g., paroxetine in women) we may be limited to detecting medium between group differences (minimum cells size 104), and in others (e.g., venlafaxine in bipolar disorder) we may be limited to detecting large differences (minimum cell size of 41). In just a few cases (topiramate in Vietnam Veterans, paroxetine and topiramate in patients with comorbid psychotic disorders, topiramate in patients with comorbid opioid use disorders), we will not have meaningful power to detect between-group differences.

Other Achievements

We have submitted a proposal to the Peer Reviewed Medical Research Program (PRMRP) in response to their call for Expansion Award applications. This project, entitled "Clinical Effectiveness of Long-Acting Injectable Naltrexone for Posttraumatic Stress Disorder and Alcohol Use Disorder", would build off our current PTSD cohort in order to assess the effectiveness of medications for Alcohol Use Disorder (AUD) in patients with comorbid AUD and PTSD. We will further improve the methodologies developed for this current project in order to expand upon current knowledge of treatments for PTSD and AUD.

Additionally, our proposal entitled "Identification of Novel Agents to Treat PTSD using Clinical Data" was selected for funding as an R-01 award from the National Institute of Mental Health. This project, which officially started in May 2020, uses a statistical method called Tree Scan to identify non-psychotropic medications that are associated with PTSD symptom improvement. Already, we have developed a phylogenetic tree of FDA-approved medications classified by mechanism. At this time, we are both setting up Tree Scan software in a special VINCI development workspace and building files to scan for non-psychotropic medications with potential PTSD effectiveness using the PCL files described above.

Goals Not Met

We have not yet finalized our larger analytic dataset for **Aim 4**. As previously discussed, we have requested and received approval for a no-cost extension in response to us needing to re-develop the cohort in Year 2. By the second quarter of Year 4, we anticipate finalizing analytic datasets for the completion of subgroup analyses (**Task 3**). Results will be disseminated through presentations at scientific conferences and manuscript publication (**Task 4**).

WHAT OPPORTUNITIES FOR TRAINING AND PROFESSIONAL DEVELOPMENT HAS THE PROJECT PROVIDED?

The primary professional development from this award has involved collaborations developed to pursue additional research funding using the cohort developed for this award. For the newly funded NIMH R01, Dr. Shiner partnered with an Multiple Principal Investigator, epidemiologist Dr. Jaimie Gradus, to learn additional data mining techniques including tree scan. For the PRMRP expansion award proposal, Dr. Shiner partnered with Dr. Gradus' colleague, epidemiologist Dr. Elanor Murray, to propose cutting edge techniques that frame retrospective comparative effectiveness analyses as the observational emulates of prospective randomized trials. This framework allows for additional analyses to control against bias due to loss to follow-up and non-completion of the intervention. Dr. Shiner has continued to work with psychologist Dr. Shira Maguen and informaticist Dr. Olga Patterson to leverage NLP products from a previous award (JW140056, PI: Maguen) to improve the quality of work performed in the current DoD award. Dr. Shiner has also been invited to work with Dr. Maguen's colleague, psychiatrist Dr. Thomas Neylan, to participate in the drug selection subgroup for DoD adaptive platform trials of medications for PTSD. Finally, VERANNE is in the late stages of talks with Otsuka and Lundbeck to fund Dr. Shiner's VA research team to examine the comparative safety and effectiveness of atypical antipsychotic augmentation of FDA-approved medications for PTSD using VA data (note: Dr. Shiner would not directly receive any funds from Pharma). A framework to evaluate the safety and effectiveness of atypical antipsychotics in Veterans with PTSD will become critical if the Otsuka product, Brexpiprazole (currently in phase III trials), is eventually approved for use in PTSD.

In sum, these collaborations have allowed us to leverage the current DoD award into multiple awards and proposals. This has both increased the impact of our work and will make us competitive if the DoD releases an RFP for center grants in psychopharmacoepidemiology.

HOW WERE THE RESULTS DISSEMINATED TO COMMUNITIES OF INTEREST?

As described in Significant Results above, a manuscript was published summarizing preliminary results of **Aims 1 – 3**. Dr. Shiner was also scheduled to present these results in August 2020 at the Military Health Research Consortium Annual Meeting in Kissimmee FL, but the conference was canceled due to the COVID-19 pandemic. Dr. Shiner did present on this general line of work, including work specifically related to this DoD award, at six meetings over the last year. These presentations are described in Products, below.

WHAT DO YOU PLAN TO DO DURING THE NEXT REPORTING PERIOD TO ACCOMPLISH THE GOALS?

During year 4, we plan to finalize our dataset and complete all Aim 4 subgroup analyses. Additionally, we plan to prepare one additional manuscript describing Aim 4 results, one additional methods paper describing the development of our PCL database, and one additional methods paper describing availability of evidence-based psychotherapy data in the 20-year longitudinal cohort developed for this award. As we have travel funds remaining from the cancellation of Military Health Research Consortium Annual Meeting, we will apply to present our work again next year.

IMPACT

WHAT WAS THE IMPACT ON THE DEVELOPMENT OF THE PRINCIPAL DISCIPLINE(S) OF THE PROJECT?

The publication resulting from work done in Years 2 and 3 has highlighted small differences in effectiveness of the five psychotropic medications primarily prescribed for PTSD. The results presented in this paper support that venlafaxine may have superior effects on acute remission of PTSD. Although more study is needed, these results may impact prescribing patterns within the VA for patients with PTSD.

WHAT WAS THE IMPACT ON OTHER DISCIPLINES?

Nothing to report.

WHAT WAS THE IMPACT ON TECHNOLOGY TRANSFER?

Nothing to report.

WHAT WAS THE IMPACT ON SOCIETY BEYOND SCIENCE AND TECHNOLOGY?

Nothing to report.

CHANGES/PROBLEMS

CHANGES IN APPROACH AND REASONS FOR CHANGE

Year 3 work was completed as anticipated. After our initial difficulty obtaining the correct cohort, the rebuild progressed smoothly and all anticipated summaries and analyses were completed as expected.

ACTUAL OR ANTICIPATED PROBLEMS OR DELAYS AND ACTIONS OR PLANS TO RESOLVE THEM

Nothing to report.

CHANGES THAT HAD A SIGNIFICANT IMPACT ON EXPENDITURES

Nothing to report.

SIGNIFICANT CHANGES IN USE OR CARE OF HUMAN SUBJECTS, VERTEBRATE ANIMALS, BIOHAZARDS, AND/OR SELECT AGENTS

Nothing to report.

PRODUCTS

PUBLICATIONS, CONFERENCE PAPERS, AND PRESENTATIONS

Journal Publications: Aims 1-3

Shiner, B., Leonard, C.E., Gui, J., Schnurr, P.P., Hoyt, J.E., Young-Xu, Y., Watts, B.V. (2020) Comparing Medications for DSM-5 PTSD in Routine VA Practice, Journal of Clinical Psychiatry (In Press).

Journal Publications: Methods

Shiner, B., Leonard Westgate, C., Gui, J., Cornelius, S., Gradus, J.L., Schnurr, P.P., Watts, B.V. (2020) Measurement Strategies for Evidence-Based Antidepressants for Posttraumatic Stress Disorder Delivery: Trends and Associations with Patient-Reported Outcomes, Administration and Policy in Mental Health and Mental Health Services Research, (Online First: doi: 10.1007/s10488-020-01047-w).

Shiner, B., Leonard Westgate, C., Gui, J., Cornelius, S., Maguen, S., Watts, B.V., Schnurr, P.P. (2020) Measurement Strategies for Evidence-Based Psychotherapy for Posttraumatic Stress Disorder Delivery: Trends and Associations with Patient-Reported Outcomes, Administration and Policy in Mental Health and Mental Health Services Research, 47(3): 451-67.

Conference Presentations: Posters

08/2020 - "Comparing Medications for DSM-5 PTSD in Routine VA Practice." Military Health Research Consortium Annual Meeting, Kissimmee FL (Conference canceled due to COVID-19 Pandemic).

Conference Presentations: Talks

04/2020 - "Transforming the Practice of Mental Health Care: The Big Picture (Symposium Member)." NIMH Division of Translational Research, Bethesda MD (Virtual due to COVID-19 Pandemic).

04/2019 - "Use of Antidepressants to Treat PTSD." VA Psychotropic Drug Safety Initiative, West Haven CT (Virtual due to COVID-19 Pandemic).

12/2019 - "Measurement Strategies for Evidence-Based Treatments for PTSD: Trends and Associations with Patient-Reported Outcomes." Dartmouth Medical School Grand Rounds, Lebanon NH

12/2019 - "Measurement Strategies for Evidence-Based Psychotherapy for PTSD: Trends and Associations with Patient-Reported Outcomes." International Society for Traumatic Stress Studies Annual Meeting, Boston MA

10/2019 - "Measurement Strategies for Evidence-Based Psychotherapy for PTSD: Trends and Associations with Patient-Reported Outcomes." VA Health Services Research and Development Annual Meeting, Washington DC

09/2019 - "Tracking Use of VA-Recommended Treatments for PTSD." Mental Health Service Grand Rounds, VA Medical Center, White River Junction VT

WEBSITE(S) OR OTHER INTERNET SITE(S)

Nothing to report.

TECHNOLOGIES OR TECHNIQUES

Nothing to report.

INVENTIONS, PATENT APPLICATIONS, AND/OR LICENSES

Nothing to report.

OTHER PRODUCTS

Nothing to report.

PARTICIPANTS

WHAT INDIVIDUALS HAVE WORKED ON THE PROJECT?

Brian Shiner, MD, MPH (Principal Investigator): No change.

Paula P. Schnurr, PhD (Co-Investigator): No change.

Bradley V. Watts, MD, MPH (Co-Investigator): No change.

Yinong Young-Xu, DSc (Co-Investigator): No change.

Jiang Gui, PhD (Co-Investigator): No change.

Christine Westgate, MS (Lead Programmer): No change.

Vincent Dufort, PhD (Programmer): No change.

Sarah Cornelius, BS (Research Coordinator): No change.

Name:	Luke Rozema
Project Role:	Programmer
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	6.0
Contribution to Project:	Mr. Rozema cleaned data for the study cohort, prepared data for the annual report, and prepared pilot data for the Expansion Award proposal.
Funding Support:	Congressionally Directed Medical Research Program

HAS THERE BEEN A CHANGE IN THE ACTIVE OTHER SUPPORT OF THE PD/PI(S) OR SENIOR/KEY PERSONNEL SINCE THE LAST REPORTING PERIOD?

As described above, Dr. Brian Shiner has received funding from the National Institute of Mental Health (NIMH) to conduct additional analyses on the cohort developed for this project. The effort for this project is counted under his position at his academic affiliate, Dartmouth-Hitchcock Clinic. Under this effort, he can continue with both the new NIMH award and the current DoD award.

WHAT OTHER ORGANIZATIONS WERE INVOLVED AS PARTNERS?

For Year 3, we have begun Joint Personnel Agreements with our academic affiliate (Dartmouth-Hitchcock Clinic) for Drs. Shiner, Watts, and Schnurr. This allows study funds to be used for salary support.

SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS

Not applicable to this project.

QUAD CHARTS

Not applicable to this project.

APPENDICES

We have attached the final versions of the three manuscripts published thus far, as mentioned in **PRODUCTS** above.

Text Word Count: 2,998; Abstract Word Count: 249; Tables: 4; Supplementary Tables: 2

Comparing Medications for DSM-5 PTSD in Routine VA Practice

Running Title: Medications for DSM-5 PTSD

Brian R. Shiner MD, MPH, National Center for PTSD and Veterans Affairs Medical Center, White River Junction, VT; Departments of Psychiatry and The Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, NH

Christine E. Leonard MS, Veterans Affairs Medical Center, White River Junction, VT

Jiang Gui PhD, Veterans Affairs Medical Center, White River Junction, VT; Departments of Biomedical Data Science, Community & Family Medicine, and The Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, NH

Sarah Cornelius BS, Veterans Affairs Medical Center, White River Junction VT.

Paula P. Schnurr PhD, National Center for PTSD, White River Junction, VT; Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH

Jessica E. Hoyt MPH, Veterans Affairs Medical Center, White River Junction, VT

Yinong Young-Xu ScD, MA, MS, Clinical Epidemiology Program and National Center for Patient Safety, White River Junction VT; Departments of Epidemiology and Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH

Bradley V. Watts MD, MPH, Office of Systems Redesign and Veterans Affairs Medical Center, White River Junction, VT, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH

Corresponding Author: Dr. Shiner; VA Medical Center; 215 North Main Street, 116D;
White River Junction, VT 05009; (t) 802-295-9363; (f) 802-291-6286; brian.shiner@va.gov

Previous Presentations: None

Disclosures and acknowledgements: The authors report no conflicts of interest.

This study was funded by the Department of Defense Peer Reviewed Medical Research Program (PR160203), Congressionally Directed Medical Research Program, Fort Dietrich, MD (Dr. Shiner) as well as a Department of Veterans Affairs Health Services Research and Development Career Development Award (CDA11-263), VA Office of Research and Development, Washington, DC (Dr. Shiner). The sponsors did not have any role in the study design, methods, analysis, and interpretation of results, or in preparation of the manuscript and the decision to submit it for publication. The views expressed in this article are those of the authors and do not necessarily represent the position or policy of the US Department of Veterans Affairs or US Department of Defense.

ABSTRACT

Objective: Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have previously shown efficacy for PTSD. One prior study using VA medical records data to compare these agents found no differences in symptom reduction in clinical practice. We address several weaknesses in that study, including limited standardization of treatment duration, inability to account for prior treatment receipt, use of an outdated symptomatic assessment for PTSD, and lack of functional outcome.

Method: We identified 834 VA outpatients with **DSM-5** clinical diagnoses of PTSD between October 2016 and March 2018 who initiated one of the medications and met pre-specified

criteria for treatment duration and dose, combined with baseline and endpoint PTSD checklist-5 (PCL-5) measurements. We compared 12-week acute phase changes in PCL score and remission of PTSD symptoms. We compared use of acute psychiatric services use in the subsequent 6-month continuation phase.

Results: In the acute phase, patients improved by a mean of 6.8-10.1 points on the PCL-5 and 0.0%-10.9% achieved remission of PTSD symptoms. Those taking venlafaxine were significantly more likely to achieve remission ($p<0.0001$). In the continuation phase, there were no differences in acute psychiatric care use between medications. Those who continued their medication were less likely to use acute psychiatric services ($HR=0.55$; $p=0.03$).

Conclusion: There may be an advantage to venlafaxine over other agents in achieving acute-phase remission for DSM-5 PTSD routine clinical practice, but this requires further study. Regardless of the agent chosen, medication cessation during the continuation phase is associated with a higher risk of acute psychiatric care use.

INTRODUCTION

Posttraumatic stress disorder (PTSD) is a serious condition that can follow exposure to a traumatic event, characterized by intrusive re-experiencing of the trauma, avoidance of trauma reminders, negative alterations in cognitions and mood, and increased arousal and reactivity.¹ PTSD has a lifetime prevalence of 6.1% in the United States.² Over 10% of Veterans receiving care in the Department of Veterans Affairs (VA) health care system have PTSD, comprising an active caseload of approximately 600,000 in 2016.³

Randomized controlled trials (RCTs) show that effective treatments for PTSD include both pharmacologic and psychotherapeutic approaches.^{4,5} Several individual medications have shown efficacy as PTSD treatments in placebo-controlled RCTs.^{4,5} Because there is limited data comparing medications that are individually superior to placebo to one another in a single population, one prior VA study used electronic medical record (EMR) data from 2008-2013 to compare the real-world clinical effectiveness of five efficacious medications.⁶ While that study found no differences in symptom reduction between fluoxetine, sertraline, paroxetine, topiramate, and venlafaxine, there were several weaknesses. These included limited standardization of treatment duration, inability to account for prior treatment receipt, use of an outdated patient-reported outcome measure (PROM) for PTSD that aligned with the fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV),⁷ and lack of a functional outcome. We sought to improve upon this study by addressing these limitations.

Therefore, we conducted a retrospective comparative effectiveness study of the same five medications for PTSD using contemporary VA EMR data. We accounted for prior receipt of evidence-based pharmacologic and psychotherapeutic approaches for PTSD dating back almost 20 years, standardized acute-phase treatment duration at 12 weeks, and aligned acute-phase treatment with administration of the PROM for PTSD that is updated for the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).¹ Additionally, we compared the functional outcome of acute psychiatric services use in the subsequent 6-month continuation phase among the five agents. This replication and extension is important both to ensure that the prior null finding is not due to type II error and because different treatments may be effective under the DSM-5 case

conceptualization of PTSD,⁸⁻¹⁰ which was implemented in 2013 and has an increased emphasis on negative alterations in cognitions and mood compared to DSM-IV.^{1,7}

Method

Data Sources

This was a retrospective chart review. We used the VA Corporate Data Warehouse (CDW) to identify all VA users with a DSM-5 clinical diagnosis of PTSD (F43.1x) from 10/1/2016-3/7/2018. While DSM-5 was published in 2013, development and EMR-based implementation of related diagnostic and outcomes assessment tools in the VA occurred slowly, thus we chose 10/1/16 as the start date. We obtained information on services use, clinical diagnoses, pharmacy data, and standardized PTSD symptom measures from the CDW for these patients. This study was approved by the **Veterans Institutional Review Board of Northern New England.**

Cohort Selection

We identified patients who initiated a course of fluoxetine, sertraline, paroxetine, topiramate, or venlafaxine. The study sample was further restricted to those who met our criteria for adequate acute phase medication management. Patients receiving continuous treatment of sertraline, fluoxetine, paroxetine, venlafaxine, or topiramate daily for ≥ 12 weeks at an adequate dose were considered to have received an adequate medication trial (AMT). Adequate doses, which were required for the final 8 weeks only to allow for titration, were as follows: fluoxetine ≥ 20 mg, paroxetine ≥ 20 mg, sertraline ≥ 100 mg, topiramate ≥ 100 mg, and venlafaxine ≥ 150 mg.

For our outcomes analysis, we further restricted to those who received baseline PTSD symptom measurement within 2 weeks of treatment initiation, as well as follow-up symptom measurement within 2 weeks of the 12-week point, and met our symptomatic criteria for PTSD at baseline (defined below).

PTSD Symptoms

We measured PTSD symptoms using the DSM-5 PTSD Checklist (PCL-5),¹¹ which is administered in routine VA clinical practice. We used a baseline cutoff score of ≥ 31 out of 80 due to optimal efficiency for diagnosing PTSD in Veterans, compared to the gold-standard Clinician Administered PTSD Scale for DSM-5.¹² Our minimal symptomatic criteria required a score of “moderate” or higher on one avoidance symptom, two negative alterations symptoms, and two increased arousal symptoms.

While a threshold for clinically meaningful change had not yet been established when we implemented our coding rules, the largest prospective trial using the PCL-5 at that time used a severity score of ≤ 18 as a cutoff for remission.¹³ Therefore, we considered a score of ≤ 18 plus no longer meeting symptomatic criteria to be consistent with remission at follow-up. In addition to examining overall change in symptoms, we evaluated change in sub-scores for PTSD symptoms clusters as well as sleep difficulties using the sum of two items: nightmares and insomnia.

Acute Psychiatric Services Use

We determined whether patients were admitted to a VA psychiatry unit (acute inpatient or observation) or visited a VA emergency room for a primary psychiatric indication during the six-month continuation phase, which followed the initial 12-week acute phase.

Independent Variables

We measured six groups of covariates that could plausibly affect the relationship between treatment and outcome. See Table 1 for details.

Analysis

To understand how AMTs with aligned PCL measurement differed from AMTs initiated without aligned PCL measurement from 10/1/2016-3/7/2018, we compared covariates describing concurrent treatment, primary prescribing clinicians, patient characteristics, VA service use characteristics, and comorbidities using χ^2 analysis and t-tests, as appropriate.

To account for differences in covariate profile among trials of each of the five medications, we used the RAND Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG).¹⁵ The TWANG package supports causal modeling of observational data through the estimation and evaluation of propensity scores and associated weights. In our application, the propensity score represented the probability that a particular trial would be of each medication.¹⁶ We estimated propensity scores with multinomial logistic regression using generalized booster effects,¹⁷ in which the dependent variable is an indicator for each of the five medications and the independent variables are an anti-parsimonious specification of variables that have a plausible correlation with the outcome (i.e. our six groups of covariates).^{16,17} Using these propensity scores, we weighted participants in order to balance the covariate distributions across medications.

We compared continuous and categorical outcomes among the five groups with regression analyses, using medication received as the sole independent variable. In

general, weighted means can have greater sampling variance than unweighted means. Therefore, we used survey commands, which account for the weights, to perform the outcomes analyses when comparing the weighted groups. These weighted groups were defined by the inverse of the propensity scores and adjusted covariates unbalanced at the $p < 0.01$ level after TWANG weighting. In balancing over 50 covariates, a Bonferroni correction would indicate a corrected alpha of $p < 0.001$. However, we conservatively maintained an alpha threshold of $p < 0.01$ for significant differences to avoid type II error. For acute-phase continuous outcomes of pre/post change in total PCL score and sub-scores, we used linear regression analysis, whereby the coefficient of the variable tests the hypothesis that each of the five psychotropic medications has the same mean change from baseline to follow-up. For our categorical outcome of remission, we used logistic regression analysis, whereby the coefficient of the variable tests the hypothesis that each of the five psychotropic medications results in the same percentage of patients achieving remission. We assessed the potential contribution of unmeasured confounding on significant baseline to follow-up comparisons by calculating E-values, which indicate the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the exposure and the outcome, conditional on the measured covariates, to fully explain away a specific exposure-outcome association.^{18,19}

Finally, for the continuation phase we used a weighted proportional hazard models to measure differences in acute psychiatric services use in the subsequent 6-month continuation phase, controlling for symptom change during the acute phase as well as whether there was prescription fill evidence that patients continued to take each medication. We performed data management in SAS version 9.4 (SAS Institute), and

developed causal models in R version 3.5.0 (R core team). This included IPTW models created using the R TWANG package,¹⁵ and models to detect unmeasured confounding using the R EVALUE package.²⁰

Results

There were 834 AMTs aligned with PCL measurement and 38,089 AMTs that were not aligned with PCL measurement. Patients who had AMTs aligned with PCL measurement generally contributed only one trial (Table 2), had received few adequate prior trials of evidence-based treatments for PTSD, and had severe baseline PTSD symptoms ($M=57.8$; $SD=11.1$). Inclusion of data from the early implementation of the EMR-based PCL-5 tool (10/1/2014-9/30/2016) would have yielded a maximum of 21 additional AMTs aligned with PCL measurement while making the analytic cohort less representative of the overall population receiving AMTs during the period of examination. There were 16 cases where AMTs aligned with PCL measurement overlapped, and all of these cases involved concurrent prescribing of topiramate with one of the four antidepressants. AMTs associated with PCL measurement in our analytic cohort differed from contemporaneous AMTs without PCL measurement in many ways (Table 3). Most notably, AMTs with measurement coincided with higher levels of all forms of individual and group psychotherapy, including PE, CPT-I, and CPT-G.

The number of participants in the analytic cohort receiving each medication ranged from 307 who received sertraline to 87 who received paroxetine. While there were differences among the medication treatment groups (Supplementary Table 1), our weighting procedure allowed us to balance almost all covariates (Supplementary Table 2). The exceptions were the percentage of time the primary prescribing clinician spent

working in the integrated care service section and the percentage of Vietnam veterans receiving each medication, with both being significantly lower in the topiramate group. Therefore, these variables were retained as covariates, along with a covariate for concurrent antidepressant and topiramate prescribing, in subsequent analyses. PTSD symptom measurement was well-aligned to acute-phase medication treatment, with participants' baseline PCLs administered at 1.1 days (SD=6.4) days after the start of the medication and end-point PCLs were administered at 80.8 days (SD=10.3) later. Mean baseline PCL scores indicated a high burden of symptoms, ranging tightly from 57.5 (SD=10.9) for the sertraline group to 58.6 (SD=11.8) for the venlafaxine group.

All five of the medications were associated with moderate acute phase improvements in PTSD symptoms (Table 4). The mean improvement in total PCL score ranged from 6.8 points for the paroxetine and topiramate groups to 10.1 points for the venlafaxine group; acute phase remission rates ranged from 0% for the paroxetine group to 10.9% for the venlafaxine group. While there was no difference in total PCL change between the agents, there was a significant overall difference in achievement of remission ($p<0.0001$). Pairwise comparisons indicated superior achievement of remission between the venlafaxine group compared to other groups (venlafaxine versus fluoxetine $p=0.008$, venlafaxine versus paroxetine, sertraline, and topiramate $p<0.0001$). We could not calculate E-values for comparisons involving paroxetine as there were no remissions in the paroxetine group. However, where they could be calculated, E-values indicated the superior achievement in acute phase for the venlafaxine group to be robust (venlafaxine versus fluoxetine 7.3, versus sertraline 4.2, versus topiramate 15.2). Similarly, pairwise comparisons indicated inferior achievement of remission for paroxetine compared to all

other groups ($p < 0.0001$). Finally, sertraline was significantly superior to topiramate in achievement of acute phase remission ($p < 0.0001$; $E = 6.0$).

There was a very limited range of change in PTSD symptom clusters and sleep item scores, with the greatest differences being between change in negative alterations in cognitions and mood for the venlafaxine group versus the other groups (-4.2 for venlafaxine versus -2.2 to -2.8 for the other groups). However, these differences were not statistically significant.

In our weighted survival analysis examining acute psychiatric care use in the six-month continuation phase, there were 57 events. We added a time-varying co-variate for whether patients stayed on their medication in the continuation phase and controlled for change in total PCL during the acute phase in addition to the unbalanced covariates. While we found no difference between medications in acute psychiatric care use during the continuation phase, there was a significant protective effect for medication adherence ($HR = 0.55$; $p = 0.03$).

Discussion

We compared the effectiveness of five evidence-based medications for DSM-5 PTSD and found that they all appear to be effective in routine clinical practice. Furthermore, we found evidence of possible superiority of venlafaxine in achieving acute phase remission. Though there were no between-groups differences in the continuation phase, our findings indicate that medication continuation beyond the initial 12 weeks of treatment is associated with lower risk of acute psychiatric care use such as psychiatric admission. This finding, combined with our finding that patients in all groups experienced a modest level of symptomatic improvement during the acute phase, even after controlling for other

important patient and concurrent treatment factors, supports our assertion that these five agents are effective in clinical practice. Our findings are consistent with meta-analytic findings that have suggested that fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine are efficacious treatments for PTSD in RCTs.^{4,5}

We believe this study achieved our goal of improving upon the prior VA study comparing these five agents in routine practice,⁶ and these changes may have accounted for the differences in findings. Firstly, we achieved far better standardization of treatment duration. While there was a wide range of time between baseline and follow-up symptomatic measurements in the prior VA study (mean length of 254.1 days; SD=119.5 days), we standardized the trial length and achieved a treatment duration that better approximated the typical acute phase clinical trial (mean length of 80.8 days; SD=10.3 days). Thus, we have significantly decreased the heterogeneity of exposure and improved the comparability of our retrospective results with those of prospective studies. Standardizing the acute phase treatment period also allowed us to add a continuation phase and related functional outcome (acute psychiatric services use). Second, we have accounted for prior evidence-based PTSD treatment receipt, including both psychotherapy and medication. We found that 19.0% of patients had previously received an adequate evidence-based medication trial and 6.8% had previously received an adequate evidence-based psychotherapy trial. Measuring this allowed us to account for differing levels of treatment resistance, as patients in the paroxetine, topiramate, and venlafaxine groups were more likely to have received prior adequate evidence-based medication trials. Third, this study used the PCL-5. The PCL-5 represents the current case conceptualization of PTSD. Importantly in this version, the avoidance and numbing items were split into

separate clusters, and additional items have been added to the prior numbing items to make the new negative alterations in cognitions and mood cluster. While the finding was not statistically significant, it was notable that patients in the venlafaxine group had the greatest magnitude of change in the negative alterations in cognitions and mood cluster. These symptoms were emphasized in the transition between DSM-IV and DSM-5 definitions of PTSD. Thus, better standardization of treatment duration, an ability to account for prior treatment resistance, and changes in the PTSD case definition may have all contributed to our finding of possible acute phase superiority for venlafaxine over other agents.

While we found that all the medication treatments for PTSD that we studied were effective in clinical practice, their effect seemed somewhat reduced compared to that seen in the clinical trials. Such comparisons are difficult to make precisely in all cases because various studies use different measures and allowed various concurrent treatments. However, as an example, Rauch et al.'s recent four-site VA and private sector study of PTSD treatment approaches for Iraq and Afghanistan Veterans included a sertraline plus enhanced medication management arm.²¹ Enhanced medication management consisted of eight manualized 30-minute appointments over the first 12 weeks for those randomized to sertraline.²² Sessions included psychoeducation and support from prescribing clinicians. Participants experienced a decrease PTSD symptom severity from 56.2 to 42.8 on the version of the PCL corresponding to DSM-IV over the first 12 weeks. This translates to an approximately 15-point improvement on the PCL-5,²³ and compares to a 7.5-point PCL-5 improvement in our sertraline group. The reasons for possible reduction in effectiveness are unknown. One possibility is that that enhanced medication management practices are

uncommon in routine practice, but as in psychotherapy, manualization may be required to obtain maximum benefit from psychopharmacologic approaches to treat PTSD.

There are several major limitations to our study, all of which are inherent to our uncontrolled, retrospective cohort design. First, participants meeting PCL-based inclusion criteria for our analytic cohort differed significantly from those receiving adequate medication trials without PCL measurement in several ways. Most notably, those with aligned PCL measurement received far more psychotherapy. The limited availability of PCL data indicates low use of measurement-based care (MBC) in routine psychopharmacology practice, despite a VA initiative to promote MBC starting in 2016.²⁴ Low use of MBC indicates an emerging quality problem,²⁵ as proactive measurement-driven approaches to psychotropic prescribing are associated with superior clinical outcomes.²⁶ Moreover, we have no clear understanding of whether these findings would apply to non-veterans with PTSD. Second, we were unable to measure all related aspects of care. As an example, we could not measure medication adherence or psychotherapy protocols that are less frequently in the VA such as EMDR. However, while patients could have met our prescribing standard with a single 90-day initial supply, 77.3% of patients finished their initial supply and requested refills. Lastly, we only considered PTSD outcomes and acute psychiatric care use, with PTSD outcomes based on a self-report measure. Depression and quality of life measures were not available, but they may have enriched our exclusive focus on PTSD outcomes.

We conclude that there may be an advantage to venlafaxine over other established medications in achieving acute-phase remission for DSM-5 PTSD routine clinical practice. However, additional prospective research is needed to confirm this result. Regardless of

the agent chosen, medication cessation during the continuation phase is associated with a higher risk of acute psychiatric care use. Our study lacks adequate sample size to adequately address issues regarding either specific medication effects on specific symptoms or patient characteristics that predict response with a particular medication. These are both fertile areas for future research.

Clinical Points:

- Five medications for PTSD with consistent efficacy in metaanalyses of randomized controlled trials—including fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine—are also effective in routine clinical practice.
- It appears that venlafaxine may have superior effects in helping patients achieve acute phase (12-week) remission, but this requires further study.
- Regardless of which agent is used, medication adherence in the continuation phase (subsequent 6 months) is associated with superior functioning, as indicated by less use of acute psychiatric services.

Additional Information: The VA Corporate Data Warehouse (CDW) contains electronic medical record data compiled from individual VA facilities and is described at http://www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm. Data are stored on geographically dispersed server farms. To access the CDW, researchers generally need to have an employment relationship with the VA. After local institutional review board approval, requests for data are submitted to VA National Data Systems using the Data

Access Request Tracker. Datasets are then built and analyzed in secure virtual project workspaces within the VA Informatics and Computing Infrastructure environment.

Researchers with VA network access can obtain descriptions of CDW data at

<http://vaww.virec.research.va.gov/>.

Podcast Text:

In this study, which used the treatment records of all patients treated in the Veterans Health Administration, authors determined that five medications that had been shown effective to treat PTSD in research studies also appear to work in real world clinical use. The medications fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine all led to improvements in PTSD symptoms during the 12-week acute treatment phase and improved functioning in the 6-month continuation phase. Patients in the venlafaxine group were more likely to experience remission of their PTSD symptoms during the acute phase, compared to patients in the other treatment groups. However, the possible superiority of venlafaxine over other established medications in achieving acute-phase remission for DSM-5 PTSD should be evaluated with additional prospective research.

REFERENCES

1. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders : DSM-5*. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
2. Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey

- on Alcohol and Related Conditions-III. *Soc Psychiatry Psychiatr Epidemiol*. 2016;51(8):1137-1148.
3. Greenberg G, Hoff R. *2016 Veterans with PTSD data sheet: National, VISN, and VAMC tables*. West Haven, CT: Northeast Program Evaluation Center; 2016.
 4. Jonas DE, Cusack K, Forneris CA, et al. In: *Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)*. Rockville (MD): Agency for Healthcare Research and Quality; 2013.
 5. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. *J Clin Psychiatry*. 2013;74(6):e541-550.
 6. Shiner B, Westgate CL, Gui J, et al. A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice. *J Clin Psychiatry*. 2018;79(5).
 7. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision: DSM-IV-TR*. Arlington, VA: American Psychiatric Association; 2000.
 8. Friedman MJ, Kilpatrick DG, Schnurr PP, Weathers FW. Correcting Misconceptions About the Diagnostic Criteria for Posttraumatic Stress Disorder in DSM-5. *JAMA Psychiatry*. 2016;73(7):753-754.
 9. Guina J. Changes to the Definition of Posttraumatic Stress Disorder in the DSM-5. *JAMA Psychiatry*. 2016;73(11):1201-1202.

10. Hoge CW, Yehuda R, Castro CA, et al. Unintended Consequences of Changing the Definition of Posttraumatic Stress Disorder in DSM-5: Critique and Call for Action. *JAMA Psychiatry*. 2016;73(7):750-752.
11. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The PTSD Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *J Trauma Stress*. 2015;28(6):489-498.
12. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. *Psychol Assess*. 2016;28(11):1379-1391.
13. Schnurr PP, Chard KM, Ruzek JI, et al. Design of VA Cooperative Study #591: CERV-PTSD, comparative effectiveness research in veterans with PTSD. *Contemp Clin Trials*. 2015;41:75-84.
14. Maguen S, Madden E, Patterson OV, et al. Measuring Use of Evidence Based Psychotherapy for Posttraumatic Stress Disorder in a Large National Healthcare System. *Adm Policy Ment Health*. 2018;45(4):519-529.
15. Ridgeway G, McCaffrey DF, Morral AR, Burgette LF, Griffin BA. *Toolkit for Weghting and Analysis of Nonequivalent Groups: A Tutorial for the TWANG Package*. Santa Monica, CA: RAND Corporation; 2017.
16. Stuart EA. Matching methods for casual inference: a review and a look forward. *Statistical Science*. 2010;25(1):1-21.
17. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. *Stat Med*. 2013;32(19):3388-3414.

18. Haneuse S, VanderWeele TJ, Arterburn D. Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. *Jama*. 2019;321(6):602-603.
19. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med*. 2017;167(4):268-274.
20. Mathur MB, Ding P, VanderWeele TJ. Package 'EValue': Sensitivity Analyses for Unmeasured Confounding in Observational Studies and Meta-Analyses. <https://cran.r-project.org/web/packages/EValue/EValue.pdf>. Published 2018. Accessed March 11, 2019.
21. Rauch SAM, Kim HM, Powell C, et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2019;76(2):117-126.
22. Rauch SAM, Simon NM, Kim HM, et al. Integrating biological treatment mechanisms into randomized clinical trials: Design of PROGrESS (PROlonGed ExpoSure and Sertraline Trial). *Contemp Clin Trials*. 2018;64:128-138.
23. Moshier SJ, Lee DJ, Bovin MJ, et al. An Empirical Crosswalk for the PTSD Checklist: Translating DSM-IV to DSM-5 Using a Veteran Sample. *J Trauma Stress*. 2019;32(5):799-805.
24. Resnick SG, Hoff RA. Observations from the national implementation of Measurement Based Care in Mental Health in the Department of Veterans Affairs. *Psychol Serv*. 2019.

25. Muir HJ, Coyne AE, Morrison NR, Boswell JF, Constantino MJ. Ethical implications of routine outcomes monitoring for patients, psychotherapists, and mental health care systems. *Psychotherapy (Chic)*. 2019;56(4):459-469.
26. Fortney JC, Unutzer J, Wrenn G, et al. A Tipping Point for Measurement-Based Care. *Psychiatr Serv*. 2017;68(2):179-188.

TABLES & APPENDICIES

Table 1: Explanation of covariates

Trial Characteristics	
Number of Adequate Medication Trials (AMTs) Aligned with PTSD Checklist (PCL) Measurement	Adequate trials of fluoxetine, paroxetine, sertraline, topiramate, or venlafaxine aligned with PCL measurement that each patient contributed to the outcomes analysis. Trials of different agents could overlap or dovetail, but we required a one-year gap in prescriptions to count as a new trial of the same agent.
PCL Severity and Timing	Baseline PCL score, number of days between first available PTSD diagnosis and baseline PCL, number of days from baseline PCL to follow-up PCL for each trial included in the outcomes analysis.
Number of Prior AMTs	AMTs with or without PCL measurement between 1999 and the start of each trial included in the outcomes analysis.
Number of Prior Adequate Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT) Trials ^a	Episodes where patients received ≥8 sessions PE or CPT over the course of one year between 1999 and the start of each medication trial included in the outcomes analysis.
Concurrent Treatments	
<i>Psychotherapy</i>	Categorical receipt and number of sessions
PE ^a	Individual only
CPT ^a	Group and individual
Other psychotherapy	Group and individual
<i>Medications</i>	Categorical receipt of other antidepressants, sedative hypnotics, opioids, atypical antipsychotics, prazosin, medications for alcohol abuse including naltrexone or acamprosate, and opioid replacement medications including buprenorphine or methadone prescribed within the context of methadone treatment clinic
Primary Prescribing Clinician Characteristics	
Age	Continuous
Gender	Categorical male or female
Professional background	e.g. psychiatrist or nurse practitioner
Percent of time spent seeing PTSD patients in various settings	e.g. specialized PTSD clinic or primary care clinic, based on assumption that prescribing clinicians who spend a higher percentage of their time in specialized PTSD settings may bring increased knowledge and experience in treating PTSD, even when seeing patients in non-specialized settings.
Baseline Patient Characteristics	
VA Health Service use Characteristics	
Outpatient visits	e.g. visits to specialized PTSD clinics or to primary care clinics
Acute psychiatric care use	e.g. emergency department visits for psychiatric indications or psychiatric hospitalizations

Residential treatment	e.g. stays in residential PTSD or substance abuse programs
Psychiatric Comorbidities	Psychiatric diagnoses in the two years preceding the baseline PCL measurement

EBP use was measured with a natural language processing algorithm that classifies psychotherapy notes in individual and group delivery formats.¹⁴

Table 2: Characteristics of New Trials of Adequate Dose and Duration Evidence-Based Medications for PTSD, with aligned PCL Measurement, including start dates from October 1, 2016 through March 7, 2018

<u>Number of AMTs Aligned with PCL Measurement Patients Contribute</u>	
1, %(n)	94.2 (786)
2, %(n)	5.8 (48)
<u>Number of Prior AMTs since October 1, 1999 (with or without PCL)</u>	
0, %(n)	81.1 (676)
1, %(n)	15.0 (125)
2+, %(n)	4.0 (33)
<u>Number of Prior Adequate PE or CPT Trials since October 1, 1999 (with or without PCL)</u>	
0, %(n)	93.2 (777)
1, %(n)	6.2 (52)
2+, %(n)	0.6 (5)
<u>Timing of PCL Measurement Relative to AMT</u>	
Days from First Available PTSD Diagnosis to Baseline PCL, M (SD)	1,074.6 (1,378.7)
Days from Baseline PCL to Follow-Up PCL, M (SD)	80.8 (10.3)
Baseline PCL Score, M (SD)	57.8 (11.1)

Abbreviations. PTSD=posttraumatic stress disorder, PCL=PTSD Checklist, FY=Fiscal Year, AMT=Adequate Medication Trial (12 or more weeks of fluoxetine, sertraline, topiramate, paroxetine, or venlafaxine at required dose at a minimally adequate dose), PE=Prolonged Exposure, CPT=Cognitive Processing Therapy

Table 3: Comparison of New Trials of Adequate Dose and Duration Evidence-Based Medications for PTSD, with and without aligned PCL Measurement, including start dates from October 1, 2016 through March 7, 2018

	Trials without PCL Measurement (n=38,089)	Trials with PCL Measurement (n=834)
Concurrent Treatment		
Any PE, % (n)***	0.8 (319)	8.2 (68)
Sessions of PE, M (SD)*	3.6 (2.8)	4.5 (3.1)
Any Individual CPT, % (n)***	2.7 (1,018)	29.6 (247)
Sessions of Individual CPT, M (SD)***	3.6 (2.9)	5.2 (3.3)
Any Group CPT, % (n)***	1.1 (421)	8.4 (70)
Sessions of Group CPT, M (SD)*	4.6 (4.3)	5.8 (4.2)
Any Non-PE/CPT Individual Therapy, % (n)***	32.2 (12,264)	62.2 (519)
Any Non-CPT Group Therapy, % (n)***	15.2 (5,792)	30.9 (258)
Any Non-F/S/P/V Antidepressant, % (n)*	51.9 (19,749)	56.0 (467)
Any Non-Topiramate Anticonvulsant, % (n)	28.7 (10,924)	27.2 (227)
Any Sedative/Hypnotics, % (n)***	21.9 (8,334)	16.1 (134)
Any Opioid, % (n)***	13.5 (5,149)	9.0 (75)
Any Atypical Antipsychotic, % (n)	16.8 (6,380)	15.2 (127)
Any Prazosin, % (n)***	29.3 (11,143)	40.5 (338)
Any Naltrexone or Acamprosate, % (n)**	2.9 (1,097)	4.8 (40)
Any Opioid Replacement Therapy, % (n)	1.3 (483)	1.3 (11)
Primary Prescribing Clinician Characteristics		
Age, M (SD)**	51.0 (12.1)	49.6 (12.3)
Women, % (n)	37.9 (14,449)	37.1 (309)
Psychiatrist, % (n)*	40.9 (15,588)	45.2 (377)
Other Physician, % (n)***	31.8 (12,103)	22.2 (185)
Physician Assistant, % (n)	4.3 (1,651)	4.9 (41)
Nurse Practitioner, % (n)	18.0 (6,858)	18.6 (155)
Pharmacist, % (n)***	2.9 (1,120)	8.6 (72)
Percentage of Time Seeing PTSD Patients in Various Settings		
PTSD Service Section (PCT or residential), M (SD)***	5.7 (19.7)	9.4 (24.1)
Substance Abuse Service Section, M (SD)	2.5 (11.4)	2.1 (9.0)
General Mental Health Service Section, M (SD)***	76.7 (39.7)	82.7 (34.3)
Integrated Care Service Section, M (SD)***	5.6 (17.3)	8.1 (21.1)
Primary Care Service Section, M (SD)***	18.3 (37.3)	12.0 (31.1)
Patient Characteristics at Baseline		
Age, M (SD)***	46.5 (14.6)	40.9 (11.1)
Women, % (n)	16.9 (6,434)	16.1 (134)
Married, % (n)	54.9 (20,925)	55.8 (465)
Rural, % (n)	33.6 (12,789)	33.0 (275)
White Non-Hispanic, % (n)	63.2 (24,079)	60.8 (507)
Black Non-Hispanic, % (n)	20.6 (7,835)	18.1 (151)
Hispanic, % (n)***	9.2 (3,491)	13.3 (111)
OEF/OIF/OND Veteran, % (n)***	48.7 (18,533)	68.9 (575)
Vietnam Veteran, % (n)***	11.9 (4,535)	4.0 (33)
Combat Exposure, % (n)***	42.2 (16,069)	49.9 (416)
Sexual Trauma while in Military, % (n)	14.9 (5,688)	15.1 (126)
VA Disability Level 70% or Greater, % (n)	49.7 (18,933)	50.8 (424)
Service Use Characteristics in the 1 Year Preceding Baseline		

Any PTSD Outpatient Clinical Team Visits, % (n)***	19.1 (7,260)	33.7 (281)
Number of PTSD Outpatient Clinical Team Visits, M (SD)	9.6 (15.7)	9.6 (11.2)
Any Outpatient Mental Health Visits, % (n)	88.3 (33,612)	88.1 (735)
Number of Outpatient Mental Health Visits, M (SD)***	20.6 (42.1)	26.9 (45.5)
Any Outpatient Substance Abuse Visits, % (n)***	11.0 (4,205)	15.4 (128)
Number of Outpatient Substance Abuse Visits, M (SD)	22.9 (37.7)	21.9 (42.7)
Any Outpatient Primary Care Visits, % (n)***	87.9 (33,495)	82.1 (685)
Number of Outpatient Primary Care Visits, M (SD)***	7.1 (7.8)	6.0 (5.9)
Any ED Visits for Psychiatric Indication, % (n)	13.1 (4,979)	13.2 (110)
Number of ED Visit for Psychiatric Indication, M (SD)	2.1 (2.2)	1.8 (1.6)
Any Acute Inpatient Mental Health Treatment, % (n)**	8.6 (3,257)	11.3 (94)
Days of Acute Inpatient Mental Health, M (SD)	16.1 (24.8)	17.8 (23.3)
Any Residential PTSD Treatment, % (n)***	1.0 (364)	2.9 (24)
Days Residential PTSD Treatment, M (SD)	44.8 (40.7)	28.8 (21.0)
Any Residential Substance Abuse Treatment, % (n)	1.9 (728)	2.5 (21)
Days Residential Substance Abuse Treatment, M (SD)	43.2 (43.3)	39.3 (33.6)
Any Integrated Care Visits, % (n)***	26.5 (10,110)	35.3 (294)
Days Integrated Care Visits, M (SD)	3.9 (7.9)	3.1 (4.3)
Any Neurology Visits, % (n)	12.1 (4,596)	10.1 (84)
Days Neurology Visits, M (SD)	2.4 (2.3)	2.3 (1.8)
Any Sleep Clinic Visits, % (n)	14.7 (5,597)	14.6 (122)
Days Sleep Clinic Visits, M (SD)	2.2 (1.6)	2.3 (1.8)
Any Polytrauma TBI Specialty Clinic Visits, % (n)***	6.3 (2,379)	11.5 (96)
Days Polytrauma TBI Specialty Clinic Visits, M (SD)	4.7 (13.7)	3.3 (4.7)
Comorbidities in the 2 Years Preceding Baseline		
Pain Disorder, % (n)	80.7 (30,749)	80.9 (675)
Headache Disorder, % (n)***	31.4 (11,974)	36.9 (308)
Psychotic Disorders, % (n)***	3.8 (1,449)	1.6 (13)
Bipolar Mood Disorders, % (n)*	8.2 (3,103)	6.0 (50)
Depressive Mood Disorders, % (n)***	73.0 (27,802)	80.8 (674)
Anxiety Disorders, % (n)	46.8 (17,840)	50.0 (417)
Traumatic Brain Injury, % (n)***	8.6 (3,267)	14.8 (123)
Alcohol Use Disorders, % (n)***	27.6 (10,522)	33.3 (278)
Opioid Use Disorders, % (n)*	5.7 (2,176)	7.3 (61)
Other Substance Use Disorders, % (n)***	16.6 (6,337)	21.0 (175)

*p<0.05, **p<0.01, ***p<0.001

Abbreviations. PTSD=posttraumatic stress disorder, PCL=PTSD Checklist, FY=Fiscal Year, PE=Prolonged Exposure, CPT=Cognitive Processing Therapy, F/S/P/V=Fluoxetine/Sertraline/Paroxetine/Venlafaxine, PCT=PTSD Care Team, OEF/OIF/OND=Operations Enduring Freedom/Iraqi Freedom/New Dawn, VA=Department of Veterans Affairs.

Table 4: Weighted Outcomes for Patients with an Adequate Trial of an Effective Medication for PTSD plus PCL Measurement

Agent	Fluoxetine (n=228)	Paroxetine (n=87)	Sertraline (n=307)	Topiramate (n=96)	Venlafaxine (n=116)	Pairwise Differences*
Raw Outcomes						
Baseline PCL Score, M (SD)	58.5 (11.7)	58.4 (11.3)	57.5 (10.9)	58.3 (15.0)	58.6 (11.8)	No differences
Change in PCL, M (SD)	-8.1 (15.0)	-6.8 (16.0)	-7.5 (12.2)	-6.8 (14.0)	-10.1 (19.5)	No differences
Remission of PTSD, % (n)	2.9 (8)	0.0 (0)	4.7 (14)	1.3 (2)	10.9 (9)	FSTV≠P; FPST≠V; S≠T
Symptom Clusters						
Baseline Reexperiencing, M (SD)	14.4 (3.6)	14.4 (3.6)	14.3 (3.8)	15.1 (3.5)	14.3 (3.9)	No differences
Change in Reexperiencing, M (SD)	-1.8 (4.2)	-1.6 (4.9)	-1.8 (3.6)	-1.8 (4.5)	-2.1 (5.2)	No differences
Baseline Avoidance, M (SD)	6.5 (1.5)	6.3 (1.8)	6.3 (1.6)	6.4 (1.8)	6.2 (1.9)	No differences
Change in Avoidance, M (SD)	-1.1 (2.4)	-0.8 (2.2)	-0.7 (1.8)	-0.7 (2.9)	-1.0 (2.6)	No differences
Baseline NACM, M (SD)	19.9 (4.6)	19.5 (5.6)	19.4 (5.2)	19.5 (6.0)	20.6 (5.3)	No differences
Change in NACM, M (SD)	-2.8 (6.2)	-2.4 (6.2)	-2.5 (5.1)	-2.2 (5.5)	-4.2 (7.6)	No differences
Baseline Hyperarousal, M (SD)	17.4 (3.9)	17.9 (3.8)	17.3 (3.9)	17.2 (7.1)	17.2 (4.7)	No differences
Change in Hyperarousal, M (SD)	-2.5 (5.2)	-2.1 (5.6)	-2.5 (4.0)	-2.1 (5.1)	-2.8 (6.2)	No differences
Baseline Sleep, M (SD)	6.0 (1.8)	6.1 (1.6)	6.2 (1.7)	6.3 (1.9)	6.1 (1.8)	No differences
Change in Sleep, M (SD)	-0.7 (2.1)	-0.8 (2.3)	-1.1 (1.8)	-0.9 (2.3)	-0.9 (2.7)	No differences

*Significant Differences are assessed at $p < 0.05$ for the Omnibus comparison, with pair-wise testing where indicated.

Abbreviations. PTSD=Posttraumatic Stress Disorder, PCL=PTSD Checklist, NACM=Negative Alterations in Cognitions and Mood

Administration and Policy in Mental Health and Mental Health Services Research

Measurement Strategies for Evidence-Based Antidepressants for Posttraumatic Stress Disorder Delivery: Trends and Associations with Patient-Reported Outcomes --Manuscript Draft--

Manuscript Number:		
Full Title:	Measurement Strategies for Evidence-Based Antidepressants for Posttraumatic Stress Disorder Delivery: Trends and Associations with Patient-Reported Outcomes	
Article Type:	Original, Unpublished Article	
Section/Category:	General - No Particular Section	
Keywords:	Quality of Healthcare; Patient Reported Outcomes Measures; Comparative Effectiveness Research; Psychopharmacology; Stress Disorders, Posttraumatic	
Corresponding Author:	Brian Shiner, MD, MPH VA Medical Center, White River Junction White River Junction, VT, UNITED STATES	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	VA Medical Center, White River Junction	
Corresponding Author's Secondary Institution:		
First Author:	Brian Shiner, MD, MPH	
First Author Secondary Information:		
Order of Authors:	Brian Shiner, MD, MPH	
	Christine Leonard Westgate, MS	
	Jiang Gui, PhD	
	Sarah Cornelius, BS	
	Jaimie L. Gradus, DMSc, DSc	
	Paula P. Schnurr, PhD	
	Bradley V. Watts, MD, MPH	
Order of Authors Secondary Information:		
Funding Information:	Health Services Research and Development (CDA11-263)	Dr. Brian Shiner
	U.S. Department of Defense (PR160206)	Dr. Brian Shiner

Running head: MEASUREMENT STRATEGIES FOR EBA FOR PTSD DELIVERY

Measurement Strategies for Evidence-Based Antidepressants for Posttraumatic Stress Disorder
Delivery: Trends and Associations with Patient-Reported Outcomes

Brian Shiner, MD, MPH, Staff Physician¹⁻³; Christine Leonard Westgate, MS, Data Analyst¹;
Jiang Gui, PhD, Biostatistician²; Sarah Cornelius, BS, Research Coordinator¹; Jaimie L. Gradus,
DMSc, DSc, Epidemiologist⁵; Paula P. Schnurr, PhD, Executive Director²⁻³; Bradley V. Watts,
MD, MPH, Executive Director^{2,4}

¹White River Junction VA Medical Center, White River Junction VT

²Geisel School of Medicine at Dartmouth, Hanover NH

³National Center for PTSD Executive Division, White River Junction VT

⁴VA Office of Systems Redesign and Improvement, Washington DC

⁵Boston University School of Public Health, Boston MA

Author Note

A VA Health Services Research & Development Career Development Award to Dr. Shiner (CDA11-263) funded the development of this cohort. A DoD Peer Reviewed Medical Research Program Award to Dr. Shiner (PR160206) funded the development of our strategy to leverage patient-reported outcomes data.

The opinions expressed herein are those of the authors and do not necessarily reflect the positions of the United States Department of Veterans Affairs or the United States Department of Defense.

Correspondence concerning this article should be addressed to Brian Shiner, MD, MPH;
White River Junction VA Medical Center, 215 North Main Street, White River Junction VT,
05009

Abstract

We sought to develop a quality standard for the prescription of antidepressants for posttraumatic stress disorder (PTSD) that is both consistent with the underlying evidence supporting antidepressants as a treatment for PTSD and associated with the best levels of symptom improvement. We quantified antidepressant receipt during the initial year of PTSD treatment in a 10-year national cohort of Department of Veterans Affairs (VA) users who completed patient-reported outcome measurement as part of routine practice. We added progressively stringent measurement requirements. The most stringent requirement was associated with superior outcomes. Prescribing quality for PTSD in the VA was stable over time.

Keywords: Quality of Healthcare; Patient Reported Outcomes Measures; Comparative Effectiveness Research; Psychopharmacology; Stress Disorders, Posttraumatic

Measurement Strategies for Evidence-Based Antidepressants for Posttraumatic Stress Disorder

Delivery: Trends and Associations with Patient-Reported Outcomes

Posttraumatic stress disorder (PTSD) is a mental health condition that sometimes follows exposure to a traumatic event (American Psychiatric Association, 2013). Symptoms include reexperiencing the trauma, avoidance of reminders of the trauma, hyperarousal, and negative cognitions. PTSD affects approximately 6% of the United States (US) population during their lifetime (Goldstein et al., 2016; Pietrzak, Goldstein, Southwick, & Grant, 2011). Rates are higher in combat or military-exposed populations such as veterans who use health services provided by the US Department of Veterans Affairs (VA; Holowka et al., 2014; Shiner, Drake, Watts, Desai, & Schnurr, 2012). Convergent findings from recent meta-analyses indicate that four antidepressant medications are effective treatments for PTSD, including the selective serotonin reuptake inhibitors (SSRI) fluoxetine, sertraline, and paroxetine, as well as the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine (Jonas et al., 2013; Watts et al., 2013). Randomized clinical trials supporting the efficacy of these four evidence-based antidepressants (EBAs) in the treatment of PTSD are 12 weeks in length (Jonas et al., 2013).

A series of national studies have been published about use of antidepressants for PTSD in routine VA practice. Mohamed and Rosenheck (2008) found that of 274,297 VA users with a PTSD diagnosis in the 2004 fiscal year, 71% (195,371) received at least one prescription for any antidepressant. Examining a similar time frame, Spoont, Murdoch, Hodges, and Nugent (2010) measured antidepressant initiation among a more restricted cohort of VA users with new PTSD treatment episodes by excluding those who previously received mental health treatment or antidepressants. Among 20,284 VA users with new PTSD treatment episodes in 2004 and 2005, 50% (10,127) received an antidepressant and 27% (5,487) received a 120-day or greater supply

1
2
3
4 of an antidepressant during the six months following their initial diagnosis. Finally, Abrams,
5
6 Lund, Bernardy, and Friedman (2013) examined a cohort of 356,958 VA users with PTSD who
7
8 regularly received medications from VA pharmacies in the 2009 fiscal year. Among this cohort,
9
10 66% received an SSRI or SNRI and 60% received a 90-day or greater supply of an SSRI or
11
12 SNRI. The results of these three studies are not directly comparable due to differences both in
13
14 cohort selection and outcome. Thus, these studies highlight how methodological choices may
15
16 lead to variation in estimates about the application of PTSD treatment evidence in clinical
17
18 practice.
19
20
21
22

23 Chassin, Loeb, Schmaltz, and Wachter (2010) proposed that to be valid, a quality
24
25 measure must capture whether an evidence-based care process has actually been provided.
26
27 Therefore, while measuring whether patients with PTSD receive an SSRI or SNRI is an
28
29 improvement over measuring whether they receive any antidepressant, a measure of whether
30
31 they receive fluoxetine, sertraline, paroxetine, or venlafaxine would more closely reflect an
32
33 evidence-based process. Similarly, while measuring treatment duration is an improvement over
34
35 examining the receipt of any prescription, it would also be important to determine whether
36
37 patients received the same antidepressant doses that were tested in clinical trials for PTSD. As
38
39 these four EBAs are prescribed for many indications other than PTSD, it also would be important
40
41 to make a stronger determination of whether they are prescribed “for PTSD.” While prescription
42
43 data is not typically associated with an indication, the Spont et al. (2010) strategy of examining
44
45 patients with new diagnoses of PTSD who have not previously received an antidepressant
46
47 excludes prescriptions that are likely to be for indications other than PTSD. Similarly, the
48
49 Spont et al. (2010) 120-day strategy has advantages and disadvantages when compared to the
50
51 Abrams et al. (2013) 90-day strategy. A 120-day supply would necessitate that patients request a
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 refill (as the VA dispenses a maximum supply of 90 days), and prior studies demonstrate that
5
6 requesting a refill is associated with higher rates of medication adherence among VA users
7
8 (Osterberg & Blaschke, 2005). However, this creates a quality standard that is more stringent
9
10 that the evidence supporting the use of treatment, as 120 days is significantly longer than the
11
12 typical 12-week (84 day) clinical trial. Finally, none of the existing studies examine follow-up
13
14 care. Clinical trials establishing the efficacy of psychotropic agents provide the same amount of
15
16 follow up care to patients randomized to active agent or placebo, so cannot be used to determine
17
18 the optimal follow-up regimen.
19
20
21
22

23
24 Due to methodological limitations, available research on use of EBAs for PTSD may
25
26 paint an overly optimistic picture of current practice, potentially obscuring an opportunity to
27
28 improve PTSD care. Our goal was to determine whether there are potentially correctable gaps in
29
30 EBA treatment of PTSD in terms of choosing the correct antidepressants, dosing, treatment
31
32 duration, and follow-up care. Our specific objectives were to: (1) measure the delivery of EBAs
33
34 for PTSD to a national cohort of Veterans initiating PTSD care; (2) determine longitudinal trends
35
36 in EBA for PTSD delivery according to potential quality measures; and (3) to determine whether
37
38 quality standards that more stringently reflect the evidence supporting EBA use are associated
39
40 with superior outcomes.
41
42
43
44

45 46 47 **Method**

48 49 **Data Source**

50
51 We used the VA corporate data warehouse (CDW) to identify patients with new PTSD
52
53 treatment episodes from fiscal year 2004 through fiscal year 2013. We obtained patient
54
55 demographic information as well as encounter, diagnostic, and pharmacy data from the CDW.
56
57 The Dartmouth College Committee for the Protection of Human Subjects, the White River
58
59
60
61
62
63
64
65

Junction VA Medical Center Research and Development Committee, and VA National Data Systems approved this study.

Patients

We included VA users who received a primary diagnosis of PTSD at two or more outpatient encounters, at least one of which occurred in a mental health setting, over the course of 90 days between October 1, 2003 and September 30, 2013, and had not met this criterion during the prior two years. We examined one year of treatment receipt following the first diagnosis of the two qualifying diagnoses. This was called the “index PTSD diagnosis.” When patients met the cohort inclusion criteria multiple times over the 10-year period, only their first episode was included. This resulted in a cohort of 731,520 patients. This cohort has been previously described elsewhere (Shiner, Leonard Westgate, Bernardy, Schnurr, & Watts, 2017; Shiner, Leonard Westgate, Harik, Watts, & Schnurr, 2016; Shiner, Westgate, Bernardy, Schnurr, & Watts, 2017).

Antidepressant Receipt

We examined all medications dispensed by VA pharmacies during the year following the index PTSD diagnosis. Antidepressant drug names were classified into categories for individual agents and an overall category. The antidepressant drug class label was used to confirm our coding. We created categories of antidepressant receipt in four ways. First, we determined whether patients received any antidepressant. Second, we determined the most commonly prescribed antidepressant and determined whether patients received it. Third, we determined whether patients received an antidepressant recommended by the 2010 clinical practice guideline for PTSD from the US Department of Veterans Affairs and Defense (VA/DoD CPG; Friedman, Lowry, & Ruzek, 2010), which were in place at the time care was delivered to patients in our

1 cohort. The 2010 VA/DoD CPG gives A- or B-level recommendations to SSRI/SNRI
2
3
4
5
6 antidepressants, mirtazapine, nefazodone, amitriptyline, imipramine, and phenelzine. Fourth, we
7
8 determined whether patients received any of the four EBAs for PTSD, including fluoxetine,
9
10 paroxetine, sertraline, and venlafaxine.
11
12

13 14 **Covariates**

15
16 We developed three groups of covariates. First, we examined patient characteristics
17
18 including age, gender, race, military service era, rurality, military-related exposures (e.g., combat
19
20 and sexual trauma), and medical and psychiatric comorbidities. Second, we examined service
21
22 use characteristics including prior use of antidepressants, outpatient visits, emergency
23
24 department visits, and admissions. For prior use of antidepressants, we assessed whether patients
25
26 received any antidepressant prescriptions in the 2 years prior to their index PTSD diagnosis.
27
28 Outpatient visits included visits to specialized PTSD clinics, general mental health clinics,
29
30 substance abuse clinics, and primary care clinics. We assessed whether patients had concurrent
31
32 evidence-based psychotherapy for PTSD, including prolonged exposure or cognitive processing
33
34 therapy, using an algorithm to classify psychotherapy notes that has been described elsewhere
35
36 (Maguen et al., 2018), and considered eight or more sessions to be a minimally adequate trial
37
38 (Hale, Bohnert, Ganoczy, & Sripada, 2019). Emergency department visits included emergency
39
40 department visits for a psychiatric indication. Admissions included stays included those to acute
41
42 mental health inpatient wards, residential PTSD treatment programs, or residential substance
43
44 abuse programs. Third, we examined prescribing clinician characteristics. Patients were
45
46 assigned a primary prescribing clinician based on the clinician who wrote the plurality of their
47
48 psychotropic prescriptions. Primary prescribing clinicians were characterized by age, gender,
49
50 professional background, and service section. Professional background included physician,
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 physician assistant, nurse practitioner, and pharmacist. Service section included specialized
5
6 PTSD, general mental health, substance abuse, primary care-mental health integration clinics,
7
8 and primary care. Because prescribing clinicians may work across multiple service sections, we
9
10 calculated the percentage of time they spend seeing PTSD patients in various settings. This was
11
12 based on our assumption that prescribing clinicians who spend a higher percentage of their time
13
14 in specialized PTSD settings may bring increased knowledge and experience in treating PTSD,
15
16 even when seeing patients in non-specialized settings.
17
18
19
20

21 **Measures of Prescribing Quality**

23
24 We examined prescribing quality among the sub-cohort of patients who had not received
25
26 an antidepressant prescription in the two years prior to their index PTSD diagnosis. For patients
27
28 who received a new prescription of any of the four EBAs for PTSD on or after their index PTSD
29
30 diagnosis, we determined whether they received an adequate treatment, which we defined as a
31
32 12-week or more continuous period where patients received the medication at an adequate dose.
33
34 We adjusted days' supply of prescription fills for discontinuations occurring prior to the
35
36 calculated end of a prescription fill. We excluded prescriptions that were never filled, that were
37
38 filled by the pharmacy and never picked up by the patient, or mailed back to the pharmacy
39
40 because they were undeliverable. Also excluded were fills provided as part of research protocols
41
42 and an insignificant number of liquid-based pharmacy orders. Because 12-week clinical trials
43
44 frequently include titration periods (Jonas et al., 2013), we required a dose that was equal to or
45
46 higher than the typical target dose in RCTs supporting the use of these treatments for at least the
47
48 final 8 weeks. We standardized and interpreted titration instructions using regular expressions.
49
50 We ignored initial titration instructions when they were erroneously carried forward to a
51
52 subsequent fill, but did capture new changes to instructions such as dose increases and tapering
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 instructions when present in a subsequent fill. Target doses were fluoxetine 20 mg daily
5
6 (Martenyi, Brown, & Caldwell, 2007; Martenyi, Brown, Zhang, Prakash, & Koke, 2002;
7
8 Martenyi & Soldatenkova, 2006; van der Kolk et al., 1994; van der Kolk et al., 2007), paroxetine
9
10 20 mg daily (Marshall, Beebe, Oldham, & Zaninelli, 2001; Tucker et al., 2001), sertraline 100
11
12 mg daily (K. Brady et al., 2000; K. T. Brady et al., 2005; J. Davidson, Rothbaum, et al., 2006; J.
13
14 R. Davidson, Rothbaum, van der Kolk, Sikes, & Farfel, 2001; Friedman, Marmar, Baker, Sikes,
15
16 & Farfel, 2007; Tucker et al., 2004; Zohar et al., 2002), and venlafaxine 150 mg daily (J.
17
18 Davidson, Baldwin, et al., 2006; J. Davidson, Rothbaum, et al., 2006). We similarly used regular
19
20 expressions to interpret instructions regarding how different strengths of the same EBA from
21
22 multiple pill bottles were to be combined (e.g. 150 mg capsules of Venlafaxine XR are
23
24 commonly combined with 75 mg capsules of Venlafaxine for a total daily dose of 225 mg daily,
25
26 but are also sometimes prescribed as 150 mg and 75 mg doses on alternating days). Use of and
27
28 dose of each EBA over the 365 days following the index PTSD diagnosis was represented as an
29
30 array, so that medication coverage could be aligned with the receipt of other services.
31
32
33
34
35
36
37

38 In addition to dose and days of coverage, we examined several additional possible quality
39
40 measures. Firstly, we added a requirement for at least one refill, as an indication that the patient
41
42 was consuming the medication. For patients who received an initial prescription that covered
43
44 84-90 days, we allowed up to the end of week 14 for receipt of a refill. Secondly, we added a
45
46 requirement that patients had at least one in person or video-based follow-up visit during the
47
48 adequate treatment trial, as an indication that the medication could have been adjusted if there
49
50 was a problem. Eligible clinicians for follow-up visits included the original prescribing
51
52 clinician, the plurality prescribing clinician, or any mental health clinician with prescription
53
54 privileges. Thirdly, we expanded the follow-up requirement to include three encounters with an
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 eligible clinician during the adequate treatment trial, at least one of which was in person or
5
6 video-based (the other two visits could be telephone calls). We chose our follow-up standards to
7
8 be consistent with a VA performance measure for antidepressant medication management in
9
10 place at the time patients in this cohort underwent treatment (Shiner, Watts, Traum, Huber, &
11
12 Young-Xu, 2011).
13
14

15 16 **Patient-Reported Outcomes Assessment** 17

18
19 Availability of structured data from patient-reported outcome measurement using the
20
21 PTSD Checklist (PCL; Weathers, Litz, Herman, Huska, & Keane, 1993) began to increase in
22
23 FY08 (Shiner et al., 2018). Therefore, we obtained available PCL data for the FY08-13 portion
24
25 of the cohort. During these years, the VA used the version of the PCL corresponding to PTSD
26
27 diagnostic criteria in the fourth version of the Diagnostic and Statistical Manual of Mental
28
29 Disorders, called DSM-IV (American Psychiatric Association, 2000). This version of the PCL
30
31 was a 17-item measure with each item rated on a five-point Likert-type scale, resulting in total
32
33 scores ranging from 17 through 85 (Weathers et al., 1993). Respondents were asked to rate how
34
35 much they are bothered by each symptom over the last month. Symptom presence was
36
37 determined by a response of “moderately” or greater (Weathers et al., 1993). Therefore, the tool
38
39 could be used to determine whether patients met minimal symptomatic criteria for PTSD
40
41 according to DSM-IV (one re-experiencing symptom, three avoidance and numbing symptoms,
42
43 and two hyperarousal symptoms). Clinically meaningful improvement has been previously
44
45 defined as a decrease of 10 points or more (Monson et al., 2008). A clinically meaningful
46
47 improvement in PTSD symptoms plus no longer meeting diagnostic criteria for PTSD has been
48
49 shown to be an important marker of improved quality of life (Schnurr & Lunney, 2016).
50
51
52
53
54
55
56

57 **Analysis** 58 59 60 61 62 63 64 65

1
2
3
4 Our analysis plan was divided into descriptive and causal elements. For descriptive
5
6 analyses using the entire FY04-13 cohort, we summarized cohort characteristics and compared
7
8 patients who received antidepressants with those who did not using t-test or χ^2 analysis, as
9
10 appropriate. We described antidepressant receipt for the entire cohort during each fiscal year and
11
12 for the overall 10-year period. We then focused on antidepressant initiation by excluding
13
14 patients who received antidepressants in the 2 years prior to their index PTSD diagnosis and then
15
16 recalculated initiation rates for any of and each of the EBAs for PTSD for each individual fiscal
17
18 year and for the overall 10-year period. We progressively added the measures of prescribing
19
20 quality described above to this sub-cohort.
21
22
23
24

25
26 For causal analyses using patients from the FY08-13 portion of the cohort, we identified
27
28 patients who initiated psychotherapy at progressively higher levels of adherence to our “quality”
29
30 measures (12 weeks at an adequate duration, plus adequate dose, plus a refill, plus 1 follow-up,
31
32 plus 3 follow-ups) and had concurrent symptoms measurement using the PCL (defined below).
33
34 When patients received multiple EBAs during the initial year, we chose the first trial. We created
35
36 orthogonal comparison groups by including patients only in the longitudinally earliest (first
37
38 during treatment year) quality standard that they met. Patients who initiated care that met
39
40 multiple quality standards on the same day were assigned to the strictest standard met on that
41
42 day. From this group, we selected patients who had a minimum of a PCL score within 2 weeks
43
44 of the start of treatment (baseline) and within 2 weeks of the 12-week point (follow-up). To
45
46 ensure patients had active PTSD symptoms at baseline, we required that they meet DSM-IV
47
48 symptomatic criteria on their baseline PCL. When there were multiple PCL scores meeting our
49
50 baseline criterion, we selected the measure closest to the start of treatment. When there were
51
52 multiple PCL scores meeting our follow-up criterion, we selected the measure closest the 12-
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 week point. We calculate two change measures from baseline to follow-up: (1) mean PCL
5
6 change, and (2) percentage with “loss of diagnosis,” which included both no longer meeting
7
8 symptomatic criteria for PTSD plus experiencing a meaningful decrease in symptoms of 10
9
10 points or more.
11
12

13
14 Following a procedure developed in prior work to assess pre/post changes (Shiner et al.,
15
16 2018), we examined both the raw change in PTSD symptoms among those with measurement
17
18 and the patient characteristic-weighted mean change, as well as the percentage of patients
19
20 achieving our loss of diagnosis criterion. Given that we were comparing five progressively strict
21
22 standards (12 weeks at an adequate duration, plus adequate dose, plus a refill, plus 1 follow-up,
23
24 plus 3 follow-ups) comprising ten comparisons (each standard versus all other standards), we
25
26 planned a conservative Bonferroni-corrected alpha of $p < 0.005$ to avoid type I error. We used
27
28 inverse propensity of treatment weighting (IPTW; Stuart, 2010) to balance covariates that have a
29
30 plausible association with the outcome. These covariates included all patient, service use, and
31
32 primary prescribing clinician covariates described above as well as days from index PTSD
33
34 diagnosis to EBA start, baseline PCL score, days from baseline PCL to day 1, days from follow-
35
36 up PCL to day 84, and fiscal year treated. We estimated propensity scores with multinomial
37
38 logistic regression using generalized booster effects (McCaffrey et al., 2013), in which case the
39
40 dependent variable is an indicator for the quality standard met and the independent variables are
41
42 an antiparsimonious specification of covariates. Using these propensity scores, we weighted
43
44 participants in order to balance the covariate distribution. In balancing almost 50 covariates, a
45
46 Bonferroni correction would indicate a corrected alpha of $p < 0.001$. However, we conservatively
47
48 maintained an alpha threshold of $p < 0.01$ for significant differences to avoid type II error.
49
50
51 Therefore, covariates that continued to differ at the $p < 0.01$ threshold after IPTW were included
52
53
54
55
56
57
58
59
60
61
62
63
64
65

as covariates in models of change in PTSD symptoms. We assessed the potential contribution of unmeasured confounding on significant pre/post comparisons by calculating E-values, which indicate the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the exposure and the outcome, conditional on the measured covariates, to fully explain away a specific exposure-outcome association (Haneuse, VanderWeele, & Arterburn, 2019; VanderWeele & Ding, 2017).

In addition to our pre/post measures, we performed a repeated measures model that included all PCL measurements between baseline and follow-up. We used a generalized linear mixed model (GLMM) to account for both within-person and across-person variability. We compared changes in PTSD symptom during the time treatment was delivered, including a time by treatment interaction which measures the change in slope over time among the three treatment groups. The model was weighted by the inverse of the propensity scores and adjusted for any unbalanced covariates. We performed data management in SAS version 9.4 (SAS Institute), and developed causal models in R version 3.5.0 (R core team). This included IPTW models created using the R twang package (Ridgeway, McCaffrey, Morral, Burgette, & Griffin, 2017), and models to detect unmeasured confounding using the R evalua package (Mathur, Ding, & VanderWeele, 2018).

Results

Of the 731,520 patients in our cohort, 83.4% (n=609,808) filled at least one antidepressant prescription during their first year of PTSD treatment. Patients who did and did not fill an antidepressant prescription differed on almost every variable (Table 1), although the differences detected were typically very small and only significant due to the large sample size. Most prominently, those who filled and antidepressant prescription were more likely to have

1
2
3
4 psychiatric and medical comorbidities (in addition to PTSD), and also higher levels of VA
5
6 service-connected disability. They were also far more likely to have received an antidepressant
7
8 in the two years prior to their index PTSD diagnosis and received more visits, admissions, and
9
10 residential treatment in the year following their index PTSD diagnosis. They were slightly less
11
12 likely to receive a minimally adequate trial of evidence-based psychotherapy. Primary
13
14
15 prescribing clinicians were most commonly male, physicians, and working in the general mental
16
17 health service section.
18
19
20

21 In the overall cohort, use of antidepressants, including those recommended in the 2010
22
23 VA/DoD CPG for PTSD, decreased slightly over the 10-year period of examination (Table 2).
24
25 For example, in FY04-05 86.6% filled any antidepressant while 78.9% filled a CPG-
26
27 recommended antidepressant. By FY12-13, those numbers had steadily dropped to 80.6% and
28
29 72.0%, respectively. Use of an EBA for PTSD was very similar at the start and end of the 10-
30
31 year period of observation. In FY04-05, 54.0% filled an EBA and this increased slightly to
32
33 54.7% in FY12-13. However, there was an approximately 10% drop in EBA use across the
34
35 middle years from FY06-FY11. The most sustained decreases in EBA fills were in fluoxetine
36
37 and paroxetine. Sertraline was the most commonly filled EBA. After a brief dip from 25.8% in
38
39 FY04-05 to 17.7% in FY06-07, sertraline fills recovered and increased to 33.4% by FY12-13.
40
41 Venlafaxine fills held steady between 9.0% and 9.9% for most of the period of observation, but
42
43 increased to 12.2% in FY12-13. Notably, trazodone, which was not recommended for PTSD in
44
45 the 2010 VA/DoD CPG, was the most commonly filled antidepressant across all years, with over
46
47 a third of patients filling trazodone prescriptions.
48
49
50
51
52
53
54

55 When we applied quality standards to medication fills among the 52.2% (n=381,698) of
56
57 patients initiating antidepressants after their index PTSD diagnosis, the number meeting those
58
59
60
61
62
63
64
65

standards decreased as the standards became more stringent (Table 3). For example, while 35.4% received at least one EBA fill in their first year of treatment, the figure dropped to 19.6% when we add an adequate duration requirement, 14.8% when we add an adequate dose requirement, 12.7% when we add a refill requirement, 9.7% when we add a one-follow-up requirement, and 4.6% when we add a three-follow-up requirement. In general, added requirements led to similar degradations in treatment adequacy across individual EBAs with the exception of sertraline and venlafaxine, which were more highly impacted by dosing requirements than fluoxetine and paroxetine. With the exception of a dip from 4.4% in FY04-05 to 3.7% in FY06-07, the percentage of patients meeting our most stringent standard held steady over time before increasing to 6.0% in FY12-13. (Appendix 1).

A small number of patients from the FY08-13 cohort who met our increasingly restrictive quality standards had PCL measurement aligned with the start of treatment and the 12-week point, so were included in analyses comparing outcomes among patients who met increasingly strict quality standards. Among the 52,907 patients who received an adequate duration of EBA from FY08-13, 2.0% (1,068) met our PCL-based inclusion criteria. Patients with the required PCL measurement differed from others receiving an adequate dose and duration of EBA in many ways (Table 4). Notably, they were almost 8 years younger, over 30% more likely to be OEF/OIF/OND Veterans, and had half the level of medical comorbidity as measured by the Charleston index, while at the same time having higher rates of depression, anxiety, TBI, alcohol use disorders, and opioid use disorders. Additionally, they had far higher rates of inpatient, residential, and outpatient services use, including a five-fold higher rate of receiving a minimally adequate trial of evidence-based psychotherapy for PTSD. Finally, patients who met our PCL-

1
2
3
4 based inclusion criteria were more likely to be treated by prescribing clinicians who work
5
6 specialized PTSD clinics rather than general mental health clinics.
7
8

9 It was rare for patients who met our PCL-based inclusion criteria to have an adequate
10 dose and duration without at least one follow-up, so the “adequate dose and duration” (n=90) as
11 well as the “adequate dose and duration plus refill” (n=47) groups were collapsed into an
12
13 “adequate dose and duration plus/minus refill” in our causal analysis. Thus, there were six rather
14 than ten comparisons in our pre/post analyses so the Bonferroni-corrected alpha was raised from
15 $p<0.005$ to $P<0.008$. Among patients with measurement, those that met the strictest quality
16 criteria were different from one or more of the less strict groups in many ways (Appendix 2).
17 Most notably patients in the strictest group started EBAs earlier in their index year of treatment
18 and were younger, more likely to be women, less likely to be married, and less likely to be rural.
19 They had higher rates of alcohol and other drug use disorders, and attended more outpatient
20 mental health visits and outpatient substance abuse visits. They were also more likely to receive
21 psychiatric care in the emergency room, acute inpatient mental health, and residential treatment
22 settings. Applying the IPTW procedure resolved these differences (Appendix 3), but one
23 difference between the quality groups remained: those in the one follow-up group had fewer
24 substance abuse visits than patients in the other groups. This unbalanced variable was used as a
25 covariate in weighted analyses.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 In both the unweighted and weighted pre/post comparisons, there were no significant
49 differences in either our continuous outcome of change in PCL or our categorical outcome of 10-
50 point drop in PCL plus loss of diagnosis (Table 5). Across groups in the weighted analysis,
51 continuous change in PCL ranged from -5.4 points to -7.0 points while 10-point drop in PCL
52 plus loss of diagnosis ranged from 10.7% to 17.3%. Because there were no significant pre/post
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 differences between quality groupings, we did not compute E-values to assess the robustness of
5
6 the finding. In the repeated measures analysis, the least strict standard was modeled as a main
7
8 effect, with an intercept of 64.4 points on the PCL. Across all groups, only the strictest standard
9
10 was associated with a small but statistically superior outcome of -1.8 points on the PCL ($t=-2.0$,
11
12 $p=0.045$). No interaction terms between time and quality groupings were significant.
13
14

15 16 17 **Discussion**

18
19 While most patients received an antidepressant during the first year of a VA PTSD
20
21 treatment episode (83.4%), many fewer received an EBA for PTSD (47.8%). Among the sub-
22
23 cohort of patients who were not already prescribed an antidepressant in the two years prior to
24
25 their index PTSD diagnosis, only 35.4% received an EBA. As proposed quality standards based
26
27 on the literature accounted for adequate dose and duration, the proportion who received adequate
28
29 care dropped to less than 15%. If basic follow-up standards were applied, including receiving
30
31 refills of the medications and having three appropriate follow-up visits over the initial 12 weeks
32
33 treatment, the proportion receiving evidence-based care fell to less than 5%. Among those
34
35 initiating an EBA, sertraline was the most commonly used medication (20.6%), and the rate of
36
37 use of other EBAs was similar and ranged from 4.9% to 8.3%. Among patients initiating an
38
39 EBA and meeting our PCL-based criteria for inclusion in causal analyses, there was a
40
41 statistically significant advantage to meeting our strictest quality standard for EBA prescribing,
42
43 which included receiving an adequate dose and duration of fluoxetine, sertraline, paroxetine, or
44
45 venlafaxine plus a refill and three appropriate follow-ups, when compared to receiving an
46
47 adequate duration alone. However, this effect was small at just under two points on the PCL
48
49 over the course of 12 weeks, and was not consistent with findings in the pre/post analysis. This
50
51 indicates that the results should be taken with caution and are less than a complete endorsement
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 of the standard. Regardless, given that this standard is consistent with the underlying evidence
5
6 for EBA treatment as well as more general guidelines for follow-up after the initiation of an
7
8 antidepressant, future researchers should consider using and improving upon our work.
9
10

11 While the high overall rate of antidepressant use in this cohort is consistent with findings
12
13 with findings by Mohamed and Rosenheck (2008), and the high rate of SSRI/SNRI use is
14
15 consistent with findings by Abrams et al. (2013), treatment adequacy for newly-initiated agents
16
17 appears to be lower than described by Spont et al. (2010). Adding any restrictions (duration,
18
19 dosing, refills, follow-ups) to the requirement to prescribe antidepressants that are effective for
20
21 PTSD (rather than any antidepressant) drives the percentage of patients meeting the measure to
22
23 below 20% (and as low as 4.6%) over the subsequent year. This is in contrast to the Spont et al.
24
25 (2010) finding of 27% initiating an adequacy supply of any antidepressant over the six months
26
27 following a new diagnosis of PTSD. The finding by Spont et al. (2010) is likely affected by
28
29 their inclusion of all antidepressants rather than an exclusive focus on EBAs for PTSD.
30
31
32
33
34
35

36 Our findings indicate major opportunities to improve antidepressant prescribing as a way
37
38 to ameliorate PTSD symptoms in the VA. When considering the need to improve prescribing for
39
40 PTSD, our focus on fluoxetine, sertraline, paroxetine, and venlafaxine is more limited than the
41
42 A- and B- level recommendations in the 2010 VA/DoD CPG in place at the time this cohort was
43
44 treated (Friedman et al., 2010). These four EBAs are now the only medications for PTSD
45
46 recommended in the most recent 2017 VA/DoD CPG (The Management of Posttraumatic Stress
47
48 Disorder Work Group, 2017). Given this design, our work is applicable for improving
49
50 prescribing practices moving forward. The depression literature indicates that improving
51
52 antidepressant prescribing as a way to improve outcomes often requires changes that are at the
53
54 same time well-organized and locally relevant (Dietrich et al., 2004; Shiner et al., 2010; Trivedi
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 et al., 2004). Efforts to apply lessons from improving depression care to improving PTSD care
5
6 have been mixed (Engel et al., 2016; Fortney et al., 2015; Schnurr et al., 2013). Therefore,
7
8 awareness regarding the effective medications and their use is necessary but unlikely to be
9
10 sufficient to improve outcomes for patients with PTSD receiving antidepressant treatment
11
12
13
14 (Watts, 2016).
15

16 Across all groups, the mean 12-week pre/post change in PTSD symptoms was modest at
17
18 a 5.4 to 7.0-point decrease on the PCL. This change is not directly comparable results from
19
20 RCTs of antidepressants for PTSD, which do not typically report PCL outcomes (Watts et al.,
21
22 2013). A recent RCT of three PTSD treatment strategies in Veterans at four VA and non-VA
23
24 sites by Rauch, Kim, et al. (2018) showed a dramatically better response in the medication
25
26 treatment group. Patients randomized to manualized enhanced medication management with
27
28 sertraline for PTSD had a mean 12-week pre/post change of 13.4 points on the PCL. The
29
30 enhanced medication management protocol was designed to ensure that patients randomized to
31
32 sertraline received a similar amount of time, psychoeducation, and clinician support as patients
33
34 receiving psychotherapy (Rauch, Simon, et al., 2018). While patient factors could account for the
35
36 less impressive results in our cohort, the Rauch, Kim, et al. (2018) results open the possibility of
37
38 achieving better PTSD outcomes through improved prescribing practices in the VA.
39
40
41
42
43
44

45 There was an unusual trend whereby any use of EBAs decreased significantly during the
46
47 middle years of our period of observation before returning to previous levels in the last two
48
49 years. In previously-published analyses looking more broadly at psychotropic prescribing in this
50
51 cohort, it appears that there may have been substitution from increased use of other classes of
52
53 medications that are not clearly effective for PTSD such as anticonvulsants (Shiner, Westgate, et
54
55 al., 2017), and that the rebound in EBA use coincided with a drop in atypical antipsychotic and
56
57
58
59
60
61
62
63
64
65

1
2
3
4 benzodiazepine use (Krystal et al., 2017). While increases in anticonvulsant use persisted
5
6 throughout the years of examination, the reemergence of EBA use in the later years may have
7
8 been driving by policies intended to decrease atypical antipsychotic and benzodiazepine use,
9
10 which coincided with efforts that focused on substituting guideline-concordant treatments for
11
12 these agents (Bernardy et al., 2013; Lund, Abrams, Bernardy, Alexander, & Friedman, 2013).
13
14

15
16 While this study makes a critical contribution to this literature by leveraging electronic
17
18 medical record data to understand prescribing practices for PTSD in the VA, there are limitations
19
20 to our work. First, we used pharmacy data including fills and refills to assess medication receipt.
21
22 Without directly monitoring or even talking to patients, it is not possible to tell whether they took
23
24 the EBAs as prescribed. For example, if patients were not adherent to their medication
25
26 instructions, it might account for low level of improvement associated with EBA receipt.
27
28 Second, only 2% of patients receiving at least an adequate duration of an EBA had PCL
29
30 measurement that was aligned with weeks one and twelve, making them eligible for inclusion in
31
32 the causal analysis. Patients who met our PCL-based inclusion criteria differed from other
33
34 patients in many important ways. Thus, our findings may not be generalizable across VA
35
36 patients. As use of measurement-based care increases in routine VA practice (Shiner et al.,
37
38 2018), our hope is that comparative effectiveness analyses can be more representative of key
39
40 groups such as older veterans. Third, our causal analyses focused on new antidepressant
41
42 prescriptions among patients initiating PTSD treatment episodes. It is possible that Veterans
43
44 who have been in VA PTSD treatment for many years realize even less benefit when switching
45
46 to an EBA from other agents. Thus, it is not currently clear that optimizing EBA management
47
48 would represent a way forward Veterans with chronic treatment-resistant PTSD (Sippel,
49
50 Holtzheimer, Friedman, & Schnurr, 2018). Future studies should use a longitudinal, rather than
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 cross-sectional window of examination in order to account more comprehensively for prior
5
6 treatment resistance.
7
8

9 In summary, we have measured prescribing practices for PTSD in routine VA practice
10 with a greater degree of granularity than in previous studies, and have shown that the quality
11 may be worse than previously estimated. Furthermore, even when examining outcomes for
12 patients who receive the highest quality of care that we can measure using medical records data,
13
14 outcomes appear to have substantial room for improvement. Many unmeasured factors could
15
16 account for our findings and an organized practice-based effort is needed to understand these
17
18 factors in order to initiate changes that will close the gap between the anticipated and observed
19
20 benefit of a very commonly delivered modality of treatment for PTSD.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- Abrams, T. E., Lund, B. C., Bernardy, N. C., & Friedman, M. J. (2013). Aligning clinical practice to PTSD treatment guidelines: medication prescribing by provider type. *Psychiatr Serv*, 64(2), 142-148. doi:10.1176/appi.ps.201200217
- American Psychiatric Association. (2000). *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision: DSM-IV-TR*. Arlington, VA: American Psychiatric Association.
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders : DSM-5* (5th ed.). Arlington, VA: American Psychiatric Association.
- Bernardy, N. C., Lund, B. C., Alexander, B., Jenkyn, A. B., Schnurr, P. P., & Friedman, M. J. (2013). Gender differences in prescribing among veterans diagnosed with posttraumatic stress disorder. *J Gen Intern Med*, 28 Suppl 2, S542-548. doi:10.1007/s11606-012-2260-9
- Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., & Farfel, G. M. (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. *JAMA*, 283(14), 1837-1844.
- Brady, K. T., Sonne, S., Anton, R. F., Randall, C. L., Back, S. E., & Simpson, K. (2005). Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. *Alcohol Clin Exp Res*, 29(3), 395-401.
- Chassin, M. R., Loeb, J. M., Schmaltz, S. P., & Wachter, R. M. (2010). Accountability measures--using measurement to promote quality improvement. *N Engl J Med*, 363(7), 683-688. doi:10.1056/NEJMSb1002320
- Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., . . . Musgnung, J. (2006). Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. *Arch Gen Psychiatry*, 63(10), 1158-1165. doi:10.1001/archpsyc.63.10.1158
- Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006). Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. *J Clin Psychopharmacol*, 26(3), 259-267. doi:10.1097/01.jcp.0000222514.71390.c1
- Davidson, J. R., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., & Farfel, G. M. (2001). Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. *Arch Gen Psychiatry*, 58(5), 485-492.
- Dietrich, A. J., Oxman, T. E., Williams, J. W., Jr., Schulberg, H. C., Bruce, M. L., Lee, P. W., . . . Nutting, P. A. (2004). Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. *BMJ*, 329(7466), 602. doi:10.1136/bmj.38219.481250.55
- Engel, C. C., Jaycox, L. H., Freed, M. C., Bray, R. M., Brambilla, D., Zatzick, D., . . . Katon, W. J. (2016). Centrally Assisted Collaborative Telecare for Posttraumatic Stress Disorder and Depression Among Military Personnel Attending Primary Care: A Randomized Clinical Trial. *JAMA Intern Med*, 176(7), 948-956. doi:10.1001/jamainternmed.2016.2402
- Fortney, J. C., Pyne, J. M., Kimbrell, T. A., Hudson, T. J., Robinson, D. E., Schneider, R., . . . Schnurr, P. P. (2015). Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial. *JAMA Psychiatry*, 72(1), 58-67. doi:10.1001/jamapsychiatry.2014.1575
- Friedman, M. J., Lowry, P., & Ruzek, J. (Producer). (2010, September 1, 2015). VA/DoD clinical practice guidelines for the management of post-traumatic stress (page 150).
- Friedman, M. J., Marmar, C. R., Baker, D. G., Sikes, C. R., & Farfel, G. M. (2007). Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. *J Clin Psychiatry*, 68(5), 711-720.
- Goldstein, R. B., Smith, S. M., Chou, S. P., Saha, T. D., Jung, J., Zhang, H., . . . Grant, B. F. (2016). The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the

- National Epidemiologic Survey on Alcohol and Related Conditions-III. *Soc Psychiatry Psychiatr Epidemiol*, 51(8), 1137-1148. doi:10.1007/s00127-016-1208-5
- Hale, A. C., Bohnert, K. M., Ganoczy, D., & Sripada, R. K. (2019). Predictors of Treatment Adequacy During Evidence-Based Psychotherapy for PTSD. *Psychiatr Serv*, 70(5), 367-373. doi:10.1176/appi.ps.201800361
- Haneuse, S., VanderWeele, T. J., & Arterburn, D. (2019). Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. *JAMA*, 321(6), 602-603. doi:10.1001/jama.2018.21554
- Holowka, D. W., Marx, B. P., Gates, M. A., Litman, H. J., Ranganathan, G., Rosen, R. C., & Keane, T. M. (2014). PTSD diagnostic validity in Veterans Affairs electronic records of Iraq and Afghanistan veterans. *J Consult Clin Psychol*, 82(4), 569-579. doi:10.1037/a0036347
- Jonas, D. E., Cusack, K., Forneris, C. A., Wilkins, T. M., Sonis, J., Middleton, J. C., . . . Gaynes, B. N. (2013). *Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)*. Rockville (MD).
- Krystal, J. H., Davis, L. L., Neylan, T. C., M, A. R., Schnurr, P. P., Stein, M. B., . . . Huang, G. D. (2017). It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group. *Biol Psychiatry*, 82(7), e51-e59. doi:10.1016/j.biopsych.2017.03.007
- Lund, B. C., Abrams, T. E., Bernardy, N. C., Alexander, B., & Friedman, M. J. (2013). Benzodiazepine prescribing variation and clinical uncertainty in treating posttraumatic stress disorder. *Psychiatr Serv*, 64(1), 21-27. doi:10.1176/appi.ps.201100544
- Maguen, S., Madden, E., Patterson, O. V., DuVall, S. L., Goldstein, L. A., Burkman, K., & Shiner, B. (2018). Measuring Use of Evidence Based Psychotherapy for Posttraumatic Stress Disorder in a Large National Healthcare System. *Adm Policy Ment Health*. doi:10.1007/s10488-018-0850-5
- Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001). Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. *Am J Psychiatry*, 158(12), 1982-1988. doi:10.1176/appi.ajp.158.12.1982
- Martenyi, F., Brown, E. B., & Caldwell, C. D. (2007). Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. *J Clin Psychopharmacol*, 27(2), 166-170. doi:10.1097/JCP.0b013e31803308ce
- Martenyi, F., Brown, E. B., Zhang, H., Prakash, A., & Koke, S. C. (2002). Fluoxetine versus placebo in posttraumatic stress disorder. *J Clin Psychiatry*, 63(3), 199-206.
- Martenyi, F., & Soldatenkova, V. (2006). Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial. *Eur Neuropsychopharmacol*, 16(5), 340-349. doi:10.1016/j.euroneuro.2005.10.007
- Mathur, M. B., Ding, P., & VanderWeele, T. J. (2018). Package 'EValue': Sensitivity Analyses for Unmeasured Confounding in Observational Studies and Meta-Analyses. Retrieved from <https://cran.r-project.org/web/packages/EValue/EValue.pdf>
- McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013). A tutorial on propensity score estimation for multiple treatments using generalized boosted models. *Stat Med*, 32(19), 3388-3414. doi:10.1002/sim.5753
- Mohamed, S., & Rosenheck, R. A. (2008). Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. *J Clin Psychiatry*, 69(6), 959-965.
- Monson, C. M., Gradus, J. L., Young-Xu, Y., Schnurr, P. P., Price, J. L., & Schumm, J. A. (2008). Change in posttraumatic stress disorder symptoms: do clinicians and patients agree? *Psychol Assess*, 20(2), 131-138. doi:10.1037/1040-3590.20.2.131

- Osterberg, L., & Blaschke, T. (2005). Adherence to medication. *N Engl J Med*, 353(5), 487-497. doi:10.1056/NEJMra050100
- Pietrzak, R. H., Goldstein, R. B., Southwick, S. M., & Grant, B. F. (2011). Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Anxiety Disord*, 25(3), 456-465. doi:10.1016/j.janxdis.2010.11.010
- Rauch, S. A. M., Kim, H. M., Powell, C., Tuerk, P. W., Simon, N. M., Acierno, R., . . . Hoge, C. W. (2018). Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. doi:10.1001/jamapsychiatry.2018.3412
- Rauch, S. A. M., Simon, N. M., Kim, H. M., Acierno, R., King, A. P., Norman, S. B., . . . Hoge, C. W. (2018). Integrating biological treatment mechanisms into randomized clinical trials: Design of PROGrESS (PROLonged ExpoSure and Sertraline Trial). *Contemp Clin Trials*, 64, 128-138. doi:10.1016/j.cct.2017.10.013
- Ridgeway, G., McCaffrey, D. F., Morral, A. R., Burgette, L. F., & Griffin, B. A. (2017). *Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial for the TWANG Package*. Santa Monica, CA: RAND Corporation.
- Schnurr, P. P., Friedman, M. J., Oxman, T. E., Dietrich, A. J., Smith, M. W., Shiner, B., . . . Thurston, V. (2013). RESPECT-PTSD: re-engineering systems for the primary care treatment of PTSD, a randomized controlled trial. *J Gen Intern Med*, 28(1), 32-40. doi:10.1007/s11606-012-2166-6
- Schnurr, P. P., & Lunney, C. A. (2016). Symptom Benchmarks of Improved Quality of Life in Ptsd. *Depress Anxiety*, 33(3), 247-255. doi:10.1002/da.22477
- Shiner, B., Drake, R. E., Watts, B. V., Desai, R. A., & Schnurr, P. P. (2012). Access to VA services for returning veterans with PTSD. *Mil Med*, 177(7), 814-822.
- Shiner, B., Green, R. L., Homa, K., Watts, B. V., Groft, A., Torrey, W. C., & Oxman, T. E. (2010). Improving depression care in a psychiatry resident psychopharmacology clinic: measurement, monitoring, feedback and education. *Qual Saf Health Care*, 19(3), 234-238. doi:10.1136/qshc.2007.023960
- Shiner, B., Leonard Westgate, C., Bernardy, N. C., Schnurr, P. P., & Watts, B. V. (2017). Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder. *J Dual Diagn*, 13(3), 201-212. doi:10.1080/15504263.2017.1325033
- Shiner, B., Leonard Westgate, C., Harik, J. M., Watts, B. V., & Schnurr, P. P. (2016). Effect of Patient-Therapist Gender Match on Psychotherapy Retention Among United States Veterans with Posttraumatic Stress Disorder. *Adm Policy Ment Health*. doi:10.1007/s10488-016-0761-2
- Shiner, B., Watts, B. V., Traum, M. K., Huber, S. J., & Young-Xu, Y. (2011). Does the Veterans Affairs depression performance measure predict quality care? *Jt Comm J Qual Patient Saf*, 37(4), 170-177.
- Shiner, B., Westgate, C. L., Bernardy, N. C., Schnurr, P. P., & Watts, B. V. (2017). Anticonvulsant Medication Use in Veterans With Posttraumatic Stress Disorder. *J Clin Psychiatry*, 78(5), e545-e552. doi:10.4088/JCP.16m11031
- Shiner, B., Westgate, C. L., Gui, J., Maguen, S., Young-Xu, Y., Schnurr, P. P., & Watts, B. V. (2018). A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice. *J Clin Psychiatry*, 79(5). doi:10.4088/JCP.18m12145
- Sippel, L. M., Holtzheimer, P. E., Friedman, M. J., & Schnurr, P. P. (2018). Defining Treatment-Resistant Posttraumatic Stress Disorder: A Framework for Future Research. *Biol Psychiatry*, 84(5), e37-e41. doi:10.1016/j.biopsych.2018.03.011
- Spoont, M. R., Murdoch, M., Hodges, J., & Nugent, S. (2010). Treatment receipt by veterans after a PTSD diagnosis in PTSD, mental health, or general medical clinics. *Psychiatr Serv*, 61(1), 58-63. doi:10.1176/appi.ps.61.1.58

- 1
2
3
4 Stuart, E. A. (2010). Matching methods for casual inference: a review and a look forward. *Statistical*
5 *Science*, 25(1), 1-21.
6
7 The Management of Posttraumatic Stress Disorder Work Group. (2017). *VA/DoD Clinical Practice*
8 *Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder*.
9 Washington, DC: United States Departments of Veterans Affairs and Defense.
10 Trivedi, M. H., Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., . . . Shon, S. P.
11 (2004). Clinical results for patients with major depressive disorder in the Texas Medication
12 Algorithm Project. *Arch Gen Psychiatry*, 61(7), 669-680. doi:10.1001/archpsyc.61.7.669
13 Tucker, P., Ruwe, W. D., Masters, B., Parker, D. E., Hossain, A., Trautman, R. P., & Wyatt, D. B. (2004).
14 Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo
15 treatment of chronic posttraumatic stress disorder. *Biol Psychiatry*, 56(2), 121-128.
16 doi:10.1016/j.biopsych.2004.03.009
17
18 Tucker, P., Zaninelli, R., Yehuda, R., Ruggiero, L., Dillingham, K., & Pitts, C. D. (2001). Paroxetine in the
19 treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-
20 dosage trial. *J Clin Psychiatry*, 62(11), 860-868.
21
22 van der Kolk, B. A., Dreyfuss, D., Michaels, M., Shera, D., Berkowitz, R., Fisler, R., & Saxe, G. (1994).
23 Fluoxetine in posttraumatic stress disorder. *J Clin Psychiatry*, 55(12), 517-522.
24
25 van der Kolk, B. A., Spinazzola, J., Blaustein, M. E., Hopper, J. W., Hopper, E. K., Korn, D. L., & Simpson,
26 W. B. (2007). A randomized clinical trial of eye movement desensitization and reprocessing
27 (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder:
28 treatment effects and long-term maintenance. *J Clin Psychiatry*, 68(1), 37-46.
29
30 VanderWeele, T. J., & Ding, P. (2017). Sensitivity Analysis in Observational Research: Introducing the E-
31 Value. *Ann Intern Med*, 167(4), 268-274. doi:10.7326/M16-2607
32
33 Watts, B. V. (2016). Current evidence does not support the widespread use of collaborative care for
34 PTSD, but it is limited by not evaluating context. *Evid Based Med*, 21(5), 176.
35 doi:10.1136/ebmed-2016-110482
36
37 Watts, B. V., Schnurr, P. P., Mayo, L., Young-Xu, Y., Weeks, W. B., & Friedman, M. J. (2013). Meta-
38 analysis of the efficacy of treatments for posttraumatic stress disorder. *J Clin Psychiatry*, 74(6),
39 e541-550. doi:10.4088/JCP.12r08225
40
41 Weathers, F. W., Litz, B. T., Herman, B. S., Huska, J. A., & Keane, T. M. (1993). *The PTSD Checklist (PCL):*
42 *Reliability, Validity, and Diagnostic Utility*. Paper presented at the Paper presented at the Annual
43 Convention of the International Society for Traumatic Stress Studies, San Antonio, Tx.
44
45 Zohar, J., Amital, D., Miodownik, C., Kotler, M., Bleich, A., Lane, R. M., & Austin, C. (2002). Double-blind
46 placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress
47 disorder. *J Clin Psychopharmacol*, 22(2), 190-195.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1: VA Users with New Episodes of PTSD Care from 2004-2013, by Receipt of an Antidepressant Prescription

		Category	
	Overall (731,520)	Received Antidepressant (609,808)	Did Not Receive Antidepressant (121,712)
Patient Characteristics			
Age, M (SD)**	49.9 (15.4)	49.7 (15.1)	51.0 (16.6)
Women, % (n)**	8.5 (61,853)	8.7 (53,314)	7.0 (8,539)
Married, % (n)**	53.2 (389,262)	53.0 (323,106)	54.4 (66,156)
White Non-Hispanic, % (n)**	62.6 (457,673)	62.8 (382,798)	61.5 (74,875)
OEF/OIF/OND Veteran, % (n)**	28.5 (208,769)	28.1 (171,572)	30.6 (37,197)
Rural, % (n)**	35.3 (258,177)	35.8 (218,231)	32.8 (39,946)
Combat Exposure, % (n)	32.8 (239,686)	32.8 (199,881)	32.7 (39,805)
Sexual Trauma while in Military, % (n)**	9.2 (67,024)	9.5 (57,929)	7.5 (9,095)
VA Disability Level 70% or Greater, % (n)**	59.0 (431,632)	60.6 (369,635)	50.9 (61,997)
Charlson Comorbidity Index 1 or greater, % (n)**	24.4 (178,575)	25.4 (154,825)	19.5 (23,750)
Psychotic Disorders, % (n)**	5.7 (41,789)	6.0 (36,385)	4.4 (5,404)
Bipolar Mood Disorders, % (n)**	7.2 (52,596)	7.5 (45,632)	5.7 (6,964)
Depressive Mood Disorders, % (n)**	65.5 (478,763)	70.7 (430,956)	39.3 (47,807)
Non-PTSD Anxiety Disorders, % (n)**	34.5 (252,107)	36.1 (220,116)	26.3 (31,991)
Traumatic Brain Injury, % (n)**	8.6 (62,936)	8.8 (53,784)	7.5 (9,152)
Alcohol Use Disorders, % (n)**	27.1 (198,166)	28.6 (174,474)	19.5 (23,692)
Opioid Use Disorders, % (n)**	3.7 (27,175)	4.1 (24,846)	1.9 (2,329)
Other Drug Use Disorders, % (n)**	19.7 (144,350)	21.0 (128,142)	13.3 (16,208)
Service Use Characteristics			
Prior Antidepressant Use (2 years), % (n)**	47.8 (349,822)	55.8 (340,336)	7.8 (9,486)
Adequate Trial of EBP for PTSD, % (n)**	3.0 (22,144)	2.9 (17,865)	3.5 (4,279)
PTSD Outpatient Clinical Team Use, % (n)**	34.9 (255,151)	34.7 (211,748)	35.7 (43,403)
Outpatient Mental Health Visits, M(SD)**	12.6 (15.1)	13.2 (15.5)	9.5 (12.3)
Outpatient Substance Abuse Visits, M(SD)**	3.0 (13.1)	3.3 (13.6)	1.7 (9.9)
Outpatient Primary Care Visits, M(SD)**	3.5 (3.5)	3.6 (3.6)	2.7 (3.0)
ED Visit for Psychiatric Indication, % (n)**	6.4 (46,616)	7.1 (43,171)	2.8 (3,445)
Acute Mental Health Inpatient Admission, % (n)**	6.6 (48,531)	7.5 (45,915)	2.2 (2,616)
Residential PTSD Admission, % (n)**	2.4 (17,278)	2.7 (16,265)	0.8 (1,013)
Residential Substance Abuse Admission**	2.7 (19,696)	3.0 (18,470)	1.0 (1,226)
Primary Prescribing Clinician Characteristics			
Age, M (SD)	-	52.2 (10.7)	-
Woman, % (n)	-	39.4 (239,988)	-
Physician, % (n)	-	77.6 (473,427)	-
Physician Assistant, % (n)	-	4.1 (25,248)	-
Nurse Practitioner, % (n)	-	17.3 (105,338)	-
Pharmacist, % (n)	-	0.6 (3,814)	-
Percentage of Time Seeing PTSD Patients in Various Settings			
PTSD Service Section (PCT or residential), M (SD)	-	11.8 (27.8)	-
Substance Abuse Service Section, M (SD)	-	2.4 (12.0)	-
Comorbid PTSD Substance Abuse Service Section, M (SD)	-	0.1 (1.7)	-
General Mental Health Service Section, M (SD)	-	61.7 (42.5)	-
Integrated Care Service Section, M (SD)	-	4.5 (15.6)	-
Primary Care Service Section, M (SD)	-	13.2 (30.4)	-

Note. VA=United States Department of Veterans Affairs; PTSD=Posttraumatic Stress Disorder; M=mean, SD=standard deviation; OEF/OIF/OND=Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn, EBP=Evidence-Based Psychotherapy; *p<0.05, **p<0.001

Table 2: Antidepressant Medication Receipt in the Year Following Initial PTSD Diagnosis

Fiscal Year	2004 – 2005	2006 – 2007	2008 – 2009	2010 – 2011	2012 – 2013	Overall
New PTSD Episodes	111,828	128,652	160,444	168,771	161,825	731,520
Number of ADs, M (SD)	2.1 (1.0)	2.0 (1.0)	2.0 (1.0)	2.0 (1.0)	2.0 (1.0)	2.0 (1.0)
Any Antidepressant	86.6% (96,887)	85.2% (109,576)	83.9% (134,635)	81.9% (138,203)	80.6% (130,507)	83.4% (609,808)
Trazodone	36.8% (41,187)	35.6% (45,777)	34.5% (55,342)	33.4% (56,388)	32.9% (53,210)	34.4% (251,904)
2010 VA/DoD CPGs	78.9% (88,202)	76.9% (98,870)	75.6% (121,313)	73.7% (124,429)	72.0% (116,581)	75.1% (549,395)
SSRI or SNRI	73.1% (81,732)	71.3% (91,737)	70.2% (112,604)	68.3% (115,244)	66.4% (107,424)	69.5% (508,741)
Mirtazapine	13.5% (15,142)	13.6% (17,488)	14.2% (22,791)	14.5% (24,454)	14.6% (23,574)	14.1% (103,449)
Nefazodone	1.2% (1,384)	0.4% (562)	0.2% (365)	0.1% (209)	0.1% (137)	0.4% (2,657)
Amitriptyline	7.3% (8,111)	6.2% (7,955)	5.5% (8,808)	4.7% (8,004)	4.6% (7,518)	5.5% (40,396)
Imipramine	0.4% (501)	0.4% (480)	0.3% (488)	0.3% (425)	0.2% (313)	0.3% (2,207)
Phenelzine	0.0% (32)	0.0% (28)	0.0% (17)	0.0% (19)	0.0% (17)	0.0% (113)
EBA for PTSD	54.0% (60,365)	43.8% (56,349)	43.4% (69,643)	44.2% (74,608)	54.7% (88,509)	47.8% (349,474)
Fluoxetine	15.9% (17,789)	14.1% (18,090)	11.6% (18,615)	10.7% (18,077)	12.5% (20,300)	12.7% (92,871)
Paroxetine	11.4% (12,723)	8.7% (11,173)	6.6% (10,616)	5.8% (9,749)	6.9% (11,101)	7.6% (55,362)
Sertraline	25.8% (28,817)	17.7% (22,812)	22.6% (36,194)	24.7% (41,681)	33.4% (54,013)	25.1% (183,517)
Venlafaxine	9.9% (11,082)	9.7% (12,500)	9.0% (14,385)	9.7% (16,311)	12.2% (19,739)	10.1% (74,017)

Note. PTSD=Posttraumatic Stress Disorder; AD=Antidepressant; M=Mean; SD=Standard Deviation; VA/DoD CPG=Departments of Veterans Affairs and Defense Clinical Practice Guideline for PTSD; EBA=Evidence-Based Antidepressant

Table 3: Antidepressant Initiation in the Year Following Initial PTSD Diagnosis among 381,698 Patients with No Antidepressant Fills in the 2 Years Prior to PTSD Diagnosis, Fiscal Years 2004-2013 (Yearly Trends in Appendix 1)

Quality Standard	Any Receipt	Adequate Duration	Plus Adequate Dose	Plus Refill	Plus 1 Follow-Up	Plus 3 Follow-Ups
EBA for PTSD	35.4% (135,160)	19.6% (74,792)	14.8% (56,300)	12.7% (48,320)	9.7% (37,163)	4.6% (17,684)
Fluoxetine	8.3% (31,528)	4.4% (16,797)	4.0% (15,392)	3.4% (13,103)	2.5% (9,607)	1.2% (4,419)
Paroxetine	4.9% (18,817)	2.4% (9,153)	2.1% (8,099)	1.8% (6,906)	1.4% (5,206)	0.7% (2,637)
Sertraline	20.6% (78,506)	10.8% (41,261)	7.2% (27,414)	6.1% (23,077)	4.8% (18,179)	2.2% (8,377)
Venlafaxine	6.0% (22,729)	2.8% (10,497)	1.9% (7,141)	1.7% (6,395)	1.3% (5,086)	0.7% (2,674)

Note. PTSD=Posttraumatic Stress Disorder; EBA=Evidence-Based Antidepressant

Table 4: VA Users Initiating Evidence-Based Antidepressants for PTSD with Adequate Duration from 2008-2013, by Receipt of Aligned PTSD Checklist Measurement

	Overall (52,907)	Category	
		With Aligned PCL Measurement (1,068)	Without Aligned PCL Measurement (51,839)
Patient Characteristics			
Age, M (SD)**	45.3 (16.0)	37.8 (12.7)	45.4 (16.0)
Women, % (n)	8.3 (4,373)	9.4 (100)	8.2 (4,273)
Married, % (n)*	58.7 (31,072)	55.8 (596)	58.8 (30,476)
White Non-Hispanic, % (n)	66.4 (35,122)	65.5 (699)	66.4 (34,423)
OEF/OIF/OND Veteran, % (n)**	47.2 (24,968)	78.8 (841)	46.5 (24,127)
Rural, % (n)	35.7 (18,893)	33.8 (361)	35.8 (18,532)
Combat Exposure, % (n)	27.4 (14,510)	30.1 (321)	27.4 (14,189)
Sexual Trauma while in Military, % (n)	8.1 (4,285)	8.2 (88)	8.1 (4,197)
VA Disability Level 70% or Greater, % (n)**	60.0 (31,743)	66.9 (714)	59.9 (31,029)
Charlerson Comorbidity Index 1 or greater, % (n)**	12.3 (6,501)	5.4 (58)	12.4 (6,443)
Psychotic Disorders, % (n)	3.4 (1,816)	3.5 (37)	3.4 (1,779)
Bipolar Mood Disorders, % (n)	4.3 (2,269)	3.5 (37)	4.3 (2,232)
Depressive Mood Disorders, % (n)**	69.2 (36,624)	77.5 (828)	69.1 (35,796)
Non-PTSD Anxiety Disorders, % (n)**	37.3 (19,726)	45.1 (482)	37.1 (19,244)
Traumatic Brain Injury, % (n)**	16.6 (8,769)	27.6 (295)	16.4 (8,474)
Alcohol Use Disorders, % (n)*	27.4 (14,490)	31.3 (334)	27.3 (14,156)
Opioid Use Disorders, % (n)*	2.8 (1,483)	4.0 (43)	2.8 (1,440)
Other Drug Use Disorders, % (n)	17.0 (8,993)	18.8 (201)	17.0 (8,792)
Service Use Characteristics			
Adequate Trial of EBP for PTSD, % (n)**	5.3 (2,798)	24.6 (263)	4.9 (2,535)
PTSD Outpatient Clinical Team Use, % (n)**	38.2 (20,189)	57.4 (613)	37.8 (19,576)
Outpatient Mental Health Visits, M(SD)**	15.0 (14.8)	22.9 (16.9)	14.9 (14.7)
Outpatient Substance Abuse Visits, M(SD)**	2.7 (11.2)	5.1 (16.0)	2.7 (11.1)
Outpatient Primary Care Visits, M(SD)*	3.5 (3.3)	3.3 (2.7)	3.5 (3.4)
ED Visit for Psychiatric Indication, % (n)	10.7 (5,677)	11.1 (118)	10.7 (5,559)
Acute Mental Health Inpatient Admission, % (n)*	8.2 (4,318)	9.9 (106)	8.1 (4,212)
Residential PTSD Admission, % (n)**	2.9 (1,518)	5.3 (57)	2.8 (1,461)
Residential Substance Abuse Admission**	2.2 (1,186)	4.2 (45)	2.2 (1,141)
Primary Prescribing Clinician Characteristics			
Age, M (SD)	51.9 (11.2)	51.8 (10.7)	51.9 (11.2)
Woman, % (n)	39.4 (20,847)	40.5 (433)	39.4 (20,414)
Physician, % (n)	76.3 (40,366)	75.8 (810)	76.3 (39,556)
Physician Assistant, % (n)	3.8 (2,004)	3.8 (41)	3.8 (1,963)
Nurse Practitioner, % (n)	19.1 (10,104)	19.3 (206)	19.1 (9,898)
Pharmacist, % (n)	0.7 (353)	0.8 (9)	0.7 (344)
Percentage of Time Seeing PTSD Patients in Various Settings			
PTSD Service Section (PCT or residential), M (SD)**	14.1 (29.8)	20.1 (33.7)	14.0 (29.7)
Substance Abuse Service Section, M (SD)	2.0 (10.2)	2.5 (12.2)	2.0 (10.1)
Comorbid PTSD Substance Abuse Service Section, M (SD)	0.1 (1.7)	0.1 (1.9)	0.1 (1.7)
General Mental Health Service Section, M (SD)**	65.8 (40.3)	61.0 (40.9)	65.9 (40.3)
Integrated Care Service Section, M (SD)	6.5 (19.2)	5.6 (17.6)	6.6 (19.3)
Primary Care Service Section, M (SD)	7.7 (24.1)	7.3 (23.6)	7.7 (24.1)

Note. VA=United States Department of Veterans Affairs; PTSD=Posttraumatic Stress Disorder; M=mean, SD=standard deviation; OEF/OIF/OND=Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn, EBP=Evidence Based Psychotherapy; *p<0.05, **p<0.001

Table 5: Comparison of PTSD Symptomatic Outcomes for Patients who Initiated an EBA and Met Various Quality Standards, FY 2008-2013

Quality Standard	Patients with Measurement (n)	Baseline PCL, mean (SD)	Change in PCL		10-Point Drop plus LOD	
			Mean (SD)	Equivalence	% (n)	Equivalence
Comparisons of Unweighted Data (Covariates in Appendix 2)						
A) Adequate Duration	471	63.9 (9.5)	7.1 (12.6)	A=B, A=C, A=D, B=C, B=D, C=D	17.4 (82)	A=B, A=C, A=D, B=C, B=D, C=D
B) Adequate Duration and Dose plus/minus Refill	137	63.7 (10.0)	5.6 (12.2)		14.6 (20)	
C) Adequate Duration and Dose plus Refill and 1 Follow-Up	216	63.8 (10.1)	5.1 (13.1)		11.6 (25)	
D) Adequate Duration and Dose plus Refill and 3 Follow-Ups	244	65.7 (9.4)	5.6 (13.0)		13.9 (34)	
Comparisons of Weighted Data (Covariates in Appendix 3)						
A) Adequate Duration	471	64.1 (9.8)	7.0 (12.9)	A=B, A=C, A=D, B=C, B=D, C=D	17.3 (82)	A=B, A=C, A=D, B=C, B=D, C=D
B) Adequate Duration and Dose plus/minus Refill	137	64.3 (11.1)	6.3 (12.6)		15.7 (20)	
C) Adequate Duration and Dose plus Refill and 1 Follow-Up	216	64.4 (9.8)	5.4 (12.5)		10.7 (25)	
D) Adequate Duration and Dose plus Refill and 3 Follow-Ups	244	65.2 (10.8)	6.3 (15.5)		14.7 (34)	
Note. PTSD=Posttraumatic Stress Disorder, PCL=PTSD Checklist; LOD=Loss of PTSD Diagnosis; alpha for significant differences is $p<0.05/6 = 0.008$						

Note. PTSD=Posttraumatic Stress Disorder, PCL=PTSD Checklist; LOD=Loss of PTSD Diagnosis; alpha for significant differences is $p < 0.05/6 = 0.008$

Fiscal Years	2004-2005	2006-2007	2008-2009	2010-2011	2012-2013	Overall
New PTSD Episodes, n	51,012	62,874	86,105	93,056	88,651	381,698
Number of ADs, M (SD)	1.8 (0.9)	1.8 (0.9)	1.8 (0.9)	1.8 (0.9)	1.8 (0.9)	1.8 (0.9)
<i>Any Receipt</i>						
Effective SSRI or SNRI	39.2% (19,979)	30.1% (18,914)	32.1% (27,629)	33.1% (30,816)	42.7% (37,822)	35.4% (135,160)
Fluoxetine	11.0% (5,612)	9.2% (5,789)	7.3% (6,276)	6.9% (6,429)	8.4% (7,422)	8.3% (31,528)
Paroxetine	7.2% (3,657)	5.7% (3,562)	4.3% (3,736)	3.9% (3,605)	4.8% (4,257)	4.9% (18,817)
Sertraline	20.1% (10,251)	13.1% (8,208)	18.8% (16,212)	20.4% (18,974)	28.0% (24,861)	20.6% (78,506)
Venlafaxine	5.5% (2,804)	5.4% (3,408)	5.1% (4,409)	5.8% (5,357)	7.6% (6,751)	6.0% (22,729)
<i>Adequate Duration</i>						
Effective SSRI or SNRI	22.7% (11,555)	16.4% (10,330)	17.4% (15,020)	17.7% (16,450)	24.2% (21,437)	19.6% (74,792)
Fluoxetine	6.3% (3,207)	5.0% (3,156)	3.8% (3,272)	3.5% (3,228)	4.4% (3,934)	4.4% (16,797)
Paroxetine	3.6% (1,841)	2.8% (1,752)	2.1% (1,817)	1.9% (1,734)	2.3% (2,009)	2.4% (9,153)
Sertraline	11.1% (5,649)	6.7% (4,211)	9.9% (8,525)	10.4% (9,631)	14.9% (13,245)	10.8% (41,261)
Venlafaxine	2.6% (1,316)	2.5% (1,576)	2.3% (1,956)	2.6% (2,395)	3.7% (3,254)	2.8% (10,497)
<i>Adequate Dose and Duration</i>						
Effective SSRI or SNRI	17.8% (9,074)	13.2% (8,265)	13.2% (11,357)	13.0% (12,120)	17.5% (15,484)	14.8% (56,300)
Fluoxetine	5.7% (2,907)	4.6% (2,898)	3.5% (3,028)	3.2% (2,949)	4.1% (3,610)	4.0% (15,392)
Paroxetine	3.3% (1,662)	2.5% (1,558)	1.9% (1,599)	1.7% (1,531)	2.0% (1,749)	2.1% (8,099)
Sertraline	7.7% (3,901)	4.7% (2,960)	6.7% (5,739)	6.8% (6,316)	9.6% (8,498)	7.2% (27,414)
Venlafaxine	1.7% (883)	1.8% (1,100)	1.6% (1,335)	1.8% (1,635)	2.5% (2,188)	1.9% (7,141)
<i>Adequate Dose and Duration plus Refill</i>						
Effective SSRI or SNRI	15.7% (8,028)	11.2% (7,070)	11.2% (9,632)	11.2% (10,421)	14.9% (13,169)	12.7% (48,320)
Fluoxetine	4.9% (2,491)	3.9% (2,418)	3.0% (2,568)	2.8% (2,565)	3.5% (3,061)	3.4% (13,103)
Paroxetine	2.9% (1,482)	2.1% (1,320)	1.6% (1,335)	1.4% (1,293)	1.7% (1,476)	1.8% (6,906)
Sertraline	6.7% (3,439)	4.0% (2,535)	5.5% (4,768)	5.7% (5,288)	8.0% (7,047)	6.1% (23,077)
Venlafaxine	1.6% (807)	1.5% (969)	1.4% (1,197)	1.6% (1,478)	2.2% (1,944)	1.7% (6,395)
<i>Adequate Dose and Duration plus Refill and 1 Follow-Up</i>						
Effective SSRI or SNRI	8.9% (4,534)	7.2% (4,538)	8.3% (7,184)	9.5% (8,877)	13.6% (12,030)	9.7% (37,163)
Fluoxetine	2.7% (1,368)	2.4% (1,509)	2.1% (1,838)	2.3% (2,116)	3.1% (2,776)	2.5% (9,607)
Paroxetine	1.7% (846)	1.4% (848)	1.2% (1,039)	1.2% (1,114)	1.5% (1,359)	1.4% (5,206)
Sertraline	3.8% (1,961)	2.6% (1,647)	4.2% (3,585)	4.9% (4,540)	7.3% (6,446)	4.8% (18,179)
Venlafaxine	0.9% (469)	1.0% (651)	1.1% (910)	1.4% (1,279)	2.0% (1,777)	1.3% (5,086)
<i>Adequate Dose and Duration plus Refill and 3 Follow-Ups</i>						
Effective SSRI or SNRI	4.4% (2,261)	3.7% (2,329)	4.3% (3,659)	4.5% (4,140)	6.0% (5,295)	4.6% (17,684)
Fluoxetine	1.3% (663)	1.2% (728)	1.1% (905)	1.0% (937)	1.3% (1,186)	1.2% (4,419)
Paroxetine	0.8% (418)	0.8% (492)	0.7% (566)	0.6% (551)	0.7% (610)	0.7% (2,637)
Sertraline	1.9% (971)	1.3% (809)	2.0% (1,754)	2.2% (2,064)	3.1% (2,779)	2.2% (8,377)
Venlafaxine	0.5% (254)	0.6% (362)	0.6% (539)	0.7% (665)	1.0% (854)	0.7% (2,674)

Note. PTSD=Posttraumatic Stress Disorder; AD=Antidepressant; M=Mean; SD=Standard Deviation

Appendix 2: Covariates for Comparisons of Quality Standards, 2008-2013 (Unweighted)

Patient Characteristics, N	A) Adequate Duration, n=471	B) Plus Adequate Dose +/- Refill, n=137	C) Plus Refill and 1 Follow-Up, n=216	D) Plus Refill and 3 Follow-ups, n=244	Pairwise Differences
Baseline PCL, M (SD)	63.9 (9.5)	63.7 (10.0)	63.8 (10.1)	65.7 (9.4)	No differences
Days Between Index PTSD diagnosis and Day 1 of AMT, M (SD)	60.1 (71.6)	72.5 (77.2)	73 (73.1)	50.5 (65.5)	B≠D
Days Between Baseline PCL and Day 1 of AMT, M (SD)	0.2 (7.0)	0.2 (6.6)	1.1 (6.8)	1.4 (7.1)	No differences
Days Between Follow-Up PCL and Day 84 of AMT, M (SD)	0.4 (8.4)	-0.1 (8.4)	-0.4 (8.0)	-1.2 (8.6)	No differences
Fiscal years 2008-2009, % (n)	5.1 (24)	5.1 (7)	3.2 (7)	4.1 (10)	No differences
Fiscal years 2010-2011, % (n)	34.4 (162)	40.1 (55)	31.5 (68)	34.4 (84)	No differences
Fiscal years 2012-2013, % (n)	60.5 (285)	54.7 (75)	65.3 (141)	61.5 (150)	No differences
Age, M (SD)	39.4 (13.8)	36.2 (12.6)	38.1 (12.3)	35.4 (10.1)	A≠D
Women, % (n)	10.6 (50)	2.9 (4)	8.3 (18)	11.5 (28)	A≠B, B≠D
Married, % (n)	55.8 (263)	62.8 (86)	60.6 (131)	47.5 (116)	B≠D, C≠D
White Non-Hispanic, % (n)	64.5 (304)	65.7 (90)	70.4 (152)	62.7 (153)	No differences
OEI/OIF/OND Veteran, % (n)	73.0 (344)	83.2 (114)	82.4 (178)	84.0 (205)	A≠C, A≠D
Rural, % (n)	34.0 (160)	38.7 (53)	38.9 (84)	26.2 (64)	C≠D
Combat Exposure, % (n)	29.3 (138)	26.3 (36)	28.2 (61)	35.2 (86)	No differences
Sexual Trauma while in Military, % (n)	8.7 (41)	5.1 (7)	6.5 (14)	10.7 (26)	No differences
VA Disability Level 70% or Greater, % (n)	63.1 (297)	63.5 (87)	71.3 (154)	72.1 (176)	No differences
Charlson Comorbidity Index 1 or greater, % (n)	6.8 (32)	4.4 (6)	6.5 (14)	2.5 (6)	No differences
Psychotic Disorders, % (n)	2.1 (10)	3.6 (5)	3.7 (8)	5.7 (14)	No differences
Bipolar Mood Disorders, % (n)	3.2 (15)	1.5 (2)	2.3 (5)	6.1 (15)	No differences
Depressive Mood Disorders, % (n)	75.8 (357)	78.1 (107)	76.9 (166)	81.1 (198)	No differences
Non-PTSD Anxiety Disorders, % (n)	45.6 (215)	44.5 (61)	48.1 (104)	41.8 (102)	No differences
Traumatic Brain Injury, % (n)	22.9 (108)	35.0 (48)	29.6 (64)	30.7 (75)	A≠B
Alcohol Use Disorders, % (n)	32.1 (151)	21.9 (30)	27.3 (59)	38.5 (94)	B≠D
Opioid Use Disorders, % (n)	2.8 (13)	4.4 (6)	3.7 (8)	6.6 (16)	No differences
Other Drug Use Disorders, % (n)	16.6 (78)	14.6 (20)	15.3 (33)	28.7 (70)	A≠D, B≠D, C≠D
Adequate Trial of Evidence-Based Psychotherapy for PTSD, % (n)	24.4 (115)	24.1 (33)	25.0 (54)	25.0 (61)	No differences
PTSD Outpatient Clinical Team Use (540 or 561), % (n)	58.8 (277)	52.6 (72)	53.2 (115)	61.1 (149)	No differences
Outpatient Mental Health Visits, M (SD)	28.2 (28.2)	25.7 (31.7)	24.4 (19.8)	40.2 (38.9)	A≠D, B≠D, C≠D
Outpatient Substance Abuse Visits, M (SD)	7.5 (31.2)	5.9 (28.7)	3.3 (9.7)	14.7 (42)	B≠D
Outpatient Primary Care Visits, M (SD)	3.4 (3.1)	3.5 (2.5)	3.4 (2.7)	3.8 (3.3)	No differences
Emergency Department Visit for Psychiatric Indication, % (n)	9.8 (46)	8.0 (11)	7.4 (16)	18.4 (45)	A≠D, B≠D, C≠D
Acute Mental Health Inpatient Admission, % (n)	7.2 (34)	5.8 (8)	6.9 (15)	20.1 (49)	A≠D, B≠D, C≠D
Residential PTSD Admission, % (n)	3.4 (16)	2.9 (4)	3.7 (8)	11.9 (29)	A≠D, B≠D, C≠D
Residential Substance Abuse Admission, % (n)	2.8 (13)	3.6 (5)	3.7 (8)	7.8 (19)	A≠D
Prescribing Clinician Characteristics, where known					
Age, M (SD)	51.7 (10.9)	54.0 (9.5)	52.8 (10.4)	49.9 (11)	C≠D
Women, % (n)	45.5 (178)	53.1 (60)	48.3 (85)	55.3 (110)	No differences
Physician, % (n)	71.3 (335)	78.1 (107)	80.6 (174)	79.5 (194)	No differences
Physician's Assistant, % (n)	5.1 (24)	3.6 (5)	3.2 (7)	2.0 (5)	No differences
Nurse Practitioner, % (n)	22.6 (106)	17.5 (24)	14.8 (32)	18.0 (44)	No differences
Pharmacist, % (n)	1.1 (5)	0.7 (1)	0.9 (2)	0.4 (1)	No differences
Percentage of time in PTSD Service, M (SD)	20.2 (33.5)	19.7 (33.9)	20.4 (35.1)	19.7 (33.0)	No differences
Percentage of time in Substance Abuse Service, M (SD)	2.5 (12.6)	2.6 (10.1)	2.3 (11.7)	2.9 (12.9)	No differences
Percentage of time in PTSD-Substance Abuse Service, M (SD)	0.0 (0.3)	0.0 (0.0)	0.0 (0.1)	0.3 (3.9)	No differences
Percentage of time in General Mental Health Service, M (SD)	58.8 (41.3)	60.9 (42.3)	65.5 (40.9)	61.3 (39.4)	No differences
Percentage of time in Integrated Care Service, M (SD)	6.7 (19.2)	3.6 (14.7)	3.5 (14.1)	6.3 (18.3)	No differences
Percentage of time in Primary Care Service, M (SD)	7.9 (24.3)	10.1 (28.1)	5.7 (21.1)	5.8 (21.1)	No differences

Appendix 3: Covariates for Comparisons of Quality Standards, 2008-2013 (Weighted)					
Patient Characteristics, N	Adequate Duration, n=471	Plus Adequate Dose +/- Refill, n=137	Plus Refill and 1 Follow- Up, n=216	Plus Refill and 3 Follow- ups, n=244	Pairwise Differences
Baseline PCL, M (SD)	64.1 (9.8)	64.3 (11.1)	64.4 (9.8)	65.2 (10.8)	No differences
Days Between Index PTSD diagnosis and Day 1 of AMT, M (SD)	59.3 (72.1)	60.7 (67.1)	63.5 (67.8)	55.1 (86.7)	No differences
Days Between Baseline PCL and Day 1 of AMT, M (SD)	0.5 (7.0)	0.7 (6.6)	1.13 (7.0)	0.8 (7.4)	No differences
Days Between Follow-Up PCL and Day 84 of AMT, M (SD)	0.3 (8.5)	-0.7 (8.7)	0.0 (8.5)	-0.5 (9.0)	No differences
Fiscal years 2008-2009, % (n)	5.2 (24)	5.3 (7)	2.5 (7)	3.1 (10)	No differences
Fiscal years 2010-2011, % (n)	33.7 (162)	37.5 (55)	32.3 (68)	34.7 (84)	No differences
Fiscal years 2012-2013, % (n)	61.1 (285)	57.2 (75)	65.2 (141)	62.2 (150)	No differences
Age, M (SD)	38.2 (12.6)	36.3 (12.8)	37.8 (13.3)	36.8 (13.3)	No differences
Women, % (n)	11.0 (50)	4.7 (4)	8.9 (18)	11.3 (28)	No differences
Married, % (n)	55.2 (263)	59.3 (86)	56.5 (131)	51.2 (116)	No differences
White Non-Hispanic, % (n)	63.9 (304)	65.4 (90)	67.6 (152)	62.7 (153)	No differences
OEI/OIF/OND Veteran, % (n)	76.6 (344)	83.4 (114)	80.5 (178)	83.0 (205)	No differences
Rural, % (n)	33.8 (160)	35.9 (53)	37.0 (84)	26.6 (64)	No differences
Combat Exposure, % (n)	29.3 (138)	24.6 (36)	26.7 (61)	34.3 (86)	No differences
Sexual Trauma while in Military, % (n)	9.0 (41)	7.1 (7)	8.0 (14)	10.1 (26)	No differences
VA Disability Level 70% or Greater, % (n)	64.4 (297)	65.0 (87)	70.5 (154)	67.3 (176)	No differences
Charlson Comorbidity Index 1 or greater, % (n)	6.4 (32)	3.2 (6)	6.4 (14)	2.6 (6)	No differences
Psychotic Disorders, % (n)	2.2 (10)	3.2 (5)	3.3 (8)	4.1 (14)	No differences
Bipolar Mood Disorders, % (n)	3.3 (15)	1.4 (2)	2.2 (5)	4.3 (15)	No differences
Depressive Mood Disorders, % (n)	76.0 (357)	80.2 (107)	77.4 (166)	79.1 (198)	No differences
Non-PTSD Anxiety Disorders, % (n)	46.3 (215)	47.6 (61)	47.8 (104)	42.3 (102)	No differences
Traumatic Brain Injury, % (n)	24.6 (108)	30.9 (48)	29.9 (64)	28.1 (75)	No differences
Alcohol Use Disorders, % (n)	32.5 (151)	24.7 (30)	27.6 (59)	30.7 (94)	No differences
Opioid Use Disorders, % (n)	2.9 (13)	4.0 (6)	2.9 (8)	3.9 (16)	No differences
Other Drug Use Disorders, % (n)	17.0 (78)	13.6 (20)	15.5 (33)	21.8 (70)	No differences
Adequate Trial of Evidence-Based Psychotherapy for PTSD, % (n)	24.4 (115)	25.2 (33)	24.9 (54)	25.0 (61)	No differences
PTSD Outpatient Clinical Team Use (540 or 561), % (n)	58.9 (277)	58.7 (72)	53.2 (115)	58.0 (149)	No differences
Outpatient Mental Health Visits, M (SD)	28.8 (30.6)	25.7 (36.4)	25.6 (23.0)	31.7 (26.0)	No differences
Outpatient Substance Abuse Visits, M (SD)	7.6 (31.3)	6.0 (35.2)	3.0 (9.4)	9.0 (27.6)	A≠C
Outpatient Primary Care Visits, M (SD)	3.5 (3.3)	3.4 (2.7)	3.6 (3.2)	3.6 (3.4)	No differences
Emergency Department Visit for Psychiatric Indication, % (n)	10.0 (46)	8.4 (11)	8.1 (16)	12.5 (45)	No differences
Acute Mental Health Inpatient Admission, % (n)	7.9 (34)	5.3 (8)	6.8 (15)	12.2 (49)	No differences
Residential PTSD Admission, % (n)	3.7 (16)	2.2 (4)	3.7 (8)	6.8 (29)	No differences
Residential Substance Abuse Admission, % (n)	2.7 (13)	3.8 (5)	3.3 (8)	4.7 (19)	No differences
Prescribing Clinician Characteristics, where known					
Age, M (SD)	51.6 (12.2)	52.7 (12.7)	52.4 (10.9)	51.0 (12.6)	No differences
Women, % (n)	46.8 (178)	52.4 (60)	50.8 (85)	55.0 (110)	No differences
Physician, % (n)	74.2 (335)	79.0 (107)	78.6 (174)	79.3 (194)	No differences
Physician's Assistant, % (n)	4.7 (24)	4.0 (5)	3.8 (7)	1.7 (5)	No differences
Nurse Practitioner, % (n)	20.3 (106)	16.4 (24)	16.5 (32)	18.9 (44)	No differences
Pharmacist, % (n)	0.9 (5)	0.6 (1)	0.9 (2)	0.2 (1)	No differences
Percentage of time in PTSD Service, M (SD)	19.7 (33.7)	21.3 (39.3)	20.1 (35.7)	20.0 (37.0)	No differences
Percentage of time in Substance Abuse Service, M (SD)	2.6 (12.8)	1.6 (6.1)	2.5 (13.5)	2.3 (10.4)	No differences
Percentage of time in PTSD-Substance Abuse Service, M (SD)	0.0 (0.3)	0.0 (0.0)	0.0 (0.2)	0.3 (2.9)	No differences
Percentage of time in General Mental Health Service, M (SD)	61.4 (40.9)	63.8 (45.0)	62.2 (44.4)	61.6 (44.9)	No differences
Percentage of time in Integrated Care Service, M (SD)	5.8 (16.8)	3.1 (11.7)	4.9 (21.8)	6.0 (19.6)	No differences
Percentage of time in Primary Care Service, M (SD)	7.1 (22.6)	7.4 (22.8)	7.3 (30.1)	6.1 (24.6)	No differences

Administration and Policy in Mental Health and Mental Health Services Research

Measurement Strategies for Evidence-Based Psychotherapy for Posttraumatic Stress Disorder Delivery: Trends and Associations with Patient-Reported Outcomes

--Manuscript Draft--

Manuscript Number:	APMH-D-19-00061R1	
Full Title:	Measurement Strategies for Evidence-Based Psychotherapy for Posttraumatic Stress Disorder Delivery: Trends and Associations with Patient-Reported Outcomes	
Article Type:	Original, Unpublished Article	
Keywords:	Quality of Healthcare; Patient Reported Outcomes Measures; Comparative Effectiveness Research; Psychotherapy; Stress Disorders, Posttraumatic	
Corresponding Author:	Brian Shiner, MD, MPH VA Medical Center, White River Junction White River Junction, VT, UNITED STATES	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	VA Medical Center, White River Junction	
Corresponding Author's Secondary Institution:		
First Author:	Brian Shiner, MD, MPH	
First Author Secondary Information:		
Order of Authors:	Brian Shiner, MD, MPH	
	Christine Leonard Westgate, MS	
	Jiang Gui, PhD	
	Sarah Cornelius, BS	
	Shira E. Maguen, PhD	
	Bradley V. Watts, MD, MPH	
	Paula P. Schnurr, PhD	
Order of Authors Secondary Information:		
Funding Information:	Health Services Research and Development (CDA11-263)	Dr. Brian Shiner
	U.S. Department of Defense Joint Warfighter Medical Research Program (JW140056)	Dr. Shira E. Maguen
	VA New England Early Career Development Award (V1CDA10-03)	Dr. Brian Shiner
	DOD Peer Reviewed Medical Research Program (US) (PR160206)	Dr. Brian Shiner

Running head: MEASUREMENT STRATEGIES FOR EBP FOR PTSD DELIVERY

Measurement Strategies for Evidence-Based Psychotherapy for Posttraumatic Stress Disorder
Delivery: Trends and Associations with Patient-Reported Outcomes

Brian Shiner, MD, MPH, Staff Physician¹⁻³; Christine Leonard Westgate, MS, Data Analyst¹;
Jiang Gui, PhD, Biostatistician²; Sarah Cornelius, BS, Research Coordinator¹; Shira E. Maguen,
PhD, Staff Psychologist⁵⁻⁶; Bradley V. Watts, MD, MPH, Executive Director^{2,4}; Paula P.
Schnurr, PhD, Executive Director²⁻³

¹White River Junction VA Medical Center, White River Junction VT

²Geisel School of Medicine at Dartmouth, Hanover NH

³National Center for PTSD Executive Division, White River Junction VT

⁴VA Office of Systems Redesign and Improvement, Washington DC

⁵San Francisco VA Medical Center, San Francisco CA

⁶University of California, San Francisco CA

Author Note

A VA Health Services Research & Development Career Development Award to Dr. Shiner (CDA11-263) funded the development of this cohort. A DoD Joint Warfighter Medical Research Program Award to Dr. Maguen (JW140056) funded the refinement of our strategy to measure evidence-based psychotherapy, which was originally supported with a VA New England Early Career Development Award to Dr. Shiner (V1CDA10-03). A DoD Peer Reviewed Medical Research Program Award to Dr. Shiner (PR160206) funded the development of our strategy to leverage patient-reported outcomes data.

The opinions expressed herein are those of the authors and do not necessarily reflect the positions of the United States Department of Veterans Affairs or the United States Department of Defense.

MEASUREMENT STRATEGIES FOR EBP FOR PTSD DELIVERY

Correspondence concerning this article should be addressed to Brian Shiner, MD, MPH;
White River Junction VA Medical Center, 215 North Main Street, White River Junction VT,
05009

Abstract

We sought to develop a quality standard for the delivery of psychotherapy for posttraumatic stress disorder (PTSD) that is both consistent with the underlying evidence supporting psychotherapy as a treatment for PTSD and associated with the best levels of symptom improvement. We quantified psychotherapy receipt during the initial year of PTSD treatment in a 10-year national cohort of Department of Veterans Affairs (VA) users who completed patient-reported outcome measurement as part of routine practice. We added progressively stringent measurement requirements. The most stringent requirement was associated with superior outcomes. Quality of psychotherapy for PTSD in the VA improved over time.

Keywords: Quality of Healthcare; Patient Reported Outcomes Measures; Comparative Effectiveness Research; Psychotherapy; Stress Disorders, Posttraumatic

Measurement Strategies for Evidence-Based Psychotherapy for Posttraumatic Stress Disorder

Delivery: Trends and Associations with Patient-Reported Outcomes

Posttraumatic stress disorder (PTSD) is a mental health condition that may follow exposure to a traumatic event (American Psychiatric Association, 2013). Symptoms include reexperiencing the trauma, avoidance of reminders of the trauma, arousal, and negative cognitions. PTSD affects approximately 6% of the United States (US) population during their lifetime (Goldstein et al., 2016; Pietrzak, Goldstein, Southwick, & Grant, 2011). Rates are higher in combat or military-exposed populations such as veterans who use health services provided by the US Department of Veterans Affairs (VA; Holowka et al., 2014; Shiner, Drake, Watts, Desai, & Schnurr, 2012). The VA has implemented multiple effective treatments for PTSD, including two specific evidence-based psychotherapy (EBP) protocols (Karlin & Cross, 2014): Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE). CPT is comprised of twelve weekly 60-minute sessions of cognitive therapy, during which veterans address maladaptive thoughts associated with their worst traumatic event (Patricia A. Resick, Monson, & Chard, 2017). CPT can be administered either in an individual therapy format or a group format (P. A. Resick et al., 2015). PE consists of nine to twelve weekly 90-minute sessions of trauma-associated imaginal and in-vivo exposures administered in an individual therapy format (Foa, Hembree, & Rothbaum, 2007). Research trials of CPT and PE have resulted in statistically significant and clinically meaningful improvement in veterans' PTSD symptoms (Haagen, Smid, Knipscheer, & Kleber, 2015). The VHA Uniform Mental Health Services Package mandated the availability of these treatments in VHA clinics beginning in 2008 (Kussman, 2008).

Measuring the implementation of EBPs for PTSD has been a challenge. Single-site studies have used labor-intensive chart review to identify psychotherapy notes indicating the

1
2
3
4 provision of EBPs (Hundt et al., 2015; Kehle-Forbes, Meis, Spoont, & Polusny, 2016; Lamp,
5
6 Maieritch, Winer, Hessinger, & Klenk, 2014; Lu, Plagge, Marsiglio, & Dobscha, 2016; Mott,
7
8 Mondragon, et al., 2014; Mott, Stanley, Street, Grady, & Teng, 2014; Shiner, Bateman, et al.,
9
10 2012). Studies attempting to measure implementation of EBPs for PTSD nationally have relied
11
12 on use of psychotherapy procedural codes (Cully et al., 2008; Mott, Hundt, Sansgiry, Mignogna,
13
14 & Cully, 2014), with some assumptions about how the number and timing of encounters indicate
15
16 that an EBP could have been delivered (Seal et al., 2010; Spoont, Murdoch, Hodges, & Nugent,
17
18 2010). For example, Spoont et al. (2010) measured whether patients had at least eight
19
20 encounters associated with a psychotherapy procedural code over the course of 6 months (Spoont
21
22 et al., 2010), while Seal et al. (2010) determined whether those encounters occurred over the
23
24 course of 15 weeks (Seal et al., 2010). However, assumptions about the use of psychotherapy
25
26 procedural codes may be incorrect, as these codes are not protocol-specific.
27
28
29
30
31
32

33 We have performed three studies using automated natural language processing (NLP) of
34
35 psychotherapy notes to bridge the gap between laborious chart review and efficient but
36
37 potentially inaccurate use of psychotherapy procedural codes. NLP is a method to abstract
38
39 information from large unstructured bodies of note text (Meystre, Savova, Kipper-Schuler, &
40
41 Hurdle, 2008). Our general approach has been to use machine learning to train a computer to
42
43 mimic the judgments of expert clinicians in classifying clinical notes (Hripcsak & Wilcox,
44
45 2002); in our case, practicing therapists classify whether a psychotherapy note describes the
46
47 provision of an EBP for PTSD. In our initial (single-site) study, we found that in 43% of
48
49 encounters with psychotherapy procedural codes, the associated notes described services other
50
51 than psychotherapy, such as intakes, psychological testing, and case management services
52
53 (Shiner, D'Avolio, et al., 2012). This raised concerns about the accuracy of psychotherapy
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 procedural codes. In our second (regional) study of 1,924 patients enrolling in six specialized
5
6 outpatient PTSD clinics, patients had a mean of 9.1 encounters with psychotherapy procedural
7
8 codes over their initial six months of treatment, but only 0.4 of these were EBP sessions (Shiner
9
10 et al., 2013). Importantly, 6.1% (n=121) patients received at least one EBP session. This
11
12 showed both that having a given number of encounters was not a proxy for receiving EBP and
13
14 that it is possible to measure EBP delivery with an automated NLP-based classifier. In our third
15
16 (national) study of 255,933 Iraq and Afghanistan Veterans, we found that 20.2% (n=51,852)
17
18 received at least one EBP session over a median of 4.1 years of observation (Maguen et al.,
19
20 2018). This showed we could efficiently apply an automated NLP-based classifier to a large
21
22 national population. However, in focusing on Iraq and Afghanistan Veterans, this study
23
24 examined only a subset of VA patients with PTSD. Additionally, this work did not examine the
25
26 adequacy of treatment for patients who received EBP.
27
28
29
30
31
32

33 Donabedian (1997) proposed a framework for measuring healthcare quality that divides
34
35 measures into domains of structure, process, and outcome (Donabedian, 1997). In Donabedian's
36
37 model, a quality measure assessing whether patients with PTSD received an EBP would fall
38
39 under the process domain. Such process measures would allow healthcare teams to assess the
40
41 effectiveness of their efforts to improve the quality of care that they deliver. For example, staff
42
43 members at a VA mental health clinic trying to increase the number of patients who receive EBP
44
45 for PTSD might use such a process measure to understand whether their improvement
46
47 intervention has worked. However, this model is predicated upon the validity of the quality
48
49 measure. Chassin, Loeb, Schmaltz, and Wachter (2010) proposed that to be valid, a quality
50
51 measure must capture whether an evidence-based care process has actually been provided. In the
52
53 case of EBP for PTSD, the receipt of at least one session is an insufficient measure of quality
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 because the studies establishing the efficacy of EBP for PTSD typically require multiple weekly
5 sessions delivered by the same therapist over several months. Therefore, now that we can
6
7 classify whether encounters associated with psychotherapy procedural codes include the
8
9 provision of EBP, the next step is to examine the effect of increased measurement requirements
10
11 designed to better approximate the evidence-based care process.
12
13
14

15
16 This study expands our work to all veterans who initiated PTSD care in VA from 2004
17 through 2013. This was a time of intense demographic change (Hermes, Rosenheck, Desai, &
18 Fontana, 2012; Rosenheck & Fontana, 2007) and resource reallocation (Wagner, Sinnott, &
19 Siroka, 2011) in VA, with a national focus on improving the capacity of the VA mental health
20 treatment system to deliver evidence-based treatments (Karlin & Cross, 2014; Rosen et al.,
21 2016). Our objectives were to: (1) measure the delivery of EBPs for PTSD to a national cohort
22 of Veterans from diverse service eras; (2) determine longitudinal trends in EBP for PTSD
23 delivery according to potential quality measures; and (3) determine whether quality measures
24 that more stringently reflect the evidence supporting EBPs are associated with superior
25 outcomes. While the VA has operationalized an EBP reporting strategy that leverages therapist-
26 completed medical record templates (Sripada, Bohnert, Ganoczy, & Pfeiffer, 2018), our prior
27 work has shown that uptake of the templates has lagged therapist-reported use of EBPs (Shiner,
28 Leonard Westgate, et al., 2018). As efforts to incentivize the use standardized reporting tools
29 such as templates are implemented (Sripada, Pfeiffer, Rauch, Ganoczy, & Bohnert, 2018), we
30 feel that our work leveraging historical data will be informative to the VA and other large
31 healthcare systems as they look to leverage these diverse data sources to develop valid quality
32 measures to help drive improvement (Brown, Scholle, & Azur, 2014; Hepner et al., 2016).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Method

Data Source

We used the VA corporate data warehouse (CDW) to identify patients with new PTSD treatment episodes from fiscal year 2004 (FY04) through FY13. We obtained patient demographic information as well as encounter, diagnostic, patient-reported outcome, and pharmacy data from the CDW. The Veterans Institutional Review Board of Northern New England and VA National Data Systems approved this study.

Patients

We included VA users who received a primary diagnosis of PTSD at two or more outpatient encounters, at least one of which occurred in a mental health setting, over the course of 90 days between October 1, 2003 and September 30, 2013 and had not met this criterion during the prior two years. We examined one year of treatment receipt following the first diagnosis of the two qualifying diagnoses. This was called the “index PTSD diagnosis.” When patients met the cohort inclusion criteria multiple times over the 10-year period, only their first episode was included. This resulted in a cohort of 731,520 patients. This cohort has been previously described elsewhere (Shiner, Leonard Westgate, Bernardy, Schnurr, & Watts, 2017; Shiner, Leonard Westgate, Harik, Watts, & Schnurr, 2016; Shiner, Westgate, Bernardy, Schnurr, & Watts, 2017).

Evidence-Based Psychotherapy for PTSD Receipt

We identified all encounters associated with psychotherapy procedural codes for each patient during the one-year period of observation and linked these encounters to the related treatment notes. This resulted in a set of 18,185,216 documents. We used our previously-developed NLP-based classifier, which has an overall classification accuracy of 0.92 (Maguen et

1
2
3
4 al., 2018), to determine whether each document described the provision of psychotherapy at all,
5
6 whether psychotherapy documents described the provision of PE or CPT, and whether CPT was
7
8 delivered in a group or an individual format (CPT-G, CPT-I). We found that 0.5% (n=88,674) of
9
10 documents described PE, 0.8% (n=143,147) of documents described CPT-G, 1.2% (n=217,250)
11
12 of documents described CPT-I, 30.6% (n=5,558,844) of documents described other group or
13
14 individual psychotherapy, and 67.0% (n=12,177,301) of documents did not describe
15
16 psychotherapy at all.
17
18
19
20

21 **Measures of Psychotherapy Quality**

22
23 We followed a series of progressively restrictive steps in calculating our putative
24
25 measures of psychotherapy quality. First, we used the NLP-based classifier results to determine
26
27 whether each patient received any psychotherapy, any individual psychotherapy, any group
28
29 psychotherapy, as well as each of the EBPs during their initial year of treatment based on their
30
31 clinical notes. Second, we added a requirement that patients had an “adequate” number of
32
33 psychotherapy sessions, defined here as eight or more sessions. Outcomes research in
34
35 psychotherapy for anxiety and depressive disorders has indicated that half of patients achieve a
36
37 clinically meaningful improvement after eight sessions (Howard, Kopta, Krause, & Orlinsky,
38
39 1986). Similarly, most patients who respond to evidence-based psychotherapies for PTSD have
40
41 achieved the bulk of their gains by session eight (Galovski, Blain, Mott, Elwood, & Houle, 2012;
42
43 Tuerk et al., 2011). Third, we added a requirement that the eight sessions be delivered by the
44
45 same therapist. Continuity of care is associated with improved health outcomes across disorders
46
47 (van Walraven, Oake, Jennings, & Forster, 2010), and in mental health treatment in particular
48
49 (Adair et al., 2005). For group therapy led by two-therapist teams, each therapist was considered
50
51 separately for meeting this requirement. Fourth, we added a requirement that eight sessions be
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 delivered during a 14-week period. Because both PE and CPT are designed for delivery in a
5
6 weekly or twice-a-week format (Foa et al., 2005; P. A. Resick, Nishith, Weaver, Astin, & Feuer,
7
8 2002), this requirement ensures that the sessions are spaced in a similar manner to the efficacy
9
10 trials supporting clinical practice, while allowing some flexibility for missed or rescheduled
11
12 sessions. This treatment density standard has been used as part of VA psychotherapy
13
14 performance measures (Trafton et al., 2013).
15
16
17

18 **Concurrent Evidence-Based Medication for PTSD Receipt**

19
20
21 We determined whether patients also received adequate trials of evidence-based
22
23 medications for PTSD. To do this, we examined all medications dispensed by VA pharmacies
24
25 during the year following the index PTSD diagnosis. Antidepressant drug names were classified
26
27 into categories for individual agents and an overall category. The antidepressant drug class label
28
29 was used to confirm our coding. We determined whether patients received one of the four
30
31 effective antidepressants for PTSD specifically recommended in the VA/Department of Defense
32
33 Clinical Practice Guideline (VA/DoD CPG) in place during the time our cohort received
34
35 treatment (Friedman, Lowry, & Ruzek, 2010). These included fluoxetine, paroxetine, sertraline,
36
37 and venlafaxine. For patients who received one of the four effective antidepressants for PTSD,
38
39 we determined whether they received an adequate treatment, which we defined as eight weeks of
40
41 a daily dose at least as high as the dose used in the efficacy trials supporting the treatment
42
43 recommendation (Jonas et al., 2013; Watts et al., 2013). While the length of efficacy trials of
44
45 psychotropic medications for PTSD varies, the VA/DoD CPG recommended medication trials of
46
47 at least eight weeks (Friedman et al., 2010). Therefore, participants receiving continuous
48
49 treatment of one of the following medications daily for eight weeks or more were considered to
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 have received an adequate medication trial (AMT): fluoxetine 20 mg or more daily, paroxetine
5
6 20 mg or more daily, sertraline 100 mg or more daily, and venlafaxine 150 mg or more daily.
7
8

9 **Covariates**

10
11 We developed three groups of covariates. First, we examined patient characteristics,
12
13 such as age, gender, race, military service era, rurality, military-related exposures (including
14
15 combat and sexual trauma), and medical and psychiatric comorbidities. Second, we examined
16
17 health service use characteristics including prior receipt of psychotherapy, outpatient visits,
18
19 emergency department visits, and admissions. For prior receipt of psychotherapy, we assessed
20
21 whether patients had an outpatient encounter associated with psychotherapy procedural codes in
22
23 the two years prior to their index PTSD diagnosis. Outpatient visits included visits to specialized
24
25 PTSD clinics, general mental health clinics, substance abuse clinics, and integrated primary care-
26
27 mental health clinics. Emergency department visits included those for a psychiatric indication.
28
29 Admissions included stays on an acute inpatient psychiatric clinic, a residential PTSD treatment
30
31 program, or a residential substance abuse program. Third, we examined therapist characteristics.
32
33 Patients were assigned a primary therapist based on the clinician who completed the plurality of
34
35 their psychotherapy encounters. Primary therapists were characterized by age, gender, service
36
37 section, and professional background. Service section included specialized PTSD, general
38
39 mental health, substance abuse, and primary care-mental health integration clinics. Because
40
41 individual therapists may work across multiple service sections, we calculated the percentage of
42
43 time they spend seeing PTSD patients in various settings. This was based on our assumption that
44
45 therapists who spend a higher percentage of their time in specialized PTSD settings may bring
46
47 increased knowledge and experience in treating PTSD, even when seeing patients in non-
48
49 specialized settings. Professional background included psychologist, social worker, nurse, and
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 psychiatrist. To account for the possibility that some psychotherapy might be delivered briefly
5
6 in the course of medication management, we assessed whether each provider had prescription
7
8 privileges.
9

10 11 **Patient-Reported Outcomes Assessment** 12

13
14 Use of patient-reported outcome measurement using the PTSD Checklist (PCL;
15
16 Weathers, Litz, Herman, Huska, & Keane, 1993) as part of routine practice became more
17
18 common beginning in FY08 (Shiner, Westgate, et al., 2018). Therefore, we obtained available
19
20 PCL data for the FY08-13 portion of the cohort. During these years, the VA used the version of
21
22 the PCL corresponding to PTSD diagnostic criteria in the fourth version of the Diagnostic and
23
24 Statistical Manual of Mental Disorders, or DSM-IV (American Psychiatric Association, 2000;
25
26 Wilkins, Lang, & Norman, 2011). This version of the PCL was a 17-item measure with each
27
28 item rated on a five-point Likert-type scale, resulting in total scores ranging from 17 through 85
29
30 (Weathers et al., 1993). Respondents were asked to rate how much they are bothered by each
31
32 symptom over the last month. Symptom presence was determined by a response of
33
34 “moderately” or greater (Weathers et al., 1993). Therefore, the tool could be used to determine
35
36 whether patients meet minimal symptomatic criteria for PTSD according to DSM-IV, defined as
37
38 one re-experiencing symptom, three avoidance and numbing symptoms, and two hyperarousal
39
40 symptoms. Clinically meaningful improvement has been previously defined as a decrease of 10
41
42 points or more on the PCL (Monson et al., 2008). A clinically meaningful improvement in PTSD
43
44 symptoms plus no longer meeting diagnostic criteria for PTSD has been shown to be an
45
46 important marker of improved quality of life (Schnurr & Lunney, 2016).
47
48
49
50
51
52
53
54

55 **Analysis** 56 57 58 59 60 61 62 63 64 65

1
2
3
4 Our analysis plan was divided into descriptive and causal elements. For descriptive
5
6 analyses using the entire FY04-13 cohort, we summarized cohort characteristics and compared
7
8 patients who had at least one encounter that was administratively coded as psychotherapy with
9
10 those who did not using t-test or χ^2 analysis, as appropriate. We then described psychotherapy
11
12 receipt as measured using both administrative coding and the NLP-based clinical note
13
14 classification algorithm for the entire cohort during each fiscal year and for the overall 10-year
15
16 period. We then focused on psychotherapy initiation by excluding patients who had encounters
17
18 that were administratively coded as psychotherapy in the two years prior to their index PTSD
19
20 diagnosis and recalculated initiation rates for each psychotherapy category for each individual
21
22 fiscal year and for the overall 10-year period. We progressively added the measures of
23
24 psychotherapy quality described above to this sub-cohort newly initiating psychotherapy,
25
26 representing the cumulative number of patients who met each increasingly restrictive standard
27
28 during their first year of PTSD treatment.
29
30
31
32
33
34

35
36 For causal analyses using patients from the FY08-13 portion of the cohort, we identified
37
38 patients who initiated EBP at progressively higher levels of adherence to our “quality” measures
39
40 (8 visits, 8 visits with the same therapist, 8 visits with the same therapist within 14 weeks) and
41
42 had concurrent symptoms measurement using the PCL, as defined below. We created
43
44 orthogonal comparison groups by including patients only in the longitudinally earliest (first
45
46 during treatment year) quality standard that they met. Patients who initiated care that met
47
48 multiple quality standards on the same day were assigned to the strictest standard met on that
49
50 day. From this group, we selected patients who had a minimum of a PCL score at or before the
51
52 second session (baseline) but no more than 14 days prior to the first session, and at or after the
53
54 seventh session (follow-up) but no more than 14 days after the eighth session. To ensure patients
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 had active PTSD symptoms at baseline, we required that they meet DSM-IV symptomatic
5
6 criteria on their baseline PCL. When there were multiple PCL scores meeting our baseline
7
8 criterion, we selected the measure closest to session 1. When there were multiple PCL scores
9
10 meeting our follow-up criterion, we selected the measure closest to session 8. We calculated two
11
12 change measures from baseline to follow-up: 1) mean PCL change, and 2) “loss of diagnosis,”
13
14 which included both no longer meeting symptomatic criteria for PTSD plus experiencing a
15
16 meaningful decrease in symptoms of 10 points or more.
17
18
19
20

21 Following a procedure developed in prior work (Shiner, Westgate, et al., 2018), we
22
23 examined both the raw change in PTSD symptoms among those with measurement and the
24
25 patient characteristic-weighted mean change, as well as the percentage of patients achieving our
26
27 reliable change and loss of diagnosis criteria. Given that we were comparing three conditions (8
28
29 visits, 8 visits with the same therapist, 8 visits with the same therapist within 14 weeks), we used
30
31 a conservative Bonferroni-corrected alpha of $p < 0.0167$ for pre/post comparisons to avoid type I
32
33 error. We balanced patient characteristics that have a plausible association with the outcome
34
35 using inverse propensity of treatment weighting (IPTW; Stuart, 2010). We estimated propensity
36
37 scores with multinomial logistic regression using generalized booster effects (McCaffrey et al.,
38
39 2013), in which case the dependent variable is an indicator for the quality standard met and the
40
41 independent variables are an antiparsimonious specification of variables that have a plausible
42
43 correlation with the outcome. Using these propensity scores, we weighted participants in order
44
45 to balance the pretreatment covariate distribution. Covariates in the IPTW model included
46
47 baseline PCL score, number of days between the baseline PCL and session 1, number of days
48
49 between follow-up PCL and session 8, and all covariates described in Table 1. In balancing
50
51 almost 50 patient characteristics, a Bonferroni correction would indicate a corrected alpha of
52
53
54
55
56
57
58
59
60
61
62
63
64
65

p<0.001. However, we conservatively maintained an alpha threshold of p<0.01 for significant differences to avoid type II error. Therefore, covariates that continued to differ at the p<0.01 threshold after IPTW were included as covariates in models of change in PTSD symptoms. We assessed the potential contribution of unmeasured confounding on our results by calculating E-values, which indicate the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the exposure and the outcome, conditional on the measured covariates, to fully explain away a specific exposure-outcome association (Haneuse, VanderWeele, & Arterburn, 2019; VanderWeele & Ding, 2017).

In addition to our pre/post measures, we performed a repeated measures model that included all PCL measurements between baseline and follow-up. We used a generalized linear mixed model (GLMM) to account for both within-person and across-person variability. We compared changes in PTSD symptom during the time treatment was delivered, including a time by treatment interaction to measure the change in slope over time among the three treatment groups. The model is weighted by the inverse of the propensity scores and adjusted for any unbalanced covariates (p<0.01). We performed data management in SAS version 9.4 (SAS Institute), and developed causal models in R version 3.5.0 (R core team). This included IPTW models created using the R twang package (Ridgeway, McCaffrey, Morral, Burgette, & Griffin, 2017), and models to detect unmeasured confounding using the R evalua package (Mathur, Ding, & VanderWeele, 2018).

Results

Of the 731,520 patients in our cohort, 88.6% (n=647,513) had at least one psychotherapy procedural code during their first year of PTSD treatment. Patients who did and did not receive a

1
2
3
4 psychotherapy procedural code differed on almost all variables (Table 1). Most prominently,
5
6 those who received a psychotherapy procedural code were more likely to be women, to have
7
8 experienced sexual trauma while in the military, and to have comorbid psychiatric and substance
9
10 abuse diagnoses. At the same time, they were less likely to be rural or to have been exposed to
11
12 combat. They also received other VA health services at higher levels, and importantly, 47.1%
13
14 (n=305,132) also received a psychotherapy procedural code in the two years prior to their index
15
16 PTSD diagnosis. Almost half of patients who received a psychotherapy procedural code saw a
17
18 woman as their primary therapist, and patients most commonly saw a psychologist or social
19
20 worker as their primary therapist. In over a third of cases, the primary therapist had prescription
21
22 privileges, indicating that therapy could have been coded as part of medication management.
23
24 Patients primary therapists generally spent most of their time in general mental health settings,
25
26 followed by specialized PTSD settings.
27
28
29
30
31
32

33 In the overall cohort, use of any psychotherapy, whether classified using procedural
34
35 codes or natural language processing, increased over the 10-year period of examination (Table
36
37 2). While the percentage of patients receiving at least one psychotherapy procedural code had
38
39 little room for improvement, the difference between receipt of any psychotherapy as measured
40
41 using procedural codes and as measured using NLP decreased from FY04-05 (86.0% versus
42
43 54.7%) to FY12-13 (90.2% versus 65.8%). At the same time, the mean number of
44
45 psychotherapy encounters remained stable (9.3 versus 10.0). This indicates that despite
46
47 persistence of procedural coding discrepancies, more patients with PTSD were actually receiving
48
49 psychotherapy during administratively coded psychotherapy encounters by the end of the period
50
51 of examination. Furthermore, there was a dramatic increase in the use of EBP for PTSD, from
52
53
54
55
56
57
58
59
60
61
62
63
64
65

0.7% in FY04-05 to 14.1% in FY12-13. The most common EBP modality was individual CPT-I, followed by CPT-G, and PE.

We then applied quality standards to psychotherapy receipt among the 54.1% (n=396,032) of patients initiating psychotherapy after their index PTSD diagnosis. This resulted in a decrease in the percentage of patients who met those standards as the standards became more stringent (Table 3). For example, while 86.5% received at least one procedural code for psychotherapy in their first year of treatment, only 13.8% received eight or more sessions (as measured using procedural codes) over the course of any 14-week period. Similarly, if we use NLP rather than procedural codes to classify psychotherapy receipt, the figure drops from 13.8% to 11.4%. If we then require that NLP indicates the sessions are EBP, the figure drops from 11.4% to 2.0%. Therefore, estimates of psychotherapy receipt appear to be highly dependent on both the restrictiveness of the quality standards and the content of the psychotherapy notes. Despite these caveats, quality as determined by all standards we applied improved over time during the period of examination (Appendix 1).

A substantial number of patients from the FY08-13 cohort who met our increasingly restrictive quality standards had PCL measurement aligned with sessions 1 and 8 and were included in analyses comparing outcomes among patients who met increasingly strict quality standards. Among the 10,765 patients who had 8 or more sessions of EBP as measured using NLP, 19.1% (n=2,052) met our PCL-based inclusion criteria. Table 4 shows that there were few significant differences among patients who had 8 or more sessions of EBP with and without aligned PCL measurement. Furthermore, where differences were significant, the magnitude was small. After applying the IPTW procedure to balance covariates across quality standard groups,

only one unbalanced variable remained (Appendix 2): days between baseline PCL and session 1. This unbalanced variable was used as a covariate in weighted analyses.

In pre/post causal analyses, the most stringent quality standard (8 EBP sessions with the same therapist within 14 weeks) was associated with significantly higher rates of loss of diagnosis (23.3% versus 13.8%; $p=0.0004$, $e=2.78$) and continuous improvement on the PCL (-9.3 versus -7.1; $p=0.0101$, $e=1.60$) than the least stringent standard (any 8 EBP sessions during the first year of treatment, but not the second most stringent quality standard (8 EBP sessions with the same therapist during the first year of treatment)). However, the second most stringent quality standard was not significantly superior to the least stringent quality standard, indicating that across data sources, only the strictest definition of treatment adequacy was consistently associated with superior pre/post outcomes. The e-value findings indicate that it would take a very strong unmeasured confounder (relative risk of 2.78 or greater) to overturn the loss of diagnosis finding and a moderately strong unmeasured confounder (relative risk of 1.60 or greater) to overturn the continuous improvement on the PCL finding. Our GLMM approach supports this assessment (Figure 1). The rate of improvement in PCL score was best when using the most stringent treatment adequacy standard. Thus, requiring a quality standard of 8 or more sessions with the same therapist within 14 weeks was associated with both the greatest amount of pre/post change and the fastest rate of change.

Discussion

We found that psychotherapy for PTSD quality standards that more stringently reflect the underlying evidence were associated with superior outcomes in clinical practice. Thus, our work provides preliminary validity for an NLP-based quality measure comprising eight or more

1
2
3
4 sessions of EBP, delivered by the same therapist, over the course of 14 weeks. The percentage of
5
6 VA patients with new PTSD treatment episodes meeting this standard improved from 0.1% to
7
8 3.7% over a 10-year period marked by investment in mental health services from 2004 through
9
10 2013. This improvement is likely a reflection of the resources invested in the national
11
12 implementation of EBP for PTSD. However, these findings highlight that while most patients
13
14 initiating PTSD care in the VA did receive some psychotherapy in the initial year, the vast
15
16 majority did not meet this quality standard. Thus, it is possible that many patients initiating care
17
18 during this period would have benefited from more intensive treatment. This work shows that by
19
20 examining the content of psychotherapy sessions, it is possible to avoid overestimating treatment
21
22 quality, providing a more accurate baseline against which to measure the effect of improvement
23
24 efforts. Regardless of how session content is measured in the future (e.g., NLP of note text
25
26 versus the use of EBP-specific note templates), our work provides a basic framework for using
27
28 the related data to develop an EBP for PTSD quality measure.
29
30
31
32
33
34
35

36 Our study addresses several gaps in the available research regarding quality measurement
37
38 for PTSD treatment. First, few studies include clinical detail from chart notes, such as whether an
39
40 EBP was delivered (Hepner et al., 2016). By using NLP, we were able to identify when an EBP
41
42 was delivered for each person in the cohort and incorporate this information into our quality
43
44 measures. Similarly, most measures of psychotherapy focus on access to care or quantifying the
45
46 number of visits, and often this is due to limited data on diagnosis, severity of illness, treatment
47
48 history, and the content and number of visits (Brown, Scholle, & Azur, 2014). Availability of
49
50 these additional factors in our dataset allowed us to perform causal analyses in order to determine
51
52 whether various definitions of quality were associated with improved PTSD outcomes.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 There are several limitations to our study. First, we did not examine a range of cutoffs
5
6 for the required number of sessions and for number of weeks over which those sessions should
7
8 be delivered. Examining multiple cutoffs would have created an unmanageable number of
9
10 comparisons, across which we would have had to balance our covariates to avoid bias in causal
11
12 analyses. Thus, we used a single standard for number of sessions supported by prior research
13
14 and a single standard for treatment density that has been used operationally in the VA. Future
15
16 research should address the question of the minimal number of sessions for an adequate
17
18 treatment and the maximum amount of time over which those sessions should be delivered.
19
20
21 Second, we did not compare EBP to non-EBP. Extensive available research already
22
23 demonstrates that trauma-focused evidence-based psychotherapy for PTSD is associated with
24
25 superior outcomes to non-specific psychotherapy in the treatment of PTSD (The Management of
26
27 Posttraumatic Stress Disorder Work Group, 2017). While additional “real world” studies about
28
29 the clinical effectiveness of EBPs for PTSD (compared to other treatments) may be warranted,
30
31 our work is not designed to make those inferences. Fourth, there were several differences in
32
33 potentially important patient and therapist characteristics among those meeting various quality
34
35 standards. However, analyses controlled for key differences and our sensitivity analyses indicate
36
37 that unmeasured confounding is unlikely to overturn our outcome. Finally, even NLP of
38
39 psychotherapy notes to detect EBP use is a proxy measure of EBP delivery. Without video, we
40
41 cannot be sure what happened during psychotherapy sessions. However, we believe that our
42
43 NLP method is the closet possible approximation to study EBP implementation in the VA during
44
45 the critical time period examined.
46
47
48
49
50
51
52
53

54
55 In summary, this research demonstrates that a theoretically-oriented approach to quality
56
57 measurement can be used to create the basic structure of a psychotherapy for PTSD quality
58
59
60
61
62
63
64
65

1
2
3
4 measure. While our work captures the receipt of effective and timely treatment, our measure of
5
6 quality is incomplete. Health systems should also seek to provide PTSD care that is safe, patient-
7
8 centered, equitable, and efficient (Pincus et al., 2007).
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- Adair, C. E., McDougall, G. M., Mitton, C. R., Joyce, A. S., Wild, T. C., Gordon, A., . . . Beckie, A. (2005). Continuity of care and health outcomes among persons with severe mental illness. *Psychiatr Serv*, 56(9), 1061-1069. doi:10.1176/appi.ps.56.9.1061
- American Psychiatric Association. (2000). *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision: DSM-IV-TR*. Arlington, VA: American Psychiatric Association.
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders : DSM-5* (5th ed.). Arlington, VA: American Psychiatric Association.
- Brown, J., Scholle, S. H., & Azur, M. (2014). *Strategies for Measuring the Quality of Psychotherapy: A White Paper to Inform Measure Development and Implementation*. Washington, DC: Mathematica Policy Research Retrieved from <https://aspe.hhs.gov/report/strategies-measuring-quality-psychotherapy-white-paper-inform-measure-development-and-implementation>.
- Chassin, M. R., Loeb, J. M., Schmaltz, S. P., & Wachter, R. M. (2010). Accountability measures--using measurement to promote quality improvement. *N Engl J Med*, 363(7), 683-688. doi:10.1056/NEJMSb1002320
- Cully, J. A., Tolpin, L., Henderson, L., Jimenez, D., Kunik, M. E., & Petersen, L. A. (2008). Psychotherapy in the Veterans Health Administration: Missed Opportunities? *Psychol Serv*, 5(4), 320-331. doi:10.1037/a0013719
- Donabedian, A. (1997). The quality of care. How can it be assessed? 1988. *Arch Pathol Lab Med*, 121(11), 1145-1150.
- Foa, E. B., Hembree, E. A., Cahill, S. P., Rauch, S. A., Riggs, D. S., Feeny, N. C., & Yadin, E. (2005). Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. *J Consult Clin Psychol*, 73(5), 953-964. doi:10.1037/0022-006X.73.5.953
- Foa, E. B., Hembree, E. A., & Rothbaum, B. O. (2007). *Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences* New York: Oxford University Press.
- Friedman, M. J., Lowry, P., & Ruzek, J. (2010). VA/DoD clinical practice guidelines for the management of post-traumatic stress Retrieved from www.healthquality.va.gov
- Galovski, T. E., Blain, L. M., Mott, J. M., Elwood, L., & Houle, T. (2012). Manualized therapy for PTSD: flexing the structure of cognitive processing therapy. *J Consult Clin Psychol*, 80(6), 968-981. doi:10.1037/a0030600
- Goldstein, R. B., Smith, S. M., Chou, S. P., Saha, T. D., Jung, J., Zhang, H., . . . Grant, B. F. (2016). The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Soc Psychiatry Psychiatr Epidemiol*, 51(8), 1137-1148. doi:10.1007/s00127-016-1208-5
- Haagen, J. F., Smid, G. E., Knipscheer, J. W., & Kleber, R. J. (2015). The efficacy of recommended treatments for veterans with PTSD: A metaregression analysis. *Clin Psychol Rev*, 40, 184-194. doi:10.1016/j.cpr.2015.06.008
- Haneuse, S., VanderWeele, T. J., & Arterburn, D. (2019). Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. *JAMA*, 321(6), 602-603. doi:10.1001/jama.2018.21554
- Hepner, K.A., Sloss, E.M., Roth, C.R., Krull, H., Paddock, S.M., Moen, S., Timmer, M.T., & Pincus, H.A. (2016). *Quality of Care for PTSD and Depression in the Military Health System: Phase I Report*. Santa Monica, CA: RAND Corporation.
- Hermes, E. D., Rosenheck, R. A., Desai, R., & Fontana, A. F. (2012). Recent trends in the treatment of posttraumatic stress disorder and other mental disorders in the VHA. *Psychiatr Serv*, 63(5), 471-476. doi:10.1176/appi.ps.201100432

- 1
2
3
4 Holowka, D. W., Marx, B. P., Gates, M. A., Litman, H. J., Ranganathan, G., Rosen, R. C., & Keane, T. M.
5 (2014). PTSD diagnostic validity in Veterans Affairs electronic records of Iraq and Afghanistan
6 veterans. *J Consult Clin Psychol*, 82(4), 569-579. doi:10.1037/a0036347
7
8 Howard, K. I., Kopta, S. M., Krause, M. S., & Orlinsky, D. E. (1986). The dose-effect relationship in
9 psychotherapy. *Am Psychol*, 41(2), 159-164.
10
11 Hripcsak, G., & Wilcox, A. (2002). Reference standards, judges, and comparison subjects: roles for
12 experts in evaluating system performance. *J Am Med Inform Assoc*, 9(1), 1-15.
13
14 Hundt, N. E., Mott, J. M., Miles, S. R., Arney, J., Cully, J. A., & Stanley, M. A. (2015). Veterans'
15 perspectives on initiating evidence-based psychotherapy for posttraumatic stress disorder.
16 *Psychol Trauma*, 7(6), 539-546. doi:10.1037/tra0000035
17
18 Jonas, D. E., Cusack, K., Forneris, C. A., Wilkins, T. M., Sonis, J., Middleton, J. C., . . . Gaynes, B. N. (2013)
19 *Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder*
20 (PTSD). Rockville (MD).
21
22 Karlin, B. E., & Cross, G. (2014). From the laboratory to the therapy room: National dissemination and
23 implementation of evidence-based psychotherapies in the U.S. Department of Veterans Affairs
24 Health Care System. *Am Psychol*, 69(1), 19-33. doi:10.1037/a0033888
25
26 Kehle-Forbes, S. M., Meis, L. A., Spoont, M. R., & Polusny, M. A. (2016). Treatment initiation and dropout
27 from prolonged exposure and cognitive processing therapy in a VA outpatient clinic. *Psychol*
28 *Trauma*, 8(1), 107-114. doi:10.1037/tra0000065
29
30 Kussman, M. J. (2008). *VHA Handbook 1160.01: Uniform Mental Health Services in VA Medical Centers*
31 *and Clinics*. Washington, D.C.: Department of Veterans Affairs Retrieved from
32 https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=1762.
33
34 Lamp, K., Maieritch, K. P., Winer, E. S., Hessinger, J. D., & Klenk, M. (2014). Predictors of treatment
35 interest and treatment initiation in a VA outpatient trauma services program providing
36 evidence-based care. *J Trauma Stress*, 27(6), 695-702. doi:10.1002/jts.21975
37
38 Lu, M. W., Plagge, J. M., Marsiglio, M. C., & Dobscha, S. K. (2016). Clinician Documentation on Receipt of
39 Trauma-Focused Evidence-Based Psychotherapies in a VA PTSD Clinic. *J Behav Health Serv Res*,
40 43(1), 71-87. doi:10.1007/s11414-013-9372-9
41
42 Maguen, S., Madden, E., Patterson, O. V., DuVall, S. L., Goldstein, L. A., Burkman, K., & Shiner, B. (2018).
43 Measuring Use of Evidence Based Psychotherapy for Posttraumatic Stress Disorder in a Large
44 National Healthcare System. *Adm Policy Ment Health*. doi:10.1007/s10488-018-0850-5
45
46 Mathur, M. B., Ding, P., & VanderWeele, T. J. (2018). Package 'EValue': Sensitivity Analyses for
47 Unmeasured Confounding in Observational Studies and Meta-Analyses. Retrieved from
48 <https://cran.r-project.org/web/packages/EValue/EValue.pdf>
49
50 McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013). A
51 tutorial on propensity score estimation for multiple treatments using generalized boosted
52 models. *Stat Med*, 32(19), 3388-3414. doi:10.1002/sim.5753
53
54 Meystre, S. M., Savova, G. K., Kipper-Schuler, K. C., & Hurdle, J. F. (2008). Extracting information from
55 textual documents in the electronic health record: a review of recent research. *Yearb Med*
56 *Inform*, 128-144.
57
58 Monson, C. M., Gradus, J. L., Young-Xu, Y., Schnurr, P. P., Price, J. L., & Schumm, J. A. (2008). Change in
59 posttraumatic stress disorder symptoms: do clinicians and patients agree? *Psychol Assess*, 20(2),
60 131-138. doi:10.1037/1040-3590.20.2.131
61
62 Mott, J. M., Hundt, N. E., Sansgiry, S., Mignogna, J., & Cully, J. A. (2014). Changes in psychotherapy
63 utilization among veterans with depression, anxiety, and PTSD. *Psychiatr Serv*, 65(1), 106-112.
64 doi:10.1176/appi.ps.201300056
65

- 1
2
3
4 Mott, J. M., Mondragon, S., Hundt, N. E., Beason-Smith, M., Grady, R. H., & Teng, E. J. (2014).
5 Characteristics of U.S. veterans who begin and complete prolonged exposure and cognitive
6 processing therapy for PTSD. *J Trauma Stress*, 27(3), 265-273. doi:10.1002/jts.21927
7
8 Mott, J. M., Stanley, M. A., Street, R. L., Jr., Grady, R. H., & Teng, E. J. (2014). Increasing engagement in
9 evidence-based PTSD treatment through shared decision-making: a pilot study. *Mil Med*, 179(2),
10 143-149. doi:10.7205/MILMED-D-13-00363
11
12 Pietrzak, R. H., Goldstein, R. B., Southwick, S. M., & Grant, B. F. (2011). Prevalence and Axis I comorbidity
13 of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the
14 National Epidemiologic Survey on Alcohol and Related Conditions. *J Anxiety Disord*, 25(3), 456-
15 465. doi:10.1016/j.janxdis.2010.11.010
16
17 Pincus, H. A., Page, A. E., Druss, B., Appelbaum, P. S., Gottlieb, G., & England, M. J. (2007). Can psychiatry
18 cross the quality chasm? Improving the quality of health care for mental and substance use
19 conditions. *Am J Psychiatry*, 164(5), 712-719. doi:10.1176/ajp.2007.164.5.712
20
21 Resick, P. A., Monson, C. M., & Chard, K. M. (2017). *Cognitive processing therapy for PTSD : a
22 comprehensive manual*. New York: Guilford Press.
23
24 Resick, P. A., Nishith, P., Weaver, T. L., Astin, M. C., & Feuer, C. A. (2002). A comparison of cognitive-
25 processing therapy with prolonged exposure and a waiting condition for the treatment of
26 chronic posttraumatic stress disorder in female rape victims. *J Consult Clin Psychol*, 70(4), 867-
27 879.
28
29 Resick, P. A., Wachen, J. S., Mintz, J., Young-McCaughan, S., Roache, J. D., Borah, A. M., . . . Peterson, A.
30 L. (2015). A randomized clinical trial of group cognitive processing therapy compared with group
31 present-centered therapy for PTSD among active duty military personnel. *J Consult Clin Psychol*,
32 83(6), 1058-1068. doi:10.1037/ccp0000016
33
34 Ridgeway, G., McCaffrey, D. F., Morral, A. R., Burgette, L. F., & Griffin, B. A. (2017). *Toolkit for Weighting
35 and Analysis of Nonequivalent Groups: A Tutorial for the TWANG Package*. Santa Monica, CA:
36 RAND Corporation.
37
38 Rosen, C. S., Matthieu, M. M., Wiltsey Stirman, S., Cook, J. M., Landes, S., Bernardy, N. C., . . . Watts, B.
39 V. (2016). A Review of Studies on the System-Wide Implementation of Evidence-Based
40 Psychotherapies for Posttraumatic Stress Disorder in the Veterans Health Administration. *Adm
41 Policy Ment Health*, 43(6), 957-977. doi:10.1007/s10488-016-0755-0
42
43 Rosenheck, R. A., & Fontana, A. F. (2007). Recent trends in VA treatment of post-traumatic stress
44 disorder and other mental disorders. *Health Aff (Millwood)*, 26(6), 1720-1727.
45 doi:10.1377/hlthaff.26.6.1720
46
47 Schnurr, P. P., & Lunney, C. A. (2016). Symptom Benchmarks of Improved Quality of Life in Ptsd. *Depress
48 Anxiety*, 33(3), 247-255. doi:10.1002/da.22477
49
50 Seal, K. H., Maguen, S., Cohen, B., Gima, K. S., Metzler, T. J., Ren, L., . . . Marmar, C. R. (2010). VA mental
51 health services utilization in Iraq and Afghanistan veterans in the first year of receiving new
52 mental health diagnoses. *J Trauma Stress*, 23(1), 5-16. doi:10.1002/jts.20493
53
54 Shiner, B., Bateman, D., Young-Xu, Y., Zayed, M., Harmon, A. L., Pomerantz, A., & Watts, B. V. (2012).
55 Comparing the stability of diagnosis in full vs. partial posttraumatic stress disorder. *J Nerv Ment
56 Dis*, 200(6), 520-525. doi:10.1097/NMD.0b013e318257c6da
57
58 Shiner, B., D'Avolio, L. W., Nguyen, T. M., Zayed, M. H., Watts, B. V., & Fiore, L. (2012). Automated
59 classification of psychotherapy note text: implications for quality assessment in PTSD care. *J Eval
60 Clin Pract*, 18(3), 698-701. doi:10.1111/j.1365-2753.2011.01634.x
61
62 Shiner, B., D'Avolio, L. W., Nguyen, T. M., Zayed, M. H., Young-Xu, Y., Desai, R. A., . . . Watts, B. V. (2013).
63 Measuring use of evidence based psychotherapy for posttraumatic stress disorder. *Adm Policy
64 Ment Health*, 40(4), 311-318. doi:10.1007/s10488-012-0421-0
65

- Shiner, B., Drake, R. E., Watts, B. V., Desai, R. A., & Schnurr, P. P. (2012). Access to VA services for returning veterans with PTSD. *Mil Med*, 177(7), 814-822.
- Shiner, B., Leonard Westgate, C., Bernardy, N. C., Schnurr, P. P., & Watts, B. V. (2017). Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder. *J Dual Diagn*, 13(3), 201-212. doi:10.1080/15504263.2017.1325033
- Shiner, B., Leonard Westgate, C., Harik, J. M., Watts, B. V., & Schnurr, P. P. (2016). Effect of Patient-Therapist Gender Match on Psychotherapy Retention Among United States Veterans with Posttraumatic Stress Disorder. *Adm Policy Ment Health*. doi:10.1007/s10488-016-0761-2
- Shiner, B., Leonard Westgate, C., Simiola, V., Thompson, R., Schnurr, P. P., & Cook, J. M. (2018). Measuring Use of Evidence-Based Psychotherapy for PTSD in VA Residential Treatment Settings with Clinician Survey and Electronic Medical Record Templates. *Mil Med*. doi:10.1093/milmed/usy008
- Shiner, B., Westgate, C. L., Bernardy, N. C., Schnurr, P. P., & Watts, B. V. (2017). Anticonvulsant Medication Use in Veterans With Posttraumatic Stress Disorder. *J Clin Psychiatry*, 78(5), e545-e552. doi:10.4088/JCP.16m11031
- Shiner, B., Westgate, C. L., Gui, J., Maguen, S., Young-Xu, Y., Schnurr, P. P., & Watts, B. V. (2018). A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice. *J Clin Psychiatry*, 79(5). doi:10.4088/JCP.18m12145
- Spoont, M. R., Murdoch, M., Hodges, J., & Nugent, S. (2010). Treatment receipt by veterans after a PTSD diagnosis in PTSD, mental health, or general medical clinics. *Psychiatr Serv*, 61(1), 58-63. doi:10.1176/appi.ps.61.1.58
- Sripada, R. K., Bohnert, K. M., Ganoczy, D., & Pfeiffer, P. N. (2018). Documentation of Evidence-Based Psychotherapy and Care Quality for PTSD in the Department of Veterans Affairs. *Adm Policy Ment Health*, 45(3), 353-361. doi:10.1007/s10488-017-0828-8
- Sripada, R. K., Pfeiffer, P. N., Rauch, S. A. M., Ganoczy, D., & Bohnert, K. M. (2018). Factors associated with the receipt of documented evidence-based psychotherapy for PTSD in VA. *Gen Hosp Psychiatry*, 54, 12-17. doi:10.1016/j.genhosppsych.2018.07.001
- Stuart, E. A. (2010). Matching methods for casual inference: a review and a look forward. *Statistical Science*, 25(1), 1-21.
- The Management of Posttraumatic Stress Disorder Work Group. (2017). *VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder*. Washington, DC: United States Departments of Veterans Affairs and Defense.
- Trafton, J. A., Greenberg, G., Harris, A. H., Tavakoli, S., Kearney, L., McCarthy, J., . . . Schohn, M. (2013). VHA mental health information system: applying health information technology to monitor and facilitate implementation of VHA Uniform Mental Health Services Handbook requirements. *Med Care*, 51(3 Suppl 1), S29-36. doi:10.1097/MLR.0b013e31827da836
- Tuerk, P. W., Yoder, M., Grubaugh, A., Myrick, H., Hamner, M., & Acierno, R. (2011). Prolonged exposure therapy for combat-related posttraumatic stress disorder: an examination of treatment effectiveness for veterans of the wars in Afghanistan and Iraq. *J Anxiety Disord*, 25(3), 397-403. doi:10.1016/j.janxdis.2010.11.002
- van Walraven, C., Oake, N., Jennings, A., & Forster, A. J. (2010). The association between continuity of care and outcomes: a systematic and critical review. *J Eval Clin Pract*, 16(5), 947-956. doi:10.1111/j.1365-2753.2009.01235.x
- VanderWeele, T. J., & Ding, P. (2017). Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med*, 167(4), 268-274. doi:10.7326/M16-2607
- Wagner, T. H., Sinnott, P., & Siroka, A. M. (2011). Mental health and substance use disorder spending in the Department of Veterans Affairs, fiscal years 2000-2007. *Psychiatr Serv*, 62(4), 389-395. doi:10.1176/ps.62.4.pss6204_0389

- 1
2
3
4 Watts, B. V., Schnurr, P. P., Mayo, L., Young-Xu, Y., Weeks, W. B., & Friedman, M. J. (2013). Meta-
5 analysis of the efficacy of treatments for posttraumatic stress disorder. *J Clin Psychiatry*, 74(6),
6 e541-550. doi:10.4088/JCP.12r08225
7
8 Weathers, F. W., Litz, B. T., Herman, B. S., Huska, J. A., & Keane, T. M. (1993). *The PTSD Checklist (PCL):*
9 *Reliability, Validity, and Diagnostic Utility*. Paper presented at the Paper presented at the Annual
10 Convention of the International Society for Traumatic Stress Studies, San Antonio, Tx.
11 Wilkins, K. C., Lang, A. J., & Norman, S. B. (2011). Synthesis of the psychometric properties of the PTSD
12 checklist (PCL) military, civilian, and specific versions. *Depress Anxiety*, 28(7), 596-606.
13 doi:10.1002/da.20837
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1: VA Users with New Episodes of PTSD Care from 2004-2013, by Receipt of Psychotherapy Procedure Code

	Overall	Category	
		Received Psychotherapy	Did Not Receive Psychotherapy
Patient Characteristics, N	731,520	647,513	84,007
Age, M (SD)**	49.9 (15.4)	49.8 (15.2)	50.8 (16.5)
Women, % (n)**	8.5 (61,853)	8.9 (57,409)	5.3 (4,444)
Married, % (n)	53.2 (389,262)	53.0 (342,970)	55.1 (46,292)
White Non-Hispanic, % (n)*	62.6 (457,673)	62.5 (404,774)	63.0 (52,899)
OEF/OIF/OND Veteran, % (n)**	28.5 (208,769)	28.5 (184,246)	29.2 (24,523)
Rural, % (n)**	35.3 (258,177)	34.8 (225,529)	38.9 (32,648)
Combat Exposure, % (n)**	32.8 (239,686)	32.1 (208,007)	37.7 (31,679)
Sexual Trauma while in Military, % (n)**	9.2 (67,024)	9.6 (62,388)	5.5 (4,636)
VA Disability Level 70% or Greater, % (n)	59.0 (431,632)	58.9 (381,621)	59.5 (50,011)
Charlson Comorbidity Index 1 or greater, % (n)**	24.4 (178,575)	24.3 (157,342)	25.3 (21,233)
Psychotic Disorders, % (n)**	5.7 (41,789)	5.9 (38,243)	4.2 (3,546)
Bipolar Mood Disorders, % (n)**	7.2 (52,596)	7.6 (49,128)	4.1 (3,468)
Depressive Mood Disorders, % (n)**	65.5 (478,763)	67.2 (435,185)	51.9 (43,578)
Non-PTSD Anxiety Disorders, % (n)**	34.5 (252,107)	35.8 (231,968)	24.0 (20,139)
Traumatic Brain Injury, % (n)**	8.6 (62,936)	7.8 (56,844)	7.3 (6,092)
Alcohol Use Disorders, % (n)**	27.1 (198,166)	28.1 (182,205)	19.0 (15,961)
Opioid Use Disorders, % (n)**	3.7 (27,175)	4.0 (25,786)	1.7 (1,389)
Other Drug Use Disorders, % (n)**	19.7 (144,350)	20.7 (134,050)	12.3 (10,300)
Service Use Characteristics, N	731,520	647,513	84,007
Prior Psychotherapy Use (2 years), % (n)**	45.9 (335,488)	47.1 (305,132)	36.1 (30,356)
Adequate Trial of EBA for PTSD, % (n)**	31.4 (229,849)	28.4 (207,632)	26.5 (22,217)
PTSD Outpatient Clinical Team Use (540 or 561), % (n)**	34.9 (255,151)	36.7 (237,541)	21.0 (17,610)
Outpatient Mental Health Visits, M (SD)**	12.6 (15.1)	13.6 (15.6)	4.3 (5.1)
Outpatient Substance Abuse Visits, M (SD)**	3.0 (13.1)	3.4 (13.8)	0.4 (4.1)
Outpatient Primary Care Visits, M (SD)**	3.5 (3.5)	3.5 (3.5)	2.9 (3.0)
Emergency Department Visit for Psychiatric Indication, % (n)**	6.4 (46,616)	6.8 (43,781)	3.4 (2,835)
Acute Mental Health Inpatient Admission, % (n)**	6.6 (48,531)	7.2 (46,429)	2.5 (2,102)
Residential PTSD Admission, % (n)**	2.4 (17,278)	2.6 (16,836)	0.5 (442)
Residential Substance Abuse Admission, % (n)**	2.7 (19,696)	3.0 (19,464)	0.3 (232)
Primary Therapist Characteristics, where known			
Age, M (SD)	-	50.8 (11.2)	-
Women, % (n)	-	47.0 (304,190)	-
Psychologist, % (n)	-	29.3 (189,719)	-
Social Worker, % (n)	-	29.2 (189,056)	-
Nurse, % (n)	-	9.0 (58,347)	-
Psychiatrist, % (n)	-	25.7 (166,326)	-
Other, % (n)	-	6.7 (43,374)	-
Prescribing Privileges, % (n)	-	36.0 (233,108)	-
Percentage of Time Seeing PTSD Patients in Various Settings	-	-	-
PTSD Service Section (PCT or residential), M (SD)	-	28.5 (37.5)	-
Substance Abuse Service Section, M (SD)	-	5.7 (19.5)	-
Comorbid PTSD Substance Abuse Service Section, M (SD)	-	0.2 (3.4)	-
General Mental Health Service Section, M (SD)	-	54.7 (39.9)	-
Integrated Care Service Section, M (SD)	-	6.5 (18.8)	-

Note. VA=United States Department of Veterans Affairs; PTSD=Posttraumatic Stress Disorder; M=mean, SD=standard deviation; OEF/OIF/OND=Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn; *p<0.05, **p<0.001

[illegible]

Table 3: Psychotherapy Initiation in the Year Following Initial PTSD Diagnosis among 396,032 Patients with No Psychotherapy Encounters in the 2 Years Prior to PTSD Diagnosis, Fiscal Years 2004-2013; Mean of 7.8 (SD=10.8) psychotherapy encounters.

Quality Standard	Any Receipt	8+ Sessions	8+ Sessions, Same Therapist	8+ Sessions in 14 weeks, Same Therapist
Any Psychotherapy: Procedure Codes	86.5% (342,381)	32.2% (127,381)	23.3% (92,374)	13.8% (54,608)
Individual	82.7% (327,358)	21.9% (86,704)	14.6% (57,954)	6.1% (24,050)
Group	28.3% (112,152)	12.6% (49,832)	10.2% (40,346)	7.9% (31,403)
Any Psychotherapy: NLP	59.5% (235,706)	21.8% (86,238)	18.1% (71,789)	11.4% (44,963)
Individual	50.4% (199,543)	11.4% (45,110)	9.9% (39,182)	4.6% (18,176)
Group	25.0% (99,185)	11.1% (44,024)	8.9% (35,124)	6.7% (26,468)
Any EBP: NLP	7.7% (30,593)	2.9% (11,353)	2.5% (9,980)	2.0% (8,058)
Group Cognitive Processing Therapy	2.2% (8,815)	0.8% (3,300)	0.6% (2,226)	0.5% (1,867)
Individual Prolonged Exposure	2.1% (8,227)	0.6% (2,440)	0.6% (2,316)	0.5% (1,913)
Individual Cognitive Processing Therapy	4.7% (18,584)	1.4% (5,375)	1.3% (5,112)	1.0% (4,005)

Note. PTSD=Posttraumatic Stress Disorder; EBP=Evidence-Based Psychotherapy for PTSD; NLP=Natural Language Processing. Yearly trends presented in Appendix 1.

Table 4: VA Users Initiating Evidence-Based Psychotherapy for PTSD and Completing 8 or More Sessions within a Year, FY 2008-2013, by Receipt of Aligned PTSD Checklist Measurement

	Overall	Category	
		With Aligned PCL Measurement	Without Aligned PCL Measurement
Patient Characteristics, N	10,765	2,052	8,713
Age, M (SD)**	47.3 (15.2)	45.2 (15.2)	47.8 (15.1)
Women, % (n)	12.9 (1,390)	13.8 (283)	12.7 (1,107)
Married, % (n)*	60.8 (6,547)	62.8 (1,288)	60.4 (5,259)
White Non-Hispanic, % (n)	63.8 (6,871)	62.3 (1,279)	64.2 (5,592)
OEF/OIF/OND Veteran, % (n)**	41.7 (4,490)	50.3 (1,033)	39.7 (3,457)
Rural, % (n)	32.8 (3,529)	31.6 (649)	33.1 (2,880)
Combat Exposure, % (n)	27.7 (2,983)	27.0 (554)	27.9 (2,429)
Sexual Trauma while in Military, % (n)	13.2 (1,417)	13.5 (277)	13.1 (1,140)
VA Disability Level 70% or Greater, % (n)	58.8 (6,334)	60.2 (1,236)	58.5 (5,098)
Charlerson Comorbidity Index 1 or greater, % (n)	12.6 (1,353)	12.3 (253)	12.6 (1,100)
Psychotic Disorders, % (n)	1.9 (209)	1.5 (31)	2.0 (178)
Bipolar Mood Disorders, % (n)	3.4 (363)	3.4 (70)	3.4 (293)
Depressive Mood Disorders, % (n)**	66.3 (7,141)	70.9 (1,455)	65.3 (5,686)
Non-PTSD Anxiety Disorders, % (n)*	37.9 (4,080)	41.0 (841)	37.2 (3,239)
Traumatic Brain Injury, % (n)**	15.6 (1,681)	18.6 (381)	14.9 (1,300)
Alcohol Use Disorders, % (n)*	24.6 (2,648)	26.5 (544)	24.2 (2,104)
Opioid Use Disorders, % (n)	1.9 (207)	2.1 (42)	1.9 (165)
Other Drug Use Disorders, % (n)	14.9 (1,607)	13.8 (283)	15.2 (1,324)
Service Use Characteristics, N			
Adequate Trial of EBA for PTSD, % (n)**	30.0 (3,227)	33.7 (691)	29.1 (2,536)
PTSD Outpatient Clinical Team Use (540 or 561), % (n)**	67.5 (7,270)	71.5 (1,467)	66.6 (5,803)
Outpatient Mental Health Visits, M (SD)*	28.6 (16.3)	27.8 (14.7)	28.8 (16.7)
Outpatient Substance Abuse Visits, M (SD)	3.8 (12.3)	4.2 (13.2)	3.8 (12.0)
Outpatient Primary Care Visits, M (SD)	3.3 (3.3)	3.3 (3.1)	3.3 (3.3)
Emergency Department Visit for Psychiatric Indication, % (n)	7.7 (829)	8.1 (166)	7.6 (663)
Acute Mental Health Inpatient Admission, % (n)	6.7 (722)	6.9 (141)	6.7 (581)
Residential PTSD Admission, % (n)	8.4 (904)	8.4 (173)	8.4 (731)
Residential Substance Abuse Admission, % (n)	2.4 (258)	2.2 (46)	2.4 (212)
Primary Therapist Characteristics, where known			
Age, M (SD)**	44.8 (10.9)	43.6 (11.1)	45.1 (10.8)
Women, % (n)	66.4 (5,825)	67.4 (1,126)	66.2 (4,699)
Psychologist, % (n)**	60.0 (6,450)	65.3 (1,339)	58.7 (5,111)
Social Worker, % (n)**	32.8 (3,529)	28.7 (588)	33.8 (2,941)
Nurse, % (n)*	2.2 (236)	1.3 (26)	2.4 (210)
Psychiatrist, % (n)*	1.6 (175)	0.8 (17)	1.8 (158)
Other, % (n)	3.4 (369)	3.9 (80)	3.3 (289)
Prescribing Privileges, % (n)*	8.9 (961)	7.6 (155)	9.3 (806)
Percentage of Time Seeing PTSD Patients in Various Settings	-	-	-
PTSD Service Section (PCT or residential), M (SD)*	56.2 (38.7)	58.3 (38.6)	55.6 (38.7)
Substance Abuse Service Section, M (SD)	3.7 (13.5)	3.5 (12.8)	3.7 (13.6)
Comorbid PTSD Substance Abuse Service Section, M (SD)**	0.4 (3.9)	0.9 (5.9)	0.3 (3.3)
General Mental Health Service Section, M (SD)*	30.7 (34.7)	28.6 (34.2)	31.2 (34.8)
Integrated Care Service Section, M (SD)	5.3 (16.1)	5.1 (16.1)	5.4 (16.1)


Note. VA=United States Department of Veterans Affairs; PTSD=Posttraumatic Stress Disorder; M=mean, SD=standard deviation; OEF/OIF/OND=Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn; *p<0.05, **p<0.001

Table 5: Inverse Propensity of Treatment Weighted Comparison of PTSD Symptomatic Outcomes for Patients Completing 8 or More Sessions of Evidence-Based Psychotherapy for PTSD with Aligned PTSD Checklist Measurement, FY 2008-2013, by Quality Standard

Quality Standard	(A) 8	(B) 8 ST	(C) 8 ST 14W	<u>A versus B</u>		<u>A versus C</u>		<u>B versus C</u>	
	n=303	n=549	n=1,200	P	E	P	E	P	E
Baseline PCL, mean (SD)	64.2 (11.0)	63.6 (10.1)	63.6 (10.0)	0.5383		0.4417		0.9994	
Change in PCL, mean (SD)	-7.1 (13.2)	-8.6 (14.2)	-9.3 (13.0)	0.1627	1.45	0.0101	1.60	0.3757	1.26
10-Poing Drop on PCL plus LOD, % (n)	13.8 (43)	21.4 (115)	23.3 (285)	0.0274	2.47	0.0004	2.77	0.4346	1.40

Note. E-value indicates the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the exposure and the outcome, conditional on the measured covariates, to fully explain away a specific exposure-outcome association; LOD=loss of diagnosis; **BOLD**=p<0.0167.

Figure 1: Repeated Measures Model of Change in Total PCL Score



Note. NLP=Natural Language Processing; EBP=Evidence-Based Psychotherapy for Posttraumatic Stress Disorder

APPENDIX 1: Psychotherapy Initiation in the Year Following Initial PTSD Diagnosis among Patients with No Psychotherapy Encounters in the 2 Years Prior to PTSD Diagnosis, by Punitive Quality Standards

Fiscal Years	2004-2005 n=58,061	2006-2007 n=69,640	2008-2009 n=90,269	2010-2011 n=92,515	2012-2013 n=85,547	Overall 396,032
Total Psychotherapy Encounters, M (SD)	8.0 (11.6)	7.5 (10.8)	7.7 (10.8)	8.0 (10.7)	7.9 (10.5)	7.8 (10.8)

Any Receipt

Any Psychotherapy: Procedural Codes	84.4% (49,022)	85.2% (59,368)	85.9% (77,548)	88.1% (81,487)	87.6% (74,956)	86.5% (342,381)
Individual	79.6% (46,199)	81.0% (56,410)	82.6% (74,606)	84.8% (78,430)	83.8% (71,713)	82.7% (327,358)
Group	30.2% (17,540)	28.3% (19,714)	26.1% (23,591)	28.0% (25,933)	29.7 (25,374)	28.3% (112,152)
Any Psychotherapy: NLP	54.2% (31,496)	56.8% (39,537)	59.4% (53,589)	61.8% (57,182)	63.0% (53,902)	59.5% (235,706)
Individual	43.6% (25,307)	47.4% (32,978)	51.2% (46,204)	52.9% (48,939)	53.9% (46,115)	50.4% (199,543)
Group	25.6% (14,835)	24.6% (17,103)	23.1% (20,885)	25.4% (23,540)	26.7% (22,822)	25.0% (99,185)
Any EBP: NLP	0.6% (373)	2.7% (1,884)	7.7% (6,939)	10.7% (9,855)	13.5% (11,542)	7.7% (30,593)
Group Cognitive Processing Therapy	0.2% (104)	0.6% (436)	2.0% (1,801)	3.4% (3,160)	3.9% (3,314)	2.2% (8,815)
Individual Prolonged Exposure	0.1% (82)	0.3% (224)	1.9% (1,687)	3.2% (2,946)	3.8% (3,288)	2.1% (8,227)
Individual Cognitive Processing Therapy	0.4% (236)	2.1% (1,449)	4.9% (4,454)	6.0% (5,545)	8.1% (6,900)	4.7% (18,584)

Eight or More Sessions

Any Psychotherapy: Procedural Codes	30.9% (17,926)	29.8% (20,757)	32.0% (28,864)	33.6% (31,079)	33.6% (28,755)	32.2% (127,381)
Individual	18.1% (10,506)	19.0% (13,214)	22.9% (20,635)	23.5% (21,741)	24.1% (20,608)	21.9% (86,704)
Group	15.4% (8,931)	13.1% (9,121)	11.5% (10,371)	12.4% (11,479)	11.6% (9,930)	12.6% (49,832)
Any Psychotherapy: NLP	19.3% (11,179)	19.6% (13,656)	21.3% (19,237)	23.4% (21,603)	24.0% (20,563)	21.8% (86,238)
Individual	7.0% (4,048)	8.8% (6,150)	11.9% (10,745)	12.8% (11,864)	14.4% (12,303)	11.4% (45,110)
Group	12.6% (7,331)	11.4% (7,927)	10.3% (9,284)	11.4% (10,519)	10.5% (8,963)	11.1% (44,024)
Any EBP: NLP	0.2% (94)	0.7% (494)	2.6% (2,326)	4.4% (4,060)	5.1% (4,379)	2.9% (11,353)
Group Cognitive Processing Therapy	0.0% (23)	0.2% (109)	0.6% (579)	1.4% (1,337)	1.5% (1,252)	0.8% (3,300)
Individual Prolonged Exposure	0.0% (11)	0.0% (31)	0.5% (493)	1.1% (991)	1.1% (914)	0.6% (2,440)
Individual Cognitive Processing Therapy	0.1% (63)	0.5% (372)	1.4% (1,226)	1.8% (1,622)	2.4% (2,092)	1.4% (5,375)

Eight or More Sessions with the Same Therapist

Any Psychotherapy: Procedural Codes	23.1% (13,389)	22.0% (15,288)	22.9% (20,635)	24.0% (22,204)	24.4% (20,858)	23.3% (92,374)
Individual	11.8% (6,841)	12.5% (8,697)	15.2% (13,717)	15.6% (14,397)	16.7% (14,302)	14.6% (57,954)
Group	12.7% (7,367)	10.9% (7,595)	9.2% (8,317)	10.0% (9,237)	9.2% (7,830)	10.2% (40,346)
Any Psychotherapy: NLP	15.8% (9,167)	16.4% (11,389)	17.8% (16,028)	19.7% (18,189)	19.9% (17,016)	18.1% (71,789)
Individual	6.0% (3,456)	7.5% (5,216)	10.3% (9,302)	11.3% (10,464)	12.6% (10,744)	9.9% (39,182)
Group	10.2% (5,941)	9.4% (6,528)	8.2% (7,377)	9.1% (8,379)	8.1% (6,899)	8.9% (35,124)
Any EBP: NLP	0.1% (78)	0.7% (458)	2.3% (2,042)	3.9% (3,562)	4.5% (3,840)	2.5% (9,980)
Group Cognitive Processing Therapy	0.0% (11)	0.1% (74)	0.4% (369)	1.0% (924)	1.0% (848)	0.6% (2,226)
Individual Prolonged Exposure	0.0% (11)	0.0% (31)	0.5% (460)	1.0% (952)	1.0% (862)	0.6% (2,316)
Individual Cognitive Processing Therapy	0.1% (55)	0.5% (361)	1.3% (1,149)	1.7% (1,549)	2.3% (1,998)	1.3% (5,112)

Eight or More Sessions in 14 Weeks with the Same Therapist

Any Psychotherapy: Procedural Codes	13.2% (7,678)	12.6% (8,747)	12.7% (11,437)	14.5% (13,390)	15.6% (13,356)	13.8% (54,608)
Individual	3.6% (2,074)	4.3% (2,971)	5.9% (5,345)	6.8% (6,300)	8.6% (6,300)	6.1% (24,050)
Group	9.6% (5,584)	8.4% (5,853)	7.0% (6,304)	7.9% (7,297)	7.4% (6,365)	7.9% (31,403)
Any Psychotherapy: NLP	9.5% (5,497)	10.0% (6,962)	10.6% (9,540)	12.7% (11,763)	13.1% (11,201)	11.4% (44,963)
Individual	2.0% (1,154)	2.8% (1,983)	4.5% (4,068)	5.6% (5,176)	6.8% (5,795)	4.6% (18,176)
Group	7.2% (4,209)	7.0% (4,863)	6.0% (5,440)	7.1% (6,534)	6.3% (5,422)	6.7% (26,468)
Any EBP: NLP	0.1% (62)	0.5% (359)	1.7% (1,557)	3.2% (2,924)	3.7% (3,156)	2.0% (8,058)
Group Cognitive Processing Therapy	0.0% (8)	0.1% (61)	0.3% (302)	0.8% (777)	0.8% (719)	0.5% (1,867)
Individual Prolonged Exposure	0.0% (9)	0.0% (22)	0.4% (366)	0.9% (801)	0.8% (715)	0.5% (1,913)
Individual Cognitive Processing Therapy	0.1% (44)	0.4% (279)	0.9% (833)	1.3% (1,245)	1.9% (1,604)	1.0% (4,005)

Note. PTSD=Posttraumatic Stress Disorder; EBP=Evidence-Based Psychotherapy for PTSD; NLP=Natural Language Processing

Appendix 2: Raw and Weighted Covariates for Comparisons of Quality Standards for Patients Receiving 8 or More Sessions of Evidence-Based Psychotherapy for PTSD and Aligned PCL Measurement, FY 2008-2013								
Patient Characteristics, N	(A) 8 n=303	Raw Data (B) 8 ST n=549	(C) 8 14W ST n=1,200	p value	(A) 8 n=303	Weighted Data (B) 8 ST n=549	(C) 8 14W ST n=1,200	p value
Baseline PCL, M (SD)	64.9 (9.9)	63.2 (9.6)	63.5 (9.8)	0.041	64.2 (11.0)	63.6 (10.1)	63.6 (10.0)	0.735
Days Between Baseline PCL and Session 1, M (SD)	2.4 (15.5)	6.9 (23.0)	0.8 (6.0)	<0.001	3.1 (22.7)	2.8 (10.4)	1.1 (8.1)	0.002
Days Between Follow-Up PCL and Session 8 M (SD)	0.2 (5.8)	-1.9 (13.7)	0.3 (5.8)	<0.001	0.2 (7.0)	-0.4 (7.3)	0.2 (6.4)	0.230
Fiscal years 2008-2009	5.3 (16)	7.7 (42)	5.7 (68)	0.220	6.3 (16)	7.2 (42)	6.1 (68)	0.678
Fiscal years 2010-2011	37.3 (113)	35.5 (195)	39.4 (473)	0.284	36.3 (113)	36.1 (195)	39.1 (473)	0.468
Fiscal years 2012-2013	57.4 (174)	56.8 (312)	54.9 (659)	0.625	57.4 (174)	56.6 (312)	54.9 (659)	0.683
Age, M (SD)	47.2 (14.6)	42.8 (14.7)	45.8 (15.5)	<0.001	46.3 (16.4)	16.3 (44.6)	45.4 (15.4)	0.326
Women, % (n)	9.6 (29)	14.6 (80)	14.5 (174)	0.070	13.6 (29)	14.4 (80)	14.3 (174)	0.963
Married, % (n)	68.6 (208)	60.3 (331)	62.4 (749)	0.050	68.1 (208)	61.8 (331)	62.5 (749)	0.252
White Non-Hispanic, % (n)	48.2 (146)	62.7 (344)	65.8 (789)	<0.001	55.3 (146)	62.0 (344)	63.8 (789)	0.053
OEF/OIF/OND Veteran, % (n)	46.9 (142)	55.2 (303)	49.0 (588)	0.024	48.8 (142)	49.0 (303)	50.2 (588)	0.877
Rural, % (n)	32.3 (98)	33.2 (182)	30.8 (369)	0.580	30.5 (98)	33.6 (182)	30.5 (369)	0.462
Combat Exposure, % (n)	28.7 (87)	27.0 (148)	26.6 (319)	0.757	30.2 (87)	25.7 (148)	27.0 (319)	0.466
Sexual Trauma while in Military, % (n)	9.2 (28)	12.4 (68)	15.1 (181)	0.020	12.8 (28)	12.3 (68)	14.8 (181)	0.358
VA Disability Level 70% or Greater, % (n)	65.3 (198)	62.7 (344)	57.8 (694)	0.023	62.1 (198)	61.8 (344)	58.5 (694)	0.337
Charleson Comorbidity Index 1 or greater, % (n)	15.8 (48)	10.2 (56)	12.4 (149)	0.056	14.8 (48)	11.1 (56)	11.9 (149)	0.355
Psychotic Disorders, % (n)	1.0 (3)	1.6 (9)	1.6 (19)	0.721	0.4 (3)	1.5 (9)	1.6 (19)	0.133
Bipolar Mood Disorders, % (n)	3.6 (11)	3.1 (17)	3.5 (42)	0.888	5.3 (11)	3.0 (17)	3.5 (42)	0.382
Depressive Mood Disorders, % (n)	68.3 (207)	71.6 (393)	71.3 (855)	0.555	68.6 (207)	72.1 (393)	71.5 (855)	0.610
Non-PTSD Anxiety Disorders, % (n)	43.6 (132)	41.3 (227)	40.2 (482)	0.550	42.1 (132)	40.1 (227)	40.0 (482)	0.833
Traumatic Brain Injury, % (n)	17.2 (52)	22.8 (125)	17.0 (204)	0.013	17.8 (52)	20.7 (125)	17.6 (204)	0.291
Alcohol Use Disorders, % (n)	28.4 (86)	27.0 (148)	25.8 (310)	0.643	24.8 (86)	27.9 (148)	25.8 (310)	0.594
Opioid Use Disorders, % (n)	2.3 (7)	2.0 (11)	2.0 (24)	0.940	1.6 (7)	2.0 (11)	2.0 (24)	0.901
Other Drug Use Disorders, % (n)	14.9 (45)	13.8 (76)	13.5 (162)	0.830	12.1 (45)	13.0 (76)	13.3 (162)	0.863
Adequate Trial of Evidence-Based Antidepressant for PTSD, % (n)	41.3 (125)	33.2 (182)	32.0 (384)	0.009	37.3 (125)	33.0 (182)	32.5 (384)	0.363
PTSD Outpatient Clinical Team Use (540 or 561), % (n)	84.5 (256)	71.2 (391)	68.3 (820)	<0.001	78.3 (256)	71.8 (391)	70.4 (820)	0.098
Outpatient Mental Health Visits, M (SD)	31.7 (16.3)	27.6 (14.2)	26.9 (14.4)	<0.001	29.0 (15.5)	27.7 (15.3)	27.3 (14.8)	0.228
Outpatient Substance Abuse Visits, M (SD)	5.3 (13.9)	3.8 (15.3)	4.1 (11.9)	0.256	3.6 (9.8)	3.9 (16.7)	4.1 (12.0)	0.804
Outpatient Primary Care Visits, M (SD)	3.8 (3.5)	3.1 (2.5)	3.2 (3.1)	0.005	3.3 (3.2)	3.2 (2.9)	3.2 (3.2)	0.752
Emergency Department Visit for Psychiatric Indication, % (n)	8.3 (25)	7.1 (39)	8.5 (102)	0.607	6.9 (25)	7.1 (39)	8.5 (102)	0.510
Acute Mental Health Inpatient Admission, % (n)	6.3 (19)	7.8 (43)	6.6 (79)	0.572	5.0 (19)	7.5 (43)	6.5 (79)	0.426
Residential PTSD Admission, % (n)	15.8 (48)	7.5 (41)	7.0 (84)	<0.001	9.8 (48)	8.2 (41)	7.6 (84)	0.432
Residential Substance Abuse Admission, % (n)	4.6 (14)	1.1 (6)	2.2 (26)	0.004	2.4 (14)	1.1 (6)	2.2 (26)	0.241
Primary Therapist Characteristics, where known								
Age, M (SD)	44.1 (12.3)	43.3 (11.0)	43.5 (10.9)	0.664	43.1 (14.3)	43.7 (12.9)	43.4 (12.6)	0.861
Women, % (n)	44.2 (134)	60.5 (332)	55.0 (660)	<0.001	64.7 (134)	68.5 (332)	68.5 (660)	0.540
Psychologist, % (n)	65.7 (199)	67.8 (372)	64.0 (768)	0.327	69.9 (199)	66.5 (372)	65.2 (768)	0.395
Social Worker, % (n)	24.1 (73)	27.0 (148)	30.6 (367)	0.046	25.2 (73)	28.0 (148)	29.5 (367)	0.410
Nurse, % (n)	0.3 (1)	1.1 (6)	1.6 (19)	0.199	0.2 (1)	1.3 (6)	1.5 (19)	0.102
Psychiatrist, % (n)	0.7 (2)	1.1 (6)	0.8 (9)	0.720	0.7 (2)	1.2 (6)	0.8 (9)	0.683
Other, % (n)	9.2 (28)	3.1 (17)	2.9 (35)	<0.001	4.1 (28)	3.0 (17)	3.0 (35)	0.510
Prescribing Privileges, % (n)	5.6 (17)	7.8 (43)	7.9 (95)	0.379	6.5 (17)	7.7 (43)	7.7 (95)	0.813
Percentage of time in PTSD Service, M (SD)	72.0 (33.7)	57.5 (38.0)	55.2 (39.2)	<0.001	63.8 (45.6)	58.7 (41.2)	57.9 (38.5)	0.111
Percentage of time in Substance Abuse Service, M (SD)	3.4 (13.2)	3.2 (10.7)	3.7 (13.5)	0.736	2.6 (9.5)	3.0 (12.0)	3.5 (12.3)	0.338
Percentage of time in PTSD-Substance Abuse Service, M (SD)	1.1 (6.3)	1.0 (6.5)	0.8 (5.4)	0.505	0.8 (4.0)	0.8 (5.6)	0.8 (6)	0.973
Percentage of time in General Mental Health Service, M (SD)	17.5 (27.8)	29.1 (33.8)	31.2 (35.3)	<0.001	24.8 (41.4)	28.6 (35.9)	29.2 (34.0)	0.245
Percentage of time in Integrated Care Service, M (SD)	3.5 (12.6)	5.8 (17.4)	5.3 (16.2)	0.120	4.5 (17.5)	5.5 (17.2)	5.0 (15.8)	0.735

Note. PTSD=Posttraumatic Stress Disorder, PCL=PTSD Checklist, 8=eight sessions of evidence-based psychotherapy (EBP), 8 ST=eight sessions of EBP with the same the same psychotherapist, 8 14W S=eight sessions with the same therapist within 14 weeks, OEF/OIF/OND=Operations Enduring Freedom/Iraqi Freedom/New Dawn